EP1133493A1 - Oxazolidinone antibacterial agents having a thiocarbonyl functionality - Google Patents

Oxazolidinone antibacterial agents having a thiocarbonyl functionality

Info

Publication number
EP1133493A1
EP1133493A1 EP98961822A EP98961822A EP1133493A1 EP 1133493 A1 EP1133493 A1 EP 1133493A1 EP 98961822 A EP98961822 A EP 98961822A EP 98961822 A EP98961822 A EP 98961822A EP 1133493 A1 EP1133493 A1 EP 1133493A1
Authority
EP
European Patent Office
Prior art keywords
oxo
phenyl
methyl
oxazolidinyl
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98961822A
Other languages
German (de)
French (fr)
Inventor
Jackson B. Hester, Jr.
Eldon George Nidy
Salvatore Charles Perricone
Toni-Jo Poel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co LLC
Original Assignee
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia and Upjohn Co
Publication of EP1133493A1 publication Critical patent/EP1133493A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to new and useful oxazolidinone compounds and their preparations, and more particularly to oxazolidinone compounds in which the carbonyl functionality of -NH-C(O)-R is converted to a thiocarbonyl functionality, such as a thiourea -NH-C(S)-NH,, an alkyl thiourea -NH-C(S)-NH-(C M alkyl), thioamide -NH-C(S)-(C M alkyl) or -NH-C(S)-H.
  • the compounds are useful antimicrobial agents, effective against a number of human and veterinary pathogens, including Gram-positive aerobic bacteria such as multiply-resistant staphylococci and streptococci, Gram-negative organisms such as H. influenzae and M. catarrahlis as well as anaerobic organisms such as bacteroides and clostridia species, and acid-fast organisms such as Mycobacterium tuberculosis and Mycobacterium a ⁇ ium.
  • the compounds are particularly useful because they are effective against the latter organisms which are known to be responsible for infection in persons with AIDS.
  • the subject invention is a compound of the Formula I
  • R j is a) H, b) NH 2 , 0 NH-C 1 4 alkyl, d) C M alkyl, e) -OC M alkyl, f) -S C M alkyl, g ) C M alkyl substituted with 1-3 F, 1-2 Cl, CN or -COOC 1 4 alkyl, h) C 3 . 6 cycloalkyl, i) N(C M alkyl) 2 or j) N(CH 2 ) 2 . 5 ;
  • R 2 is a) H, b) F,
  • R 5 and R 6 at each occurrence are the same or different and are a) C j.2 alkyl, or b) R 5 and R 6 taken together are -(CH 2 ) k -;
  • R 8 is a) H, or b) C,. 8 alkyl optionally substituted with one or more halos, or C 3. , cycloalkyl;
  • R I0 and R n at each occurrence are the same or different and are a) H, b) C[. 4 alkyl, or c) C 3 . 8 cycloalkyl;
  • R 13 is a) H, or b) C M alkyl
  • R 14 and R lf i at each occurrence are the same or different and are a) C alkyl, or b) R 14 and R 15 taken together are -(CH) r ; R 16 is a) H, b) C j . 4 alkyl, or
  • R 17 is a) C M alkyl, or b) C 3.8 cycloalkyl
  • R 18 is a) H, b) C__ 4 alkyl, c) C 2 . 4 alkenyl, d) C 3 . 4 cycloalkyl, e) -OR 13 or f) -NR 21 R 22 ;
  • R 19 is a) Cl, b) Br, or c) I;
  • R 20 is a physiologically acceptable cation
  • R 21 and R 2 at each occurrence are the same or different and are a) H, b) C,. 4 alkyl, or c) -N ,,R 22 taken together are -(CH 2 ) m -; wherein R 23 and R 24 at each occurrence are the same or different and are a) H, b) F, c) Cl, d) C,. 2 alkyl, e) CN f) OH, g) C h2 alkoxy, h) nitro, or i) amino;
  • Z 1 is a) -CH 2 -, b) -CH(R 104 )-CH 2 -, c) -C(O)-, or d) -CH,CH 2 CH,-;
  • Z 2 is a) -O 2 S-, b) -O-, c) -N(R 107 )-, d) -OS-, or e) -S-;
  • Z 3 is a) -O 2 S-, b) -O-, c) -OS-, or d) -S-;
  • a 1 is a) H-, or b) CH 3 ;
  • a 2 is a) H-, b) HO-, c) CH 3 -, d) CH 3 O-, e) R 102 O-CH 2 -C(O)-NH- f) R 103 O-C(O)-NH-, g) (C I -C 2 )alkyl-0-C(0)-, h) HO-CH 2 -, i) CH 3 O-NH-, j) (C r C 3 )alkyl-O 2 C- k) CH 3 -C(O)-;
  • a 1 and A 2 taken together are: a)
  • R 102 is a) H-, b) CH 3 -, c) phenyl-CH 2 -, or d) CH 3 C(O)-; wherein R 103 is a) (C j -C ⁇ alkyl-, or b) phenyl-; wherein R 104 is a) H-, or b) HO-; wherein R 105 is a) H-, b) (C 1 -C !
  • R 106 is a) CH 3 -C(O)-, b) H-C(O)-, c) C1.,CH-C(0)-, d) HOCH,-C(0)-, e) CH 3 S0 2 -,
  • R 107 is a) R 102 O-C(R no )(R )-C(O)-, b) R 103 O-C(O)-, c) R 108 -C(O)-,
  • R 109 is a) alkylC 1 -C 4 , b) -CH 2 C1
  • R 110 and R 111 are independently a) H-, b) CH 3 -; or wherein R 112 is a) H-, b) CH 3 O-CH O-CH 2 -, or
  • R 113 is a) CH 3 -, b) HOCH 2 -, c) (CH 3 ) N-phenyl, or d) (CH ) N-CH -; wherein R 114 is a) HO-, b) CH 3 O-, c) H 2 N-, d) CH :!
  • R 113 is a) CH 3 -, b) HOCH 2 -, c) (CH 3 ) 2 N-phenyl, or d) (CH 3 ) 2 N-CH 2 -;
  • R 115 is a) H-, or b) C1-;
  • R 116 is a) HO- b) CH 3 O-, or c) F;
  • R 150 and R 151 are each H or alkyl C,-C 4 or R 150 and R 151 taken together with the nitrogen atom to which each is attached form a monocyclic heterocyclic ring having from 3
  • W is a) CH, b) N, or c) S or O when Z is NM;
  • Y is a) H, b) F, c) Cl, d) Br, e) C ⁇ alkyl, or f) NO 2 ;
  • R 4 , R 5 , R 6 , R 7 , R j j , R 14 , R, 5 , R 16 , and R 17 are the same as defined above;
  • R 7 and R 28 at each occurrence are the same or different and are a) H, b) C_ .a alkyl, c) C 3.8 cycloalkyl, d) -(CH 2 ) m OR 13 , e) -(CH 2 ) h -NR 21 R 22 , or f) R 27 and R 8 taken together are -(CH 2 ) 2 O(CH 2 ) 2 -, JCH ⁇ CH CORM or -(CH 2 ) 2 N(CH 2 ) 2 (R 7 );
  • R 38 is a) H, b) C.. 6 alkyl, c) -(CH ) q -aryl, or d) halo;
  • R 40 is a) H, b) C 1 6 alkyl optionally substituted with one or more OH, halo, or -CN, c) -(CHJ q -aryl, or d) -(CH 2 ) q -OR 42 ;
  • R 41 is a) C [ . 6 alkyl optionally substituted with one or more OH, halo, or -CN, b) -(CH ) q -aryl, or c) -(CH 2 ) q -OR 42 ;
  • aryl is a) phenyl, b) pyridyl, or c) napthyl; a to c optionally substituted with one or more halo, -CN, OH, SH, C j . 6 alkyl, C ⁇ alkoxy, or C 1 6 alkylthio; wherein R 43 is a) H, b) C ⁇ jj alkyl, c) F, or d) OH; R 4 is a) H, b) CF 3 , c) C 1 3 alkyl optionally substituted with one or more halo, d) phenyl optionally substituted with one or more halo, e) R 44 and R 45 taken together are a 5-, 6-, or 7-membered ring of the formula, or
  • R 44 and R 45 taken together are -(CH 2 ) k -, when R 46 is an electron- withdrawing group; R 45 and R 46 at each occurrence are the same or different and are a) an electron-withdrawing group, b) H,
  • U is a) CH 2 , b) O,
  • R 47 is a) H, or b) C..5 alkyl; wherein R 48 is a) carboxyl, b) halo,
  • R 49 and R 50 at each occurrence are the same or different and are a) H, b) C,. regularly alkyl, c ) C 5 . 6 cycloalkyl, or d) R 49 and R 50 taken together with the nitrogen atom is a 5-, 6- membered saturated heterocyclic moiety which optionally has a further hetero atom selected from the group consisting of S, N, and O, and can in turn be optionally substituted with, including on the further nitrogen atom, C 1 alkyl, or C ⁇ acyl;
  • R 51 is a) carboxyl, b) halo, c) -CN, d) mercapto, e) formyl, f) CF 3 , g) -NO , h) alkoxy, i) Ci. 6 alkoxycarbonyl,
  • R 52 and R 53 at each occurrence are the same or different and are a) H, b) C,. 6 alkyl, or c) phenyl;
  • R 56 and R 57 at each occurrence are the same or different and are a) H, b) formyl, c) C M alkyl, d) C ⁇ . 4 acyl, e) phenyl, ) C 3 . 6 cycloalkyl, or g) R 56 and R 57 taken membered saturated heterocyclic moiety which optionally has a further hetero atom selected from the group consisting of S, N, and O, and can in turn be optionally substituted with, including on the further nitrogen atom, phenyl, pyrimidyl, C,. 3 alkyl, or C ⁇ acyl;
  • R 58 is a) carboxyl, b) halo, c) -CN, d) mercapto, e) formyl, f) CF 3 , g) -NO 2 , h) C__ 6 alkoxy, i) C j . 6 alkoxycarbonyl, j) C j .g alkythio, k) C 1 6 acyl,
  • R 54 is the same as defined above;
  • R 59 and R 60 at each occurrence are the same or different and are a) H, b) alkyl, c) phenyl, or d) tolyl;
  • R 62 and R 63 at each occurrence are the same or different and are a) H, or b) C 1 4 alkyl optionally substituted with phenyl or pyridyl;
  • R 64 is a) H, or b) a sodium ion;
  • R 65 and R 66 at each occurrence are the same or different and are a) H, b) formyl, c) C M alkyl, d) C,. 4 acyl, e) phenyl, f) C .6 cycloalkyl, g) R 65 and R 66 taken together are a 5-, 6-membered saturated heterocyclic moiety having one to three atoms selected from the group consisting of S, N, and O, optionally substituted with, including on the nitrogen atom, phenyl, pyrimidyl, C 1 3 alkyl, or C i acyl, h) -P(OXOR 70 XOR 7] ), or i) -SO ⁇ R,,,; R 67 is
  • R 68 is Ci. 3 alkyl
  • R 69 is a) alkoxycarbonyl, or b) carboxyl
  • Kj 0 and R 71 at each occurrence are the same or different and are a) H, or b) C V3 alkyl;
  • R ⁇ is a) methyl, b) phenyl, or c) tolyl; wherein K is a) O, or b) S;
  • R 76 , and R 77 at each occurrence are the same or different and are a) H, b) carboxyl,
  • halo d) -CN, e) mercapto, f) formyl, g ) CF-, h) -NO 2 , i) alkoxy, j) C j .g alkoxycarbonyl, k) C j . 5 alkythio, 1) C,. 6 acyl, m) -J ⁇ 78 79 , n) C,.g aallkkyyll ooppttiioonnaallllyy substituted with OH, C ⁇ alkoxy, C,.
  • R / g and R- 9 at each occurrence are the same or different and are a) H, b) C M alkyl, c) phenyl, or d) R ⁇ g and R 79 taken together with the nitrogen atom is a 5-, 6- membered saturated heterocyclic moiety which optionally has a further hetero atom selected from the group consisting of S, N, and O, and can in turn be optionally substituted with, including on the further nitrogen atom, C w alkyl, or C j _ 3 acyl; wherein T is a) O, b) S, or 0 SO 2 ;
  • R ⁇ s, R 76 , and R 77 are the same as defined above;
  • R 80 is a) H, b) formyl, c) carboxyl, d) Ci_ 6 alkoxycarbonyl, e) C,. 8 alkyl, f) C 2 .
  • R 81 and R 82 at each occurrence are the same or different and are a) H, b) C 3.6 cycloalkyl, c) phenyl, d) C w acyl, e) Cj. 8 alkyl optionally substituted with OH, C j 6 alkoxy which can be substituted with OH, a 5-, or 6-membered aromatic heterocyclic moiety having one to three atoms selected from the group consisting of
  • V is a) O, b) CH , or c) NR 87 ;
  • R 83 and R 84 at each occurrence are the same or different and are a) H, or b) C,. 4 alkyl;
  • R 85 is a) OH, b) C M alkoxy, or
  • R 88 and R 89 at each occurrence are the same or different and are a) H, b) C ⁇ . 5 alkyl c) C . 6 cycloalky, or d) phenyl;
  • R 90 is a) C l _ s alkyl optionally substituted with C ⁇ g alkoxy or C ⁇ _ 6 hydroxy,
  • C 3 . 6 cycloalkyl a 6-membered aromatic optionally benzo-fused heterocyclic moiety having one to three nitrogen atoms, which can in turn be substituted with one or two -N0 , CF 3 , halo, -CN, OH, C ⁇ alkyl, C,. 5 alkoxy, or C 1 5 acyl;
  • Rg 2 and R y ! at each occurrence are the same or different and are a) H, b) phenyl, c) C,. 6 alkyl, or d) benzyl;
  • R g7 is co- a) morpholinyl, b) OH, or c) C,. 6 alkoxy; h is 1, 2, or 3; i is 0, 1, or 2; j is 0 or 1; k is 3, 4, or 5;
  • the new compounds of the invention can be prepared using known compounds and intermediates of oxzolidinones, isoxazolines and butyolactones as intermediates and synthetic methods known in the art.
  • Thioamides of the invention can typically be prepared by the reaction of the corresponding amide with Lawesson's reagent.
  • the carbon content of various hydrocarbon containing moieties is indicated by a prefix designating the minimum and maximum number of carbon atoms in the moiety, 1 e
  • the prefix C, j defines the number of carbon atoms present from the integer "1" to the integer "j", inclusive
  • C 1 4 alkyl refers to alkyl of 1-4 carbon atoms, inclusive, or methyl, ethyl, propyl, butyl and lsomenc forms thereof
  • C, _, alkyl refers to an alkyl group having one to two, one to three, one to four, one to five, one to six, one to eight, or one to sixteen carbon atoms respectively such as, for example, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl and their lsomenc forms thereof
  • C 2 4 alkenyl refers at least one double bond alkenyl group
  • C 2 _ alkynyl refers to at least one triple bond alkynyl group having two to five, two to eight, or two to ten carbon atoms respectively such as, for example, ethynyl, propynyl, butynyl, pentynyl, pentdiynyl, hexynyl, hexdiynyl, heptynyl, heptdiynyl, octynyl, octdiynyl, octatnynyl, nonynyl, nonediynyl, nonat ⁇ ynyl and their lsomenc forms thereof
  • C J 4 cycloalkyl refers to a cycloalkyl having three to four, three to six, five to six, or three to eight carbon atoms respectively such as, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and their lsomenc forms thereof
  • C, , alkoxy refers to an alkyl group having one to four, one to six, or one to eight carbon atoms respectively attached to an oxygen atom such as, for example, methoxy, ethoxy, propyloxy, butyloxy, pentyloxy, hexyloxy, heptyloxy, or octyloxy and their isomeric forms thereof.
  • C I 6 alkylamino and "C, .8 alkylamino” refer to an alkyl group having one to six, or one to eight carbon atoms respectively attached to an amino moiety such as, for example, methylamino, ethylamino, propylamino, butylamino, pentylamino, hexylamino, heptylamino, or octoylamino and their isomeric forms thereof.
  • dialkylamino refer to two alkyl groups having one to six, or one to eight carbon atoms respectively attached to an amino moiety such as, for example, dimethylamino, methylethylamino, diethylamino, dipropylamino, methypropylamino, ethylpropylamino, dibutylamino, dipentylamino, dihexylamino, methylhecylamino, diheptylamino, or dioctoylamino and their isomeric forms thereof.
  • C,. 3 acyl "C M acyl", “C ⁇ acyl", "C,. 6 acyl", “C,. 8 acyl"
  • C 2.8 acyl refer to a carbonyl group having an alkyl group of one to three, one to four, one to five, one to six, one to eight, or two to eight carbon atoms.
  • alkoxycarbonyl refer to an ester group having an alkyl group of one to four, one to six, or one to eight carbon atoms.
  • C ⁇ alkyl phenyl refers to an alkyl group having one to eight carbon atoms and isomeric forms thereof which is substituted with at least one phenyl radical.
  • C 2 8 alkenyl phenyl refers to a at least one double bond alkenyl group having one to eight carbon atoms and isomeric forms thereof which is substituted with at least one phenyl radical.
  • C [.8 alkyl pyridyl” refers to an alkyl group having one to eight carbon atoms and isomeric forms thereof which is substituted with at least one pyridyl radical.
  • C,. 8 hydroxyl refers to an alkyl group having one to eight carbon atoms and isomeric forms thereof attached to a hydroxy group.
  • C,. 8 alkylsulfonyl refers to an alkyl group having one to eight carbon atoms and isomeric forms thereof attached to a S0 moiety.
  • C 1 6 alkylthio refers to an alkyl group having one to six carbon atoms and isomeric forms thereof attached to a sulfur atom.
  • Het refers to 5 to 10 membered saturated, unsaturated or aromatic heterocyclic rings containing one or more oxygen, nitrogen, and sulfur forming such groups as, for example, pyridine, thiophene, furan, pyrazoline, pyrimi- dine, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 3- pyridazinyl, 4-pyridazinyl, 3-pyrazinyl, 2-quinolyl, 3-quinolyl, 1-isoquinolyl, 3- isoquinolyl, 4-isoquinolyl, 2-quinazolinyl, 4-quinazolinyl, 2-quinoxalinyl, 1- phthalazinyl, 4-oxo-2-imidazolyl, 2-imidazolyl, 4-imidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 3-
  • halo refers to fluoro, chloro, bromo, or iodo.
  • the compounds of the present invention can be converted to their salts, where appropriate, according to conventional methods.
  • pharmaceutically acceptable salts refers to acid addition salts useful for administering the compounds of this invention and include hydrochloride, hydrobromide, hydroiodide, sulfate, phosphate, acetate, propionate, lactate, mesylate, maleate, malate, succinate, tartrate, citric acid, 2-hydroxyethyl sulfonate, fumarate and the like. These salts may be in hydrated form.
  • the dotted line in the heterocyclic ring means that this bond can be either single or double. In the case where the dotted line is a double bond, the R 39 group will not be present.
  • the compounds of Formula I of this invention contain a chiral center at C5 of the isoxazoline ring, and as such there exist two enantiomers or a racemic mixture of both. This invention relates to both the enantiomers, as well as mixtures containing both the isomers. In addition, depending on substituents, additional chiral centers and other isomeric forms may be present in any of A or R : group, and this invention embraces all possible stereoisomers and geometric forms in these groups.
  • the compounds of this invention are useful for treatment of microbial infections in humans and other warm blooded animals, under both parenteral and oral administration.
  • compositions of this invention may be prepared by combining the compounds of this invention with a solid or liquid pharmaceutically acceptable carrier and, optionally, with pharmaceutically acceptable adjuvants and excipients employing standard and conventional techniques.
  • Solid form composi- tions include powders, tablets, dispersible granules, capsules, cachets and suppositories.
  • a solid carrier can be at least one substance which may also function as a diluent, flavoring agent, solubilizer, lubricant, suspending agent, binder, tablet disintegrating agent, and encapsulating agent.
  • Inert solid carriers include magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, cellulosic materials, low melting wax, cocoa butter, and the like.
  • Liquid form compositions include solutions, suspensions and emulsions.
  • solutions of the compounds of this invention dissolved in water and water-propylene glycol and water-polyethylene glycol systems, optionally containing suitable conventional coloring agents, flavoring agents, stabilizers and thickening agents.
  • the pharmaceutical composition is provided employing conventional techniques in unit dosage form containing effective or appropriate amounts of the active component, that is, the compound according to this invention.
  • the quantity of active component, that is the compound according to this invention, in the pharmaceutical composition and unit dosage form thereof may be varied or adjusted widely depending upon the particular application, the potency of the particular compound, the desired concentration. Generally, the quantity of active component will range between 0.5% to 90% by weight of the composition.
  • the compounds or pharmaceutical compositions thereof will be administered orally, parenterally and/or topically at a dosage to obtain and maintain a concentration, that is, an amount, or blood-level of active component in the animal undergoing treatment which will be antibacterially effective.
  • a concentration that is, an amount, or blood-level of active component in the animal undergoing treatment which will be antibacterially effective.
  • such antibacterially effective amount of dosage of active component will be in the range of about OJ to about 100, more preferably about 3.0 to about 50 mg/kg of body weight/day. It is to be understood that the dosages may vary depending upon the requirements of the patient, the severity of the bacterial infection being treated, and the particular compound being used.
  • the initial dosage administered may be increased beyond the above upper level in order to rapidly achieve the desired blood-level or the initial dosage may be smaller than the optimum and the daily dosage may be progressively increased during the course of treatment depending on the particular situation. If desired, the daily dose may also be divided into multiple doses for administration, e.g., 2-4 four times per day.
  • compositions for parenteral administration will generally contain a pharmaceutically acceptable amount of the compound or a soluble salt (acid addition salt or base salt) dissolved in a pharmaceutically acceptable liquid carrier such as, for example, water-for-injection and a buffer to provide a suitably buffered isotonic solution, for example, having a pH of about 3.5-6.
  • a pharmaceutically acceptable liquid carrier such as, for example, water-for-injection
  • a buffer to provide a suitably buffered isotonic solution, for example, having a pH of about 3.5-6.
  • Suitable buffering agents include, for example, trisodium orthophosphate, sodium bicarbonate, sodium citrate, N-methylglucamine, L(+)-lysine and L(+)-arginine to name but a few representative buffering agents.
  • the compound of this invention generally will be dissolved in the carrier in an amount sufficient to provide a pharmaceutically acceptable injectable concentration in the range of about 1 mg/mL to about 400 mg/mL of solution.
  • the resulting liquid pharmaceutical composition will be administered so as to obtain the above-mentioned antibacterially effective amount of dosage.
  • the compounds according to this invention are advantageously administered orally in solid and liquid dosage forms.
  • Formula I As a topical treatment an effective amount of Formula I is admixed in a pharmaceutically acceptable gel or cream vehicle that can be applied to the patient's skin at the area of treatment. Preparation of such creams and gels is well known in the art and can include penetration enhancers.
  • test compounds were determined by a standard agar dilution method.
  • a stock drug solution of each analog is prepared in the preferred solvent, usually DMSO:H,0 (1:3).
  • Serial 2-fold dilutions of each sample are made using 1.0 ml aliquots of sterile distilled water.
  • To each 1.0 ml aliquot of drug is added 9 ml of molten Mueller Hinton agar medium.
  • the drug-supplemented agar is mixed, poured into 15 x 100 mm petri dishes, and allowed to solidify and dry prior to inoculation. Vials of each of the test organisms are maintained frozen in the vapor phase of a liquid nitrogen freezer. Test cultures are grown overnight at 35°C on the medium appropriate for the organism.
  • Colonies are harvested with a sterile swab, and cell suspensions are prepared in Trypticase Soy broth (TSB) to equal the turbidity of a 0.5 McFarland standard. A 1:20 dilution of each suspension is made in TSB.
  • the plates containing the drug supplemented agar are inoculated with a 0.001 ml drop of the cell suspension using a Steers replicator, yielding approximately 10 4 to 10 5 cells per spot. The plates are incubated overnight at 35°C.
  • SEPI S. epidermidia
  • SEPI 30593 S. epidermidis
  • SPNE 9912 S. pneumoniae
  • SPYO 152 S. pyogenes
  • HINF 30063 Haemophilus influenzae
  • the intermediates II for the compounds of this invention are also intermediates disclosed in the oxazolidinone patents and published applications hereinabove incorporated by reference.
  • the intermediates IV for this invention are final products (Examples) from the oxazolidinone patents and published applications hereinabove incorporated by reference.
  • the isothiocyanates III can be conveniently prepared by allowing the amine intermediates (II) to react with lJ'-thiocarbonyldi-2(lH)-pyridone in solvents such as methylene chloride at 0 to 25°C.
  • Step 4 as illustrated in Example 4.
  • This reaction is carried out in aqueous-alcoholic solvents at 0-50°C in the presence of an equivalent of an alkali metal hydroxide.
  • This reaction especially when R"' is methyl or ethyl, can be catalyzed by an alkali metal fluoride.
  • the thioamides (lb, R" - H, alkyl,_ 4 ) can also be conveniently prepared (Step 5) by allowing the appropriate amide intermediates (IV) to react with reagents such as 2,4-bis(p-methoxyphenyl)-l,3-dithiadiphosphetane-2,4-disulfide (Lawesson's Reagent) in 1,4-dioxane, benzene, toluene or tetrahydrofuran at 60- 110°C; phosphorus decasulfide and sodium carbonate in tetrahydrofuran at 20-50°C [Brillon, D., Synthetic Communications, 20, 3085 ( 1990)] or phosphorus decasulfide and sodium fluoride in 1,2-dimethoxyethane at 20-50°C [Hartke, K., Gerber, H.-D
  • Compounds Ic are prepared (Step 6) by allowing II to react first with carbon disulfide and a tertiary amine base such as triethylamine in solvent mixtures containing water and methanol, ethanol or isopropanol at 10-50°C for 5-24 hours.
  • the resulting intermediate is treated with an alkylating agent (R"" X where X represents bromo. iodo, alkylsulfonyloxy or arylsulfonyloxy) at 0-30°C to give compounds Ic.
  • R"" X where X represents bromo. iodo, alkylsulfonyloxy or arylsulfonyloxy
  • compounds Ic are allowed to react with alkali metal alkoxide such as sodium methoxide or potassium ethoxide in the corresponding alkanol as solvent. This reaction is conveniently carried out at the reflux temperature of the alkanol for 1-24 hr.
  • Example 1 for the preparation of 1, 21 (PCT/US97/01970) was allowed to react with Lawesson's Reagent in refluxing dioxane to give 2: mp 222-223 °C; HRMS theory for C 19 H 24 FN fi O,S, (M+HJ: 451.1386; found 451.1381.
  • STEP B (S)-N-[[3-[3-Fluoro-4-[2',5'-dioxospiro[piperidine-4,4'Jmidazolidine]- l-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl] thioacetamide (3).
  • Step 1 A mixture of (S)J-)-N-[[3-[3-fluoro-4-(3,6-dihydro-2H-thiopyran-4- yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide S-oxide (4.50 g, can be obtained according to the procedures disclosed in International Publication No. WO 97/09328) and platinum oxide (697 mg) in methanol (164 mL) is shaken on the Parr apparatus under a hydrogen atmosphere at 40 psi for 18 hours.
  • the catalyst is then removed by filtration through Celite, and the filtrate is concentrated under reduced pressure and the residue chromatographed on silica gel (230 - 400 mesh, 350 g), eluting with a gradient of methanol/methylene chloride (3/97 - 7/93).
  • Step 2 A mixture of the compound prepared in Step 1 (2.50 g) and hydroxylamine hydrochloride (2.36 g) in pyridine (30.6 mL) and ethanol (3.4 mL) is stirred in a screw-cap vial at 100°C for 22 hrs and at ambient temperature for 16 hrs, during which additional hydroxylamine hydrochloride (944 mg) and pyridine (4 mL) is added.
  • the reaction mixture is then concentrated under reduced pressure, diluted with saturated aqueous sodium bicarbonate (100 mL) and saline (50 mL), adjusted to pH 11 with solid sodium carbonate and extracted with methanol methylene chloride (10/90, 5 x 100 mL).
  • Step 3 A solution of ethyl dithioacetate (105 mL, 0.919 mmol) and sodium fluoride (39 mg, 0.919 mmol) in ethanol (9.2 mL) under a nitrogen atmosphere was treated with a mixture of (S)-cis-3-[3-fluoro-4-(tetrahydro-l-oxido-2H-thiopy ⁇ an-4- yl)phenyl]-5-aminomethyl-2-oxazolidinone, as prepared in Step 2,(300 mg, 0.919 mmol) and aqueous potassium hydroxide (IM, 0.92 mL) in ethanol (46 mL).
  • IM aqueous potassium hydroxide
  • Step 1 A solution of l,r-thiocarbonyldi-2(lH)-pyridone (235 mg, 1.01 mmol) in anhydrous methylene chloride (10 mL) at 0°C under a nitrogen atmosphere was treated with a solution of (S)-cis-3-[3-fluoro-4-(tetrahydro-l-oxido- 2H-thiopyran-4-yl)phenyl]-5-aminomethyl-2-oxazolidinone, as prepared in Example 7, Step 2, (275 mg, 0.843 mmol) in anhydrous methylene chloride (34 mL) over 30 minutes.
  • the resulting mixture was stirred at 0°C for 30 minutes and at ambient temperature for 1 hour and was then diluted with methylene chloride (40 mL), washed with water (25 mL) and brine (25 mL), dried over anhydrous sodium sulfate and concentrated in ⁇ acuo.
  • Step 2 A solution of (S)-cis-3-[3-fluoro-4-(tetrahydro-l-oxido-2H-thiopyran-4- yl)phenyl]-5-isothiocyanatomethyl-2-oxazolidinone (Step 1, 290 mg, 0.787 mmol) in anhydrous tetrahydrofuran (39 mL) at 0°C under a nitrogen atmosphere was treated (bubbled) with a stream of ammonia gas for 5 minutes. The reaction pot was sealed, and the resulting mixture was stirred at 0°C for 1 hour. The excess ammonia was then removed under a stream of nitrogen, and the reaction mixture was concentrated in ⁇ acuo to give the crude product. Recrystallization from methanol methylene chloride/diethyl ether gave the title compound, mp 206 - 208°C (dec).
  • Step 1 (S)-(-)-N-[[3-[3-fluoro-4-(3,6-dihydro-2H-thiopyran-4-yl)phenyl]-2-oxo- 5-ox azolidinyl] methyl] acetamide
  • S-oxide (disclosed in International Publication No. WO 97/09328) may be reduced to the corresponding cis- and trans-sulfoxides by catalytic hydrogenation in the presence of a catalyst and solvent.
  • the sulfide by product of this reduction reaction can be oxidized with an oxidizing agent such NaIO 4 or meta-chloroperoxybenzoic acid in solvent to provide the cis- and trans-sulfoxides.
  • the sulfide byproduct acn be oxidized selectively to the trans isomer using t-butyl hydroperoxide and a catalyst such as Ti(OiPr)4 and D-diisopropyl tartrate in a suitable solvent.
  • the isomeric mixture can then be separated by chromatography to isolate the trans-sulfoxide, mp 211 - 212°C (dec).
  • reaction mixture is then concentrated under reduced pressure, diluted with saturated aqueous sodium carbonate (50 mL) and saline (50 mL) and extracted with methanol/methylene chloride ( 10/90, 6 x 100 mL).
  • the combined organic phase is concentrated under reduced pressure, and the crude product is chromatographed on silica gel (230 - 400 mesh, 45 g), eluting with a gradient of methanol/methylene chloride (7.5/92.5 - 10/90).
  • Step 2 A solution of ethyl dithioacetate (105 mL, 0.919 mmol) and sodium fluoride (39 mg, 0.919 mmol) in ethanol (9.2 mL) under a nitrogen atmosphere was treated with a mixture of (S)-trans-3-[3-fluoro-4-(tetrahydro-l-oxido-2H-thiopyran-4- yl)phenyl]-5-aminomethyl-2-oxazolidinone, as prepare in Step 1, (300 mg, 0.919 mmol) and aqueous potassium hydroxide (IM, 0.92 mL) in ethanol (46 mL).
  • IM aqueous potassium hydroxide
  • Step 1 A solution of lJ'-thiocarbonyldi-2(lH)-pyridone (192 mg,
  • the resulting mixture was stirred at 0°C for 30 minutes and at ambient temperature for 40 minutes and was then diluted with methylene chloride (20 mL), washed with water ( 15 mL) and brine ( 15 mL), dried over anhydrous sodium sulfate and concentrated in ⁇ acuo.
  • Step 2 A solution of (S)-trans-3-[3-fluoro-4-(tetrahydro-l-oxido-2H- thiopyran-4-yl)phenyl]-5-isothiocyanatomethyl-2-oxazolidinone (Step 1, 230 mg, 0.624 mmol) in anhydrous tetrahydrofuran (31.2 mL) at 0°C under a nitrogen atmosphere was treated (bubbled) with a stream of ammonia gas for 5 minutes. The reaction pot was sealed, and the resulting mixture was stirred at 0°C for 1 hour. The excess ammonia was then removed under a stream of nitrogen, and the reaction mixture was concentrated in ⁇ acuo to give the crude product. Trituration with methanol/methylene chloride/diethyl ether gave the title compound, mp 209 - 210°C (dec).
  • Step 1 Starting with (S)-cis-(-)-N-[[3-[3-Fluoro-4-(tetrahydro-l-oxido-
  • Step 2 A solution of ethyl dithioacetate (100 mL, 0.876 mmol) and sodium fluoride (37 mg, 0.876 mmol) in ethanol (8.8 mL) under a nitrogen atmosphere was treated with a mixture of (S)-(-)-3-[3-fluoro-4-(tetrahydro-lJ-dioxido-2H-thiopyran-4- yl)phenyl]-5-aminomethyl-2-oxazolidinone, as prepared in Step 1, (300 mg, 0.876 mmol) and aqueous potassium hydroxide (IM, 0.88 mL) in ethanol (43.8 mL).
  • IM aqueous potassium hydroxide
  • Step 1 A solution of l,l'-thiocarbonyldi-2(lH)-pyridone (304 mg, 1.31 mmol) in anhydrous methylene chloride (13 mL) at 0°C under a nitrogen atmosphere was treated with a solution of (S)-(-)-3-[3-fluoro-4-(tetrahydro-lJ-dioxido-2H-thiopyran-4- yl)phenyl]-5-aminomethyl-2-oxazolidinone, as prepared in Example 11, Step 1, (375 mg, 1.09 mmol) in anhydrous methylene chloride (88 mL) over 30 minutes.
  • Step 2 A solution of (S)-3-[3-fluoro-4-(tetrahydro-lJ-dioxido-2H- thiopyran-4-yl)phenyl]-5-isothiocyanatomethyl-2-oxazolidinone (Step 1, 380 mg, 0.988 mmol) in anhydrous tetrahydrofuran (49 mL) at 0°C under a nitrogen atmosphere was treated (bubbled) with a stream of ammonia gas for 5 minutes. The reaction pot was sealed, and the resulting mixture was stirred at 0°C for 1 hour. The excess ammonia was then removed under a stream of nitrogen, and the reaction mixture was concentrated in ⁇ acuo to give the crude product. Recrystallization from methanol methylene chloride/diethyl ether gave the title compound, mp 196 - 198°C (dec).
  • EXAMPLE 16 (S)-N-[[3-[3-Fluoro-4-(4-moropholinyl)phenyl]-2-oxo-5- oxazolidinyl]methyl]- ⁇ , ⁇ , ⁇ -trifluorothioacetamide (13).
  • 33 34 A stirred suspension of 33 (3.7 g, 0.011 mol) and triethylamine (3.5 mL, 0.025 mol) in THF ( 120 mL) was cooled, in an ice bath, under nitrogen, treated, dropwise during 2 min, with a solution of ethyl dithioacetate (1.47 mL, 0.0128 mol) in THF (2 mL) and kept at ambient temperature for 22 h.
  • EXAMPLE 28 (S)-N-[[3-[3-Fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5- oxazolidinyl]methyl]thio-acetamide, thiomorpholine S, S-dioxide (36).
  • Example 35 When in the procedure of Example 35 an appropriate amount of sodium ethoxide was substituted for sodium methoxide, the compound of Example 36 below in Table A was obtained.
  • the isopropylcarboxamide and the cyclopropylcarboxamide are obtained by following the procedure in Example 5 of U.S. Patent No. 5,688,792 only substituting isobutyric anhydride and cyclopropane carbonyl chloride respectively for acetic anhydride in step 7.
  • the acetamide is obtained as described in U.S. Patent No. 5,688,792 at Example 4.
  • step B an excess amount of dimethylamine in THF is substituted for anhydrous ammonia, the compound of Example 40 set forth below in Table A is obtained.
  • R" 37 (S)-N-[[3-[3-Fluoro-4-(4-mo ⁇ holinyD- R H.
  • R' CH(CH- 2 phenyl]-2-oxo-5-oxazohd ⁇ nyl]methyl]-2- methylpropanethioamide; mp 152- 153 °C (dec);
  • step 4 an appropriate amount of the amine listed below is reacted with the dithio compound listed below the respective compounds. Examples 41 to 61 of Table C are obtained.
  • Example 41 The amine utilized in Examples 41 to 53 is prepared as described in Example 27, step 3
  • the amine utilized in Examples 54 to 57 is prepared by the procedure of Example 27, steps 1 to 3 by substituting the appropriate (S)-N-[[3-[3.5-d ⁇ fluoro-4-(4-th ⁇ o- mo ⁇ hol ⁇ nyl)phenyl]-2-oxo-5-oxazohd ⁇ nyl]methanol for compound 62 in step 1 of Example 27
  • Example 27 The amine utilized in Examples 58 to 61 is prepared by the procedure of Example 27, steps 1 to 3 by substituting the appropriate (S)-N-[[3-[4-(4-th ⁇ omo ⁇ hohnyl)phenyl]-2- oxo-5-oxazol ⁇ d ⁇ nyl]methanol for compound 62 in Example 27. step 1
  • the appropriate oxazolidinyl methanol compound is obtained by following the procedure of Example 1 in U S Patent 5 688,792, steps 1 through 3 only substituting 4-fluoron ⁇ trobenzene for 3,4- difluoronitrobenzene in step 1 thereof
  • Example 62 to 64 is prepared as compound 37 in Example 29 from the amide. 65, which is prepared as described in Example 32 of U S Patent No 5,700,799
  • the amine utilized in Examples 65 to 67 is prepared by the general procedure of Example 29 from the following amide, the preparation of which is dec ⁇ bed in Example 3 of U S Patent 5.700,799
  • Example 71 to 74 The amine utilized in Examples 71 to 74 is prepared as described in Example 28 by substituting (S)-N-[[3-[3,5-d ⁇ fluoro-4-(4-th ⁇ omo ⁇ hol ⁇ nyl)phenyl]-2-oxo-5- oxazolidinyljmethanol for compound 62 in step 1 and lollowing the procedure of steps 1 and 2
  • the appropriate oxazolidinyl methanol compound is prepared by following the general procedure of Example 4 of U S Patent No 5,688,792, steps 1 through 4, only substituting thiomo ⁇ hohne tor mo ⁇ hohne in step 1 thereot
  • Example 75 to 78 The amine utilized in Examples 75 to 78 is prepared as described in Example 28, step 1, above by substituting (S)-N-[3-[4-(4-th ⁇ omo ⁇ hohnyl)phenyl]-2-oxo-5- oxazo dinyljmethanol for compound 62 in step 1
  • the appropriate oxazolidinyl methanol is obtained by following the procedure of Example 1 in U S Patent No 5,688.792, steps 1 through 3, only substituting 4-fluoron ⁇ trobenzene tor 3,4-d ⁇ fluoromtrobenzene in step 1 thereof
  • the amine utilized in Examples 79 to 91 is prepared as described in Example 1, step
  • EXAMPLE 1 12 (S)-N-[[3-[3-Fluoro-4-(4-th ⁇ omo ⁇ hohnyl)phenyl]-2-oxo-5- oxazohd ⁇ nylJmethyl]-O-ethylth ⁇ ocarbamate;
  • EXAMPLE 1 13 (S)-N-[[3-[3-Fluoro-4-(4-th ⁇ omo ⁇ hol ⁇ nyl)phenylJ-2-oxo-5- oxazohd ⁇ nyl]methyl]-O- ⁇ so-propylth ⁇ ocarbamate,
  • EXAMPLE 1 16 (S)-N-[[3-[3-Fluoro-4-(4-th ⁇ omo ⁇ hohnyl)phenyl]-2-oxo-5- oxazol ⁇ d ⁇ nyl]methylJ- l-azet ⁇ d ⁇ nec ⁇ rboth ⁇ oam ⁇ de, thiomo ⁇ holine S-oxide, Anal Calcd for C, 8 H 2 FN 4 O 3 S2, C, 50 69, H, 5 43, N, 13 14 Found C, 50 79, H, 5 45, N. 12 82, mp 213- 214°C
  • Example 137 and 138 are obtained
  • step 1 Following the procedure of Example 33, step 1, only substituting an appropriate amount of compound 37 from Example 29 step 5 tor compound 33 (5)-N- [[3,5-[3-difluoro-4-[4-(hydroxyacetyl)- l-piperazinyl]phenyl]-2-oxo-5-oxazolidinylJ- methyljisothiocyanate is obtained.
  • Part B Upon substitution of an appropriate amount of (S)-N-[[3-[3,5-difluoro-4-[4- (hydroxyacetyl)- l-piperazinylJphenylJ-2-oxo-5-oxazolidinyl]methylJisothiocyanate for compound 82 in the general procedure of Example 100, the title compound is obtained.
  • step 1 Following the procedure of Example 33, step 1, only substituting an appropriate amount of (S)-N-[[3-[4-[4-(hydroxyacetyl)- 1 -piperazinylJphenyl]-2-oxo-5- oxazolidinyljmethyljamine for compound 33, (S)-N-[[3-[4-[4-(hydroxyacetyl)-l- piperazinyl]phenylJ-2-oxo-5-oxazolidinyl]methyl]isothiocyanate is obtained.
  • Example 25 step 1), and triethylamine ( 15.4 mL, 1 10 mmol) in methylene chloride (2570 mL) is treated with /w-nitrobenzenesulfonyl chloride (18.8 g, 84.9 mmol) and kept, under nitrogen, at ambient temperature (24 °C) for 24 hours. Additional m-nitrobenzenesulfonyl chloride (1.88 g) and triethylamine (1.54 mL) are added and the mixture is kept for one additional day at ambient temperature, washed with water, saturated sodium bicarbonate and brine, dried (Na 2 SO 4 ) and concentrated to give an oily product, 85.
  • the alcohol, 58 is prepared according to the procedures of Brickner (J. Med. Chem. 1996, 39, 673-679), see compound 5a therein.
  • x and y are prepared according to the procedures of B ⁇ ckner (J Med Chem , 1996, 39, 673-679), by substituting an approp ⁇ ate amount of 2,6-d ⁇ fluoro-4-n ⁇ trobenzene (t ⁇ fluoromethane) sulfonate and 4-fluoron ⁇ trobenzene respectively for 3,4-d ⁇ fluoron ⁇ trobenzene in the preparation of 2a therein
  • the amine compound set forth below as P- 129 is obtained by refluxing tor 6 days a solution of compound 88 ( 1 00 g, 2 54 mmol), sultamide (305 mg, 3 18 mmol) and 1,2- dimethyoxyethane (6 mL)
  • the solid which precipitates is collected by filtration and chromatographed on silica gel with 5% methanol-methylene chloride Crystallization of the product from methanol-methylene chloride gives 0 551 g of the sulfamoyl derivative, which is used in step 6 of Example 141 to g ⁇ e P- 129
  • Preparations P- 130 and P- 131 respectively set forth below are obtained.
  • Preparation P- 138 The amine compound set forth below as Preparation P- 138 is obtained by combining compound 88 ( 1 J0 g, 2J5 mmol) set forth in step 5 of Example 141 with N- formylbenzotriazole (493 mg, 3J5 mmol) in THF (30 mL) and the mixture is kept at ambient temperature for 18 hours. The mixture is concentrated and the residue in methylene chloride is washed with IN sodium hydroxide and dilute sodium chloride, dried (MgS0 ).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present invention provides compounds of formula (1) or pharmaceutical acceptable salts thereof wherein, A, G and R1 are as defined in the claims which are antibacterial agents.

Description

OXAZOLIDINONE ANTIBACTERIAL AGENTS HAVING A THIOCARBONYL FUNCTIONALITY
BACKGROUND OF THE INVENTION
The present invention relates to new and useful oxazolidinone compounds and their preparations, and more particularly to oxazolidinone compounds in which the carbonyl functionality of -NH-C(O)-R is converted to a thiocarbonyl functionality, such as a thiourea -NH-C(S)-NH,, an alkyl thiourea -NH-C(S)-NH-(CM alkyl), thioamide -NH-C(S)-(CM alkyl) or -NH-C(S)-H.
Replacement of the oxygen atom with a sulfur atom has unexpectedly improved the antimicrobial properties of the compounds. The compounds are useful antimicrobial agents, effective against a number of human and veterinary pathogens, including Gram-positive aerobic bacteria such as multiply-resistant staphylococci and streptococci, Gram-negative organisms such as H. influenzae and M. catarrahlis as well as anaerobic organisms such as bacteroides and clostridia species, and acid-fast organisms such as Mycobacterium tuberculosis and Mycobacterium aυium. The compounds are particularly useful because they are effective against the latter organisms which are known to be responsible for infection in persons with AIDS.
SUMMAEY OF THE INVENTION
In one aspect the subject invention is a compound of the Formula I
I or pharmaceutical acceptable salts thereof wherein:
G is
Rj is a) H, b) NH2, 0 NH-C1 4 alkyl, d) CM alkyl, e) -OCM alkyl, f) -S CM alkyl, g) CM alkyl substituted with 1-3 F, 1-2 Cl, CN or -COOC1 4 alkyl, h) C3.6 cycloalkyl, i) N(CM alkyl)2 or j) N(CH2)2.5;
A is
d) a 5-membered heteroaromatic moiety having one to three atoms selected from the group consisting of S, N, and O, wherein the 5-membered heteroaromatic moiety is bonded via a carbon atom, wherein the 5-membered heteroaromatic moiety can additionally have a fused-on benzene or naphthyl ring, wherein the heteroaromatic moiety is optionally substituted with one to three R v4,8> e) a 6-membered heteroaromatic moiety having at least one nitrogen atom, wherein the heteroaromatic moiety is bonded via a carbon atom, wherein the 6-membered heteroaromatic moiety can additionally have a fused-on benzene or naphthyl ring, wherein the heteroaromatic moiety is optionally substituted with one to three R55, f) a β-carbolin-3-yl, or indolizinyl bonded via the 6-membered ring, optionally substituted with one to three R55,
wherein R2 is a) H, b) F,
0 Cl, d) Br, e) C^ alkyl, f) NO2, or g) R2 and R:! taken together are -0-(CH )h-O-;
R3 is a) -S(=O), R4, b) -S(=O)2-N=S(O)JR5R6, c) -SC(=O)R7, d) -C(=O)R8, e) -C(=O)R,, f) -C(=O)NRI0Ru, g) -C(=NR12)R8, h) -C(R8)(Rn)-OR13, i) -CCRgXRnJ-OR.a, j) -C(R8)(Ru)-OC(=O)R13, k) -C(R9)(RI1)-OC(=O)R13,
1) -NR10RU, m) -N(R10)-C(=O)R7, n) -N(R,0)-S(=O)iR7, o) -C(OR14)(OR15)R8, p) -C(R8)(R16)-NR10Rn, or q) Cj.8 alkyl substituted with one or more =0 other than at alpha position, -S(=O)iR17, -NR10Rn, C2.5 alkenyl, or C2.5 alkynyl; R4 is a) C].4 alkyl optionally substituted with one or more halos, OH, CN, NR10R„, or -CO2R13, b) C2.4 alkenyl,
0 -NR16R18, d) -N3, e) -NHC(=O)R7, f) -NR20C(=O)R7, g) -N(R19)2, h) -NRι6R19, or i) -NR19R20,
R5 and R6 at each occurrence are the same or different and are a) Cj.2 alkyl, or b) R5 and R6 taken together are -(CH2)k-;
I γ IS *■— ' 1.4 < ilkyl optionally substituted with one or more halos;
R8 is a) H, or b) C,.8 alkyl optionally substituted with one or more halos, or C3., cycloalkyl;
Rg is C].4 alkyl substituted with one or more a) -S(=O)R17, c) -OC(=O)R13, d) -NR10Rn, or e) C,.5 alkenyl optionally substituted with CHO;
RI0 and Rn at each occurrence are the same or different and are a) H, b) C[.4 alkyl, or c) C3.8 cycloalkyl; R12 is a) -NR10Rn, b) -OR10; or c) -NHC(=O)R10;
R13 is a) H, or b) CM alkyl;
R14 and Rlf i at each occurrence are the same or different and are a) C alkyl, or b) R14 and R15 taken together are -(CH)r; R16 is a) H, b) Cj.4 alkyl, or
0 C3.8 cycloalkyl;
R17 is a) CM alkyl, or b) C3.8 cycloalkyl;
R18 is a) H, b) C__4 alkyl, c) C2.4 alkenyl, d) C3.4 cycloalkyl, e) -OR13 or f) -NR21R22;
R19 is a) Cl, b) Br, or c) I;
R20 is a physiologically acceptable cation;
R21 and R2 at each occurrence are the same or different and are a) H, b) C,.4 alkyl, or c) -N ,,R22 taken together are -(CH2)m-; wherein R23 and R24 at each occurrence are the same or different and are a) H, b) F, c) Cl, d) C,.2 alkyl, e) CN f) OH, g) Ch2 alkoxy, h) nitro, or i) amino;
Q is
h)
j) JX
1)
m) a diazinyl group optionally substituted with X and Y, n) a triazinyl group optionally substituted with X and Y, o) a quinolinyl group optionally substituted with X and Y, p) a quinoxalinyl group optionally substituted with X and Y, q) a naphthyridinyl group optionally substituted with X and Y,
s)
u)
z) =fcN
N -N.
\
Q and R24 taken together are
wherein Z1 is a) -CH2-, b) -CH(R104)-CH2-, c) -C(O)-, or d) -CH,CH2CH,-;
wherein Z2 is a) -O2S-, b) -O-, c) -N(R107)-, d) -OS-, or e) -S-; wherein Z3 is a) -O2S-, b) -O-, c) -OS-, or d) -S-; wherein A1 is a) H-, or b) CH3; wherein A2 is a) H-, b) HO-, c) CH3-, d) CH3O-, e) R102O-CH2-C(O)-NH- f) R103O-C(O)-NH-, g) (CI-C2)alkyl-0-C(0)-, h) HO-CH2-, i) CH3O-NH-, j) (CrC3)alkyl-O2C- k) CH3-C(O)-,
1) CH3-C(O)-CH2-,
m) or o o
A1 and A2 taken together are: a)
>+
b) 0=: or
\
0
wherein R102 is a) H-, b) CH3-, c) phenyl-CH2-, or d) CH3C(O)-; wherein R103 is a) (Cj-C^alkyl-, or b) phenyl-; wherein R104 is a) H-, or b) HO-; wherein R105 is a) H-, b) (C1-C !)alkyl-, c) CH2 = CH-CH2-, or d) CH3-0-(CH2)2-; wherein R106 is a) CH3-C(O)-, b) H-C(O)-, c) C1.,CH-C(0)-, d) HOCH,-C(0)-, e) CH3S02-,
g) F CHC(O)-, h*) N^N-C(O)-
\=J i) H3C-C(O)-O-CH2-C(O)-, j) H-C(O)-O-CH2-C(O)-,
1) HC≡C-CH2O-CH -C(0)-, or m) phenyl-CH2-O-CH2-C(O)-; wherein R107 is a) R102O-C(Rno)(R )-C(O)-, b) R103O-C(O)-, c) R108-C(O)-,
f) H3C-C(O)-(CH2)2-C(O)-, g) R109-SO2-, o
h) <x^
1) HO-CH2-C(O)-, j) R116-(CH2)2-, k) R113-C(0)-0-CH2-C(O)-,
1) (CH3)2N-CH,-C(0)-NH-, m) NC-CH -, n) F2-CH-CH -, or o) R150R151NSO2 wherein R108 is a) H-, b) (C,-C4)alkyl,
0 aryl -(CH2)p, d) C1H2C-, e) C12HC-,
0 FH2C-, g) F2HC-, h) (C3-C6)cycloalkyl, or i) CNCH2-. wherein R109 is a) alkylC1-C4, b) -CH2C1
0 -CH2CH=CH2, d) aryl, or e) -CH2CN; wherein R110 and R111 are independently a) H-, b) CH3-; or wherein R112 is a) H-, b) CH3O-CH O-CH2-, or
0 HOCH2-; wherein R113 is a) CH3-, b) HOCH2-, c) (CH3) N-phenyl, or d) (CH ) N-CH -; wherein R114 is a) HO-, b) CH3O-, c) H2N-, d) CH:!0-C(0)-0-, e) CH3-C(0)-0-CH2-C(0)-0-, f) phenyl-CH -O-CH2-C(O)-0-, g) HO-(CH )2-O-, h) CH3O-CH,-0-(CH2) -0-, or i) CH3O-CH -0-;wherein R113 is a) CH3-, b) HOCH2-, c) (CH3)2N-phenyl, or d) (CH3)2N-CH2-; wherein R115 is a) H-, or b) C1-; wherein R116 is a) HO- b) CH3O-, or c) F; wherein R150 and R151 are each H or alkyl C,-C4 or R150 and R151 taken together with the nitrogen atom to which each is attached form a monocyclic heterocyclic ring having from 3 to 6 carbon atoms; B is an unsaturated 4-atom linker having one nitrogen and three carbons; M is a) H, b) C,.8 alkyl, c) C3.8 cycloalkyl, d) -(CH )mOR13, or e) -(CH2)h-NR21R22; is a) O, b) S, or c) NM;
W is a) CH, b) N, or c) S or O when Z is NM; Y is a) H, b) F, c) Cl, d) Br, e) C^ alkyl, or f) NO2;
X is a) H, b) -CN, c) OR,,, d) halo, e) NO2, f) tetrazoyl, g) -SH, h) -S(=O),R4, i) -S(=O)2-N=S(O)JR5R6, j) -SC(=O)R7, k) -C(=O)R25,
1) -C(=O)NR27R28, m) -C(=NR29)R25, n) -C(R25)(R 8)-OR13> o) -C(R25)(R28)-OC(=O)R13, p) -C(R28)(OR13)-(CH2)h-NR27R28, q) -NR27R28, r) -N(R27)C(=O)R7, s) -N(R27)-S(=O),R7, t) -C(ORl4)(OR15)R28, u) -C(R25)(R16)-NR27R26, or v) Cj.8 alkyl substituted with one or more halos, OH, =O other than at alpha position, -S(=O),R17, -NR27R28, C2 5 alkenyl, C2.5 alkynyl, or C3.8 cycloalkyl;
R4, R5, R6, R7, Rj j, R14, R,5, R16, and R17 are the same as defined above; R25 is a) H, b) CU8 alkyl optionally substituted with one or more halos, C3.8 cycloalkyl, C,.4 alkyl substituted with one or more of -S(=O),Rπ, -OR13, or OC(=0)RH, NR27R28, or c) C2.5 alkenyl optionally substituted with CHO, or CO2R13;
b) NR,7N28;
R 7 and R28 at each occurrence are the same or different and are a) H, b) C_.a alkyl, c) C3.8 cycloalkyl, d) -(CH2)mOR13, e) -(CH2)h-NR21R22, or f) R27 and R 8 taken together are -(CH2)2O(CH2)2-, JCH^CH CORM or -(CH2)2N(CH2)2(R7);
R 9 is a) -NR27R28, b) -OR^ or c) -NHC(=O)R28; wherein R30 is a) H, b) Cλ_a alkyl optionally substituted with one or more halos, or c) Cj.g alkyl optionally substituted with one or more OH, or Cx_6 alkoxy; wherein E is a) NR39, b) -S(=O)„ or c) O;
R38 is a) H, b) C..6 alkyl, c) -(CH )q-aryl, or d) halo;
R 9 is a) H, b) C^ alkyl optionally substituted with one or more OH, halo, or -CN, c) -(CH2)q-aryl, d) -CO2R40, e) -COR41, f) -C(=O)-(CH2)q-C(=O)R40, g) -S(=O)2-C,.6 alkyl, h) -S(=0)2-(CH2)q-aryl, or i) -(C=O) Het; R40 is a) H, b) C1 6 alkyl optionally substituted with one or more OH, halo, or -CN, c) -(CHJq-aryl, or d) -(CH2)q-OR42; R41 is a) C[.6 alkyl optionally substituted with one or more OH, halo, or -CN, b) -(CH )q-aryl, or c) -(CH2)q-OR42;
R 42 IS a) H, b) C,.g alkyl, c) -(CH2)q-aryl, or d) -C(=O)-C,.6 alkyl;
aryl is a) phenyl, b) pyridyl, or c) napthyl; a to c optionally substituted with one or more halo, -CN, OH, SH, Cj.6 alkyl, C^ alkoxy, or C1 6 alkylthio; wherein R43 is a) H, b) C^jj alkyl, c) F, or d) OH; R 4 is a) H, b) CF3, c) C1 3 alkyl optionally substituted with one or more halo, d) phenyl optionally substituted with one or more halo, e) R44 and R45 taken together are a 5-, 6-, or 7-membered ring of the formula, or
"Jx; o ( C H _ ) t
f) R44 and R45 taken together are -(CH2)k-, when R46 is an electron- withdrawing group; R45 and R46 at each occurrence are the same or different and are a) an electron-withdrawing group, b) H,
0 CF3, d) Cj.3 alkyl optionally substituted with one halo, e) phenyl, provided at least one of R45 or R46 is an electron-withdrawing group, or f) R45 and R46 taken together are a 5-, 6-, 7-membered ring of the formula
O
C 1 1 — C ^ ' \
( C H 2 ) r
U is a) CH2, b) O,
0 S, or d) NR47;
R47 is a) H, or b) C..5 alkyl; wherein R48 is a) carboxyl, b) halo,
0 -CN, d) mercapto, e) formyl, ) CF3, g) -NO2, h) C,.6 alkoxy, i) alkoxycarbonyl, j) alkythio, k) C 6 acyl, 1) -NR49 R50) m) Mg alkyl optionally substituted with OH, C1 5 alkoxy, Ch5 acyl, or
-NR49R50, n) C2.8 alkenylphenyl optionally substituted with one or two R51, o) phenyl optionally substituted with one or two R51, p) a 5-, or 6-membered (un)saturated heterocyclic moiety having one to three atoms selected from the group consisting of S, N, and O, optionally substituted with one or two R51, or
R49 and R50 at each occurrence are the same or different and are a) H, b) C,.„ alkyl, c) C5.6 cycloalkyl, or d) R49 and R50 taken together with the nitrogen atom is a 5-, 6- membered saturated heterocyclic moiety which optionally has a further hetero atom selected from the group consisting of S, N, and O, and can in turn be optionally substituted with, including on the further nitrogen atom, C1 alkyl, or C^ acyl;
R51 is a) carboxyl, b) halo, c) -CN, d) mercapto, e) formyl, f) CF3, g) -NO , h) alkoxy, i) Ci.6 alkoxycarbonyl,
J) C,.6 alkythio, k) Cι-6 acyl, 1) C,.6 alkyl optionally substituted with OH, C__5 alkoxy, Cj.5 acyl, or
-NR49R50, m) phenyl, n) -C(=O)NR52 R53, o) -NR49R50, p) -N(R52)(-SO2R54), q) -SO2-NR52R53, or r) -S(=O)iR54;
R52 and R53 at each occurrence are the same or different and are a) H, b) C,.6 alkyl, or c) phenyl;
R 5, 4 IS a) Cj.4 alkyl, or b) phenyl optionally substituted with C__4 alkyl; wherein R55 is a) carboxyl, b) halo, c) -CN, d) mercapto, e) formyl, ) CF3, g) -NO2, h) C^ alkoxy, i) Cj.6 alkoxycarbonyl, j) C,.6 alkythio k) Cj.g acyl,
1) -NR56 R57, m) C,.6 alkyl optionally substituted with OH, C^ alkoxy, C S acyl, or -NR56R57, n) C2.8 alkenylphenyl optionally substituted with one or two R58, o) phenyl optionally substituted with one or two R58, p) a 5- or 6-membered (un)saturated heterocyclic moiety having one to three atoms selected from the group consisting of S, N, and O, optionally substituted with one or two R58, or
R56 and R57 at each occurrence are the same or different and are a) H, b) formyl, c) CM alkyl, d) C ι.4 acyl, e) phenyl, ) C3.6 cycloalkyl, or g) R56 and R57 taken membered saturated heterocyclic moiety which optionally has a further hetero atom selected from the group consisting of S, N, and O, and can in turn be optionally substituted with, including on the further nitrogen atom, phenyl, pyrimidyl, C,.3 alkyl, or C^ acyl;
R58 is a) carboxyl, b) halo, c) -CN, d) mercapto, e) formyl, f) CF3, g) -NO2, h) C__6 alkoxy, i) Cj.6 alkoxycarbonyl, j) Cj.g alkythio, k) C1 6 acyl,
1) phenyl, m) Cj.g alkyl optionally substituted with OH, azido, C_ .5 alkoxy, CH acyl, -NR65Rg6, -SR67, -0-SO R68, or
R69— \ /— NH-CO-O-
o) -NR56R57, p) -N(R59X-SO,R54), q) -SO2-NR59R60,
D -S(=O)iR54, s) -CH=N-R61, or t) -CH(OH)-SO3R64; R54 is the same as defined above;
R59 and R60 at each occurrence are the same or different and are a) H, b) alkyl, c) phenyl, or d) tolyl;
R61 is a) OH, b) benzyloxy, c) -NH-C(=O)-NH2, d) -NH-C(=S)-NH2, or e) -NH-C(=NH)-NR62R63;
R62 and R63 at each occurrence are the same or different and are a) H, or b) C1 4 alkyl optionally substituted with phenyl or pyridyl; R64 is a) H, or b) a sodium ion;
R65 and R66 at each occurrence are the same or different and are a) H, b) formyl, c) CM alkyl, d) C,.4 acyl, e) phenyl, f) C .6 cycloalkyl, g) R65 and R66 taken together are a 5-, 6-membered saturated heterocyclic moiety having one to three atoms selected from the group consisting of S, N, and O, optionally substituted with, including on the nitrogen atom, phenyl, pyrimidyl, C1 3 alkyl, or C i acyl, h) -P(OXOR70XOR7]), or i) -SO^R,,,; R67 is
N — N " \' N — N
N .. N (CH,)3C-
C H
R68 is Ci.3 alkyl; R69 is a) alkoxycarbonyl, or b) carboxyl;
Kj0 and R71 at each occurrence are the same or different and are a) H, or b) CV3 alkyl;
R^is a) methyl, b) phenyl, or c) tolyl; wherein K is a) O, or b) S;
■^73' -^74' ^75: , R76, and R77 at each occurrence are the same or different and are a) H, b) carboxyl,
0 halo, d) -CN, e) mercapto, f) formyl, g) CF-, h) -NO2, i) alkoxy, j) Cj.g alkoxycarbonyl, k) Cj.5 alkythio, 1) C,.6 acyl, m) -J\ 78 79, n) C,.g aallkkyyll ooppttiioonnaallllyy substituted with OH, C^ alkoxy, C,.5 acyl, -NR78R79, -N(phenyl)(CH2-CH2-OH), -O-CH(CH3)(OCH2CH3), or -O-phenyl- [para-NHC(=O)CH3] , o) C2.8 alkenylphenyl optionally substituted with R51, p) phenyl optionally substituted with R5I, or q) a 5-, or 6-membered (un)saturated heterocyclic moiety having one to three atoms selected from the group consisting of S, N, and O, optionally substituted with R51; R51 is the same as defined above;
R/g and R-9 at each occurrence are the same or different and are a) H, b) CM alkyl, c) phenyl, or d) Rγg and R79 taken together with the nitrogen atom is a 5-, 6- membered saturated heterocyclic moiety which optionally has a further hetero atom selected from the group consisting of S, N, and O, and can in turn be optionally substituted with, including on the further nitrogen atom, Cw alkyl, or Cj_3 acyl; wherein T is a) O, b) S, or 0 SO2;
Rγs, R76, and R77 are the same as defined above; R80 is a) H, b) formyl, c) carboxyl, d) Ci_6 alkoxycarbonyl, e) C,.8 alkyl, f) C2.8 alkenyl, wherein the substituents (e) and (f) can be optionally substituted with OH, halo, C: 6 alkoxy, C_ 6 acyl, Cx 6 alkylthio or Ct 6 alkoxycarbonyl, or phenyl optionally substituted with halo, g) an aromatic moiety having 6 to 10 carbon atoms optionally substituted with carboxyl, halo, -CN, formyl, CF3, -NO2, C1 6 alkyl, C1 6 alkoxy,
C, g acyl, C] 6 alkylthio, or C1 6 alkoxycarbonyl; h) -NR81R82, i) -OR90, j) -S(=O),-R91, k) -SO2-N(R92)(R93), or
1) a radical of the following formulas:
R81 and R82 at each occurrence are the same or different and are a) H, b) C3.6 cycloalkyl, c) phenyl, d) Cw acyl, e) Cj.8 alkyl optionally substituted with OH, Cj 6 alkoxy which can be substituted with OH, a 5-, or 6-membered aromatic heterocyclic moiety having one to three atoms selected from the group consisting of
S, N, and O, phenyl optionally substituted with OH, CF3, halo, -NO2, M4 alkoxy, -NR83R84, or
V is a) O, b) CH , or c) NR87;
R83 and R84 at each occurrence are the same or different and are a) H, or b) C,.4 alkyl;
R85 is a) OH, b) CM alkoxy, or
0 -NK88 89;
R86 is a) H, or b) C, 7 aallkkyyll ooppttiiconally substituted with indolyl, OH, mercaptyl, imidazoly, methylthio, amino, phenyl optionally substituted with OH, -C(=O)-NH,, -CO,H, or -C(=NH)-NH ;
a) H, b) phenyl, or
0 alkyl optionally substituted by OH;
R88 and R89 at each occurrence are the same or different and are a) H, b) Cχ.5 alkyl c) C .6 cycloalky, or d) phenyl;
R90 is a) Cl_s alkyl optionally substituted with C^g alkoxy or Cλ_6 hydroxy,
C3.6 cycloalkyl, a 6-membered aromatic optionally benzo-fused heterocyclic moiety having one to three nitrogen atoms, which can in turn be substituted with one or two -N0 , CF3, halo, -CN, OH, C^ alkyl, C,.5 alkoxy, or C1 5 acyl;
b) ^~Λ v' 7N-(CH2)t-
c) phenyl, or d) pyridyl; a) C, ig alkyl, b) C ig alkenyl, wherein the substituents (a) and (b) can be optionally substituted with Cj.g alkoxycarbonyl, or a 5-, 6-, 7-membered aromatic heterocyclic moiety having one to three atoms selected from the group consisting of S, N, and O, c) an aromatic moiety having 6 to 10 carbon atoms, or d) a 5-, 6-, 7-membered aromatic heterocyclic moiety having one to three atoms selected from the group consisting of S, N, and O, wherein the substituents (c) and (d) can be optionally substituted with carboxyl, halo, -CN, formyl, CF,, -NO2, C,.6 alkyl, C,.6 alkoxy, C,.6 acyl, C, R alkylthio, or alkoxycarbonyl; Rg2 and Ry ! at each occurrence are the same or different and are a) H, b) phenyl, c) C,.6 alkyl, or d) benzyl;
Rg4 and RO5 at each occurrence are the same or different and are a) H, b) OH, c) C,.6 alkyl optionally substituted with -NR83 R84, or d) R94 and R)5 taken together are =0;
a) an aromatic moiety having 6 to 10 carbon atoms, b) a 5-, or 6-membered aromatic optionally benzo-fused heterocyclic moiety having one to three atoms selected from the group consisting of S, N, and O, wherein the substituents (a) and (b) which can in turn be substituted with one or three -NO2, CF„ halo, -CN, OH, phenyl, C, 3 alkyl, C,.5 alkoxy, or C1 5 acyl, c) morpholinyl, d) OH, e) C, g alkoxy, f) -NR83R84, g) -C(=O)-R.,7, or h)
Rg7 is co- a) morpholinyl, b) OH, or c) C,.6 alkoxy; h is 1, 2, or 3; i is 0, 1, or 2; j is 0 or 1; k is 3, 4, or 5;
1 is 2 or 3; m is 4 or 5; n is 0, 1, 2, 3, 4, or 5; p is 0, 1, 2, 3, 4, or 5; with the proviso that n and p together are 1, 2, 3, 4, or 5; q is 1, 2, 3, or 4; r is 2, 3, or 4; t is 0, 1, 2, 3, 4, 5, or 6; u is 1 or 2; w is 0, 1, 2, or 3.
DETAILED DESCRIPTION OF THE INVENTION
The new compounds of the invention can be prepared using known compounds and intermediates of oxzolidinones, isoxazolines and butyolactones as intermediates and synthetic methods known in the art. Thioamides of the invention can typically be prepared by the reaction of the corresponding amide with Lawesson's reagent.
Compounds disclosed in the following publications are suitable intermediates for preparation of the compounds of this invention and are hereby incorporated by reference for their disclosure of suitable compounds that can be converted to the subject thiocarbonyl derivatives.
U.S. Patents 5,225,565; 5,182,403; 5,164,510; 5,247,090; 5,231,188; 5,565,571; 5,547,950; and 5,523,403.
PCT Application and publications PCT US93/04850, WO94/01110; PCT/US94/08904, WO95/07271; PCT/US95/02972, WO95/25106; PCT US95/10992, WO96/13502; PCT US96/05202, W096/35691; PCT US96/12766; PCT US96/13726; PCT US96/14135, PCT/US96/17120, PCT US96/19149, PCT/US97/01970, PCT/US95/12751, WO96/15130. and PCT/US96/00718, WO96/23788
Chemical conversion techniques for converting various intermediates having a CHjNH, on the oxazolidinone ring to CH_,NH-C(S)-CHj is disclosed by Hartke, K , Barrmeyer, S , J prakt Chem 1996, 338, 251-6 Similarly, conversion of
CH2NHC(=0)CHs to CH_,NHC(S)NHCH, is reported by Cava, M P , Levinson, M I , Thionation Reactions of Lawesson's Reagents, Tetrahedron 1985, 41, 5061-87 For the purpose of the present invention, the carbon content of various hydrocarbon containing moieties is indicated by a prefix designating the minimum and maximum number of carbon atoms in the moiety, 1 e , the prefix C,j defines the number of carbon atoms present from the integer "1" to the integer "j", inclusive Thus, C1 4 alkyl refers to alkyl of 1-4 carbon atoms, inclusive, or methyl, ethyl, propyl, butyl and lsomenc forms thereof
The terms "C, _, alkyl", "C, , alkyl", "C, 4 alkyl", "C. , alkyl", "C, β alkyl", "C1 8 alkyl", and "C! 16 alkyl" refer to an alkyl group having one to two, one to three, one to four, one to five, one to six, one to eight, or one to sixteen carbon atoms respectively such as, for example, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl and their lsomenc forms thereof The terms "C2 4 alkenyl", "C 5 alkenyl", "C2 8 alkenyl", "C 14 alkenyl" and "C2 ,„ alkenyl" refer to at least one double bond alkenyl group having two to four, two to five, two to eight, two to fourteen, or two to sixteen carbon atoms, respectively such as, for example, ethenyl, propenyl, butenyl, pentenyl, pentdienyl, hexenyl, hexdienyl, heptenyl, heptdienyl, octenyl, octdienyl, octatrienyl, nonenyl, nonedienyl, nonatπenyl, undecenyl, undecdienyl, dodecenyl, t decenyl, tetradecenyl and their lsomenc forms thereof
The terms "C2 _ alkynyl", "C 8 alkynyl", and "C 10 alkynyl" refer to at least one triple bond alkynyl group having two to five, two to eight, or two to ten carbon atoms respectively such as, for example, ethynyl, propynyl, butynyl, pentynyl, pentdiynyl, hexynyl, hexdiynyl, heptynyl, heptdiynyl, octynyl, octdiynyl, octatnynyl, nonynyl, nonediynyl, nonatπynyl and their lsomenc forms thereof
The terms "CJ 4 cycloalkyl", "Ci 6 cycloalkyl", "C5 6 cycloalkyl", and "CJ 8 cycloalkyl" refer to a cycloalkyl having three to four, three to six, five to six, or three to eight carbon atoms respectively such as, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and their lsomenc forms thereof
The terms "C, , alkoxy", "C, 6 alkoxy", and "C, 8 alkoxy" refer to an alkyl group having one to four, one to six, or one to eight carbon atoms respectively attached to an oxygen atom such as, for example, methoxy, ethoxy, propyloxy, butyloxy, pentyloxy, hexyloxy, heptyloxy, or octyloxy and their isomeric forms thereof.
The terms "CI 6 alkylamino", and "C,.8 alkylamino" refer to an alkyl group having one to six, or one to eight carbon atoms respectively attached to an amino moiety such as, for example, methylamino, ethylamino, propylamino, butylamino, pentylamino, hexylamino, heptylamino, or octoylamino and their isomeric forms thereof.
The terms dialkylamino" refer to two alkyl groups having one to six, or one to eight carbon atoms respectively attached to an amino moiety such as, for example, dimethylamino, methylethylamino, diethylamino, dipropylamino, methypropylamino, ethylpropylamino, dibutylamino, dipentylamino, dihexylamino, methylhecylamino, diheptylamino, or dioctoylamino and their isomeric forms thereof. The terms "C,.3 acyl", "CM acyl", "C^ acyl", "C,.6 acyl", "C,.8 acyl", and
"C2.8 acyl" refer to a carbonyl group having an alkyl group of one to three, one to four, one to five, one to six, one to eight, or two to eight carbon atoms.
The terms alkoxycarbonyl" refer to an ester group having an alkyl group of one to four, one to six, or one to eight carbon atoms.
The term "C^ alkyl phenyl" refers to an alkyl group having one to eight carbon atoms and isomeric forms thereof which is substituted with at least one phenyl radical.
The term "C2 8 alkenyl phenyl" refers to a at least one double bond alkenyl group having one to eight carbon atoms and isomeric forms thereof which is substituted with at least one phenyl radical.
The term "C[.8 alkyl pyridyl" refers to an alkyl group having one to eight carbon atoms and isomeric forms thereof which is substituted with at least one pyridyl radical. The term "C,.8 hydroxyl" refers to an alkyl group having one to eight carbon atoms and isomeric forms thereof attached to a hydroxy group.
The term "C,.8 alkylsulfonyl" refers to an alkyl group having one to eight carbon atoms and isomeric forms thereof attached to a S0 moiety.
The term "C1 6 alkylthio" refers to an alkyl group having one to six carbon atoms and isomeric forms thereof attached to a sulfur atom.
The term "Het" refers to 5 to 10 membered saturated, unsaturated or aromatic heterocyclic rings containing one or more oxygen, nitrogen, and sulfur forming such groups as, for example, pyridine, thiophene, furan, pyrazoline, pyrimi- dine, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 3- pyridazinyl, 4-pyridazinyl, 3-pyrazinyl, 2-quinolyl, 3-quinolyl, 1-isoquinolyl, 3- isoquinolyl, 4-isoquinolyl, 2-quinazolinyl, 4-quinazolinyl, 2-quinoxalinyl, 1- phthalazinyl, 4-oxo-2-imidazolyl, 2-imidazolyl, 4-imidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 3-pyrazolyl, 4-pyrazolyl, 5-pyrazolyl, 2-oxazolyl, 4-oxazolyl, 4-oxo-2- oxazolyl, 5-oxazolyl, 4,5,-dihydrooxazole, 1,2,3-oxathiole, 1,2,3-oxadiazole, 1,2,4- oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 3- isothiazole, 4-isothiazole, 5-isothiazole, 2-indolyl, 3-indolyl, 3-indazolyl, 2- benzoxazolyl, 2-benzothiazolyl, 2-benzimidazolyl, 2-benzofuranyl, 3-benzofuranyl, benzoisothiazole, benzisoxazole, 2-furanyl, 3-furanyl, 2-thienyl, 3-thienyl, 2-pyrrolyl, 3-pyrrolyl, 3-isopyrrolyl, 4-isopyrrolyl, 5-isopyrrolyl, 1,2,3, -oxathiazole-1-oxide, 1,2,4- oxadiazol-3-yl, l,2,4-oxadiazol-5-yl, 5-oxo-l,2,4-oxadiazol-3-yl, l,2,4-thiadiazol-3-yl, l,2,4-thiadiazol-5-yl, 3-oxo-l,2,4-thiadiazol-5-yl, l,3,4-thiadiazol-5-yl, 2-oxo-l,3,4- thiadiazol-5-yl, l,2,4-triazol-3-yl, l,2,4-triazol-5-yl, l,2,3,4-tetrazol-5-yl, 5-oxazolyl, 1- pyrrolyl, 1-pyrazolyl, 1,2,3-triazol-l-yl, 1,2,4-triazol-l-yl, 1-tetrazolyl, 1-indolyl, 1- indazolyl, 2-isoindolyl, 7-oxo-2-isoindolyl,l-purinyl, 3-isothiazolyl, 4-isothiazolyl and 5-isothiazolyl, 1,3,4,-oxadiazole, 4-oxo-2-thiazolinyl, or 5-methyl-l,3,4-thiadiazol-2-yl, thiazoledione, 1,2,3,4-thiatriazole, 1,2,4-dithiazolone. Each of these moieties may be substituted as appropriate.
The term halo refers to fluoro, chloro, bromo, or iodo. The compounds of the present invention can be converted to their salts, where appropriate, according to conventional methods. The term "pharmaceutically acceptable salts" refers to acid addition salts useful for administering the compounds of this invention and include hydrochloride, hydrobromide, hydroiodide, sulfate, phosphate, acetate, propionate, lactate, mesylate, maleate, malate, succinate, tartrate, citric acid, 2-hydroxyethyl sulfonate, fumarate and the like. These salts may be in hydrated form. When Q is the structure of
the dotted line in the heterocyclic ring means that this bond can be either single or double. In the case where the dotted line is a double bond, the R39 group will not be present. The compounds of Formula I of this invention contain a chiral center at C5 of the isoxazoline ring, and as such there exist two enantiomers or a racemic mixture of both. This invention relates to both the enantiomers, as well as mixtures containing both the isomers. In addition, depending on substituents, additional chiral centers and other isomeric forms may be present in any of A or R: group, and this invention embraces all possible stereoisomers and geometric forms in these groups.
The compounds of this invention are useful for treatment of microbial infections in humans and other warm blooded animals, under both parenteral and oral administration.
The pharmaceutical compositions of this invention may be prepared by combining the compounds of this invention with a solid or liquid pharmaceutically acceptable carrier and, optionally, with pharmaceutically acceptable adjuvants and excipients employing standard and conventional techniques. Solid form composi- tions include powders, tablets, dispersible granules, capsules, cachets and suppositories. A solid carrier can be at least one substance which may also function as a diluent, flavoring agent, solubilizer, lubricant, suspending agent, binder, tablet disintegrating agent, and encapsulating agent. Inert solid carriers include magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, cellulosic materials, low melting wax, cocoa butter, and the like. Liquid form compositions include solutions, suspensions and emulsions. For example, there may be provided solutions of the compounds of this invention dissolved in water and water-propylene glycol and water-polyethylene glycol systems, optionally containing suitable conventional coloring agents, flavoring agents, stabilizers and thickening agents.
Preferably, the pharmaceutical composition is provided employing conventional techniques in unit dosage form containing effective or appropriate amounts of the active component, that is, the compound according to this invention. The quantity of active component, that is the compound according to this invention, in the pharmaceutical composition and unit dosage form thereof may be varied or adjusted widely depending upon the particular application, the potency of the particular compound, the desired concentration. Generally, the quantity of active component will range between 0.5% to 90% by weight of the composition.
In therapeutic use for treating, or combatting, bacterial infections in warm- blooded animals, the compounds or pharmaceutical compositions thereof will be administered orally, parenterally and/or topically at a dosage to obtain and maintain a concentration, that is, an amount, or blood-level of active component in the animal undergoing treatment which will be antibacterially effective. Generally, such antibacterially effective amount of dosage of active component will be in the range of about OJ to about 100, more preferably about 3.0 to about 50 mg/kg of body weight/day. It is to be understood that the dosages may vary depending upon the requirements of the patient, the severity of the bacterial infection being treated, and the particular compound being used. Also, it is to be understood that the initial dosage administered may be increased beyond the above upper level in order to rapidly achieve the desired blood-level or the initial dosage may be smaller than the optimum and the daily dosage may be progressively increased during the course of treatment depending on the particular situation. If desired, the daily dose may also be divided into multiple doses for administration, e.g., 2-4 four times per day.
When the compounds according to this invention are administered parenterally, i.e., by injection, for example, by intravenous injection or by other parenteral routes of administration. Pharmaceutical compositions for parenteral administration will generally contain a pharmaceutically acceptable amount of the compound or a soluble salt (acid addition salt or base salt) dissolved in a pharmaceutically acceptable liquid carrier such as, for example, water-for-injection and a buffer to provide a suitably buffered isotonic solution, for example, having a pH of about 3.5-6. Suitable buffering agents include, for example, trisodium orthophosphate, sodium bicarbonate, sodium citrate, N-methylglucamine, L(+)-lysine and L(+)-arginine to name but a few representative buffering agents. The compound of this invention generally will be dissolved in the carrier in an amount sufficient to provide a pharmaceutically acceptable injectable concentration in the range of about 1 mg/mL to about 400 mg/mL of solution. The resulting liquid pharmaceutical composition will be administered so as to obtain the above-mentioned antibacterially effective amount of dosage. The compounds according to this invention are advantageously administered orally in solid and liquid dosage forms.
As a topical treatment an effective amount of Formula I is admixed in a pharmaceutically acceptable gel or cream vehicle that can be applied to the patient's skin at the area of treatment. Preparation of such creams and gels is well known in the art and can include penetration enhancers. MIC Test Method
The in vitro MICs of test compounds were determined by a standard agar dilution method. A stock drug solution of each analog is prepared in the preferred solvent, usually DMSO:H,0 (1:3). Serial 2-fold dilutions of each sample are made using 1.0 ml aliquots of sterile distilled water. To each 1.0 ml aliquot of drug is added 9 ml of molten Mueller Hinton agar medium. The drug-supplemented agar is mixed, poured into 15 x 100 mm petri dishes, and allowed to solidify and dry prior to inoculation. Vials of each of the test organisms are maintained frozen in the vapor phase of a liquid nitrogen freezer. Test cultures are grown overnight at 35°C on the medium appropriate for the organism. Colonies are harvested with a sterile swab, and cell suspensions are prepared in Trypticase Soy broth (TSB) to equal the turbidity of a 0.5 McFarland standard. A 1:20 dilution of each suspension is made in TSB. The plates containing the drug supplemented agar are inoculated with a 0.001 ml drop of the cell suspension using a Steers replicator, yielding approximately 104 to 105 cells per spot. The plates are incubated overnight at 35°C.
Following incubation the Minimum Inhibitory Concentration (MIC μg/ml), the lowest concentration of drug that inhibits visible growth of the organism, is read and recorded. The data is shown in Tables I and II.
TABLE 1
*not a compound of the subject invention
IΔB EJL (cont'd)
•not a compound of the subject invention
TΔB ϊa (cont'd)
SAUR: S. aur uβ
SEPI: S. epidermidia
EFAE: E. faecaliβ
SPNE: S. pntumoniae
SPYO: S. pyogeneβ
*not a compound of the subject invention
TABLE II (cont'd)
Key: SAUR 9213: S. aureus
SEPI 30593: S. epidermidis
EFAE 12712: E. Faecium
SPNE 9912: S. pneumoniae
SPYO 152: S. pyogenes
HINF 30063: Haemophilus influenzae
MCAT 30610: Moraxella catarrhalis
EFAE 9217: Enterococcus faecalis
As shown in Scheme 1, the intermediates II for the compounds of this invention are also intermediates disclosed in the oxazolidinone patents and published applications hereinabove incorporated by reference. The intermediates IV for this invention are final products (Examples) from the oxazolidinone patents and published applications hereinabove incorporated by reference.
As shown in Scheme 1, Step 1, and illustrated in Example 5, the isothiocyanates III can be conveniently prepared by allowing the amine intermediates (II) to react with lJ'-thiocarbonyldi-2(lH)-pyridone in solvents such as methylene chloride at 0 to 25°C. The thioureas (la, R' = H, alkyl ) can then be prepared as shown in Step 2 by the reaction of III with ammonia or the appropriate primary amines in solvents such as 1,4-dioxane or tetrahydrofuran at 0-50°C. Alternatively, as illustrated in Example 6 and shown in Step 3, the thioureas can be prepared by allowing II to react with an appropriate isothiocyanate (R' - N = C = S) in solvents such as tetrahydrofuran at 0-50°C. Thioamides (lb, R" = H, alkylj.4) are prepared by allowing II to react with an appropriate dithioester (R'" S-C(=S)-R",
Step 4 as illustrated in Example 4. This reaction is carried out in aqueous-alcoholic solvents at 0-50°C in the presence of an equivalent of an alkali metal hydroxide. This reaction, especially when R"' is methyl or ethyl, can be catalyzed by an alkali metal fluoride. The reaction of II with R"'-S-C(S)-R'" (R'"=CH3, C2H5) to give lb (Step 4) can also be carried out in the presence of a tertiary amine base such as triethylamine in solvents such as THF, dioxane or methylene chloride at 10-50°C for 3-48 hr.
When the reaction conditions are tolerated by the substituents on R (see, for example, Examples 1-3) the thioamides (lb, R" - H, alkyl,_4) can also be conveniently prepared (Step 5) by allowing the appropriate amide intermediates (IV) to react with reagents such as 2,4-bis(p-methoxyphenyl)-l,3-dithiadiphosphetane-2,4-disulfide (Lawesson's Reagent) in 1,4-dioxane, benzene, toluene or tetrahydrofuran at 60- 110°C; phosphorus decasulfide and sodium carbonate in tetrahydrofuran at 20-50°C [Brillon, D., Synthetic Communications, 20, 3085 ( 1990)] or phosphorus decasulfide and sodium fluoride in 1,2-dimethoxyethane at 20-50°C [Hartke, K., Gerber, H.-D., J. Prakt. Chem., 338, 763 (1996)].
Compounds Ic are prepared (Step 6) by allowing II to react first with carbon disulfide and a tertiary amine base such as triethylamine in solvent mixtures containing water and methanol, ethanol or isopropanol at 10-50°C for 5-24 hours. The resulting intermediate is treated with an alkylating agent (R"" X where X represents bromo. iodo, alkylsulfonyloxy or arylsulfonyloxy) at 0-30°C to give compounds Ic. In Step 7, compounds Ic are allowed to react with alkali metal alkoxide such as sodium methoxide or potassium ethoxide in the corresponding alkanol as solvent. This reaction is conveniently carried out at the reflux temperature of the alkanol for 1-24 hr.
SCHEME 1
=C=S
s
R'-— NH2 R— NH— C — NH-R' (R' = H, alkyM) la
STEP 2
II R- — N=C=S la (R' = H, alkyM) STEP 3 s S
II II
II FT— S— C-R" R-NH- -c - — R" (R" = H, alkyl,^)
STEP 4 lb
(R1 "' = CH3, C2H5 HOOC—CH
0 I I
R— NH — C— R" lb (R" = H, alkyl1.4)
IV STEP 5
S
II 1 ) CS2/Et3N II (R"" = C,.4 alkyl, X=Br, I,
RNH-C-St-i OS02 alkyl, OS02 aryl)
2)R"" X
STEP 6 Ic
S
Ic MOR""
II
HOR"" RNH-C-OR (M=Li,+ Na,+K+)
STEP 7 Id
In order to more fully illustrate the nature of the invention and the manner of practicing the same, the following experimental examples are presented. EXAMPLE 1: (S)-N-[[3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5- oxazolidinyl] methyl] thioacetamide (I)
" C16H20FN303S
I
A stirred mixture of II (PCT/US94/08904, 3.37 g, 10.0 mmol) in dry dioxane (100 mL), under nitrogen was treated with Lawesson's Reagent (4.04g, 10.0 mml), warmed to reflux during 1 h and refluxed for 1.5 h. The reaction was complete by TLC on silica gel with 10% MeOH-CHCl.,. It was kept at ambient temperature for 18 h and concentrated in vacuo. Chromatography of the residue on silica gel with mixtures of acetone-methylene chloride containing 10-15% acetone gave the product which was crystallized from acetone-hexane to give 1: mp 157.5-158.5 °C; HRMS theory for C16H20FN3O3S (M+): 353.1209; found: 353.1212. Anal, calcd for C16H20FN3O3S: C, 54.38; H, 5.38; N, 11.89; S, 9.07. Found: C, 54.21; H, 5.58; N, 11.78; S, 8.93.
EXAMPLE 2: (5)-N-[[3-[3-Fluoro-4-[4-(5-methyl-lJ,4-thiadiazol-2-yl)-l- piperazinyl] phenyl] -2-oxo-5-oxazolidinyl] methyl] thioacetamide (2 )
21 ^ PW
2
According to Example 1, for the preparation of 1, 21 (PCT/US97/01970) was allowed to react with Lawesson's Reagent in refluxing dioxane to give 2: mp 222-223 °C; HRMS theory for C19H24FNfiO,S, (M+HJ: 451.1386; found 451.1381.
EXAMPLE 3: (S)-N-[[3-[3-Fluoro-4-[2',5'-dioxospiro[piperidine-4,4'-imidazolidine]- 1-yl] phenyl] -2-oxo-5-oxazolidinyl]methyl] thioacetamide ( 3 ). STEP A: (S)-N-[[3-[3-Fluoro-4-[2',5'-dioxospiro[piperidine-4.4'-imidazolidine]-
1-yl] phenyl] -2-oxo-5-oxazolidinyl] methyl] acetamide (32 ).
KCN ■ IYMVP *»--NNHAc
31
A stirred suspension of 31 (WO95/25106, 0.349 g, 1.00 mmol) in 1:1 EtOH:H O (5 mL), under nitrogen, was treated with potassium cyanide (0.130 g, 2.00 mmol) and ammonium carbonate (0.701 g, 7.30 mmol), warmed at 55-60 °C for 5 h 15 min and kept at ambient temperature for 17 h 15 min. It was then chromatographed on silica gel with mixtures of MeOH-NH4OH-CHCl3 containing 5-20% MeOH and 0.5% NH4OH to give 0.280 g of 32: HRMS calcd for C19H FN5O5: 419.1605 (M+); found 419.1613; Anal, calcd for C)9H22FN5O5 • 1 H2O: C, 52.17; H, 5.53; N, 16.01. Found: C, 52.44; H, 5.30; N, 16.11.
STEP B: (S)-N-[[3-[3-Fluoro-4-[2',5'-dioxospiro[piperidine-4,4'Jmidazolidine]- l-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl] thioacetamide (3).
32 C1 H; 2FN504S 3
A stirred suspension of 32 (0.210 g, 0.500 mmol) in dioxane (5.0 mL), under nitrogen was treated with Lawesson's Reagent (0.202 g, 0.500 mmol), refluxed for 4 h and concentrated in vacuo. The residue was chromatographed on silica gel with mixtures of MeOH-NH4OH-CHCl3 containing 1-10% MeOH and 0.1-0.5% NH4OH and the resulting product was crystallized from MeOH-CHCl -EtOAc to give 0.0491 of 3: mp 218.5 °C; HR FAB MS theory for C19H FN504S (MJ: 435.1376; found 435.1370. Anal, calcd for C19H 2FN50 S • 0.5 H,0: C, 51.34; H, 5.21; N, 15.76. Found: C, 51.69; H, 5.00; N, 15.25. EXAMPLE 4: (S)-N-[[3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5- oxazolidinyl] methyl] thioacetamide (4).
C16H2oFN303S 4
A solution of 41 (148 mg, 0.500 mmol) and 0.97 M KOH (0.515 mL) in absolute EtOH (5 mL) was added to a solution of ethyl dithioacetate (57 μL, 0.50 mmol) and sodium fluoride (20 mg, 0.47 mmol) in absolute EtOH (5 mL) and the mixture was kept at ambient temperature for 3 h 40 min. Additional ethyl dithioacetate (5 μL) was added after 1 h 55 min and additional 0.97 M KOH (40 mL) and sodium fluoride (6 mg) were added to the mixture after 3h 5 min. The reaction was followed by TLC on silica gel with 10% MeOH-CHCl3 and 30% acetone-CH,Cl2. The major product had an Rf on TLC that was the same as that of 4.
EXAMPLE 5: (S)-N-[[3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5- oxazolidinyl]methyl]thiourea (5).
STEP A:
A solution of 51 (PCT/US94/08904, 2.07 g, 7.00 mmol) in CH2C12 was added, dropwise during 30 min, under nitrogen to an ice cold, stirred solution of l J '-thiocarbonyldi- 2( lH)-pyridone ( 1.95 g, 8.40 mmol) in CH2C12 (70 mL). The mixture was warmed slowly to ambient temperature and kept for 18 h. It was then diluted with CH2C12, washed with water and aqueous NaCl, dried (Na2SO4) and concentrated. Chromatography of the residue on silica gel with 10% acetonitrile-CH2Cl2 gave 1.60 g of the isothiocyanate: HRMS theory for C15H16FN,0?S (MJ: 337.0896: found 337.0888.
STEP B:
C,5H,9FN403S 5
Anhydrous ammonia was bubbled for 7 min through a stirred solution of the product from Step I (1.00 g, 2.96 mmol) in THF ( 10 mL) and the mixture was kept at ambient temperature for 3 h 25 min and concentrated in vacuo. Crystallization of the residue from acetone-hexane gave 0.861 g of 5: mp 199-199.5 °C; MS m z 354 (M+). Anal. calcd for ClsHI9FN4O,S: C, 50.84; H, 5.40; N, 15.81. Found: C, 50.87; H, 5.39; N, 15.72.
EXAMPLE 6: (S)-N-[[3-[3-Fluoro-4-(4-morpholinyI)phenyl]-2-oxo-5- oxazolidinyl]methyl]-N'-methylthiourea (6).
-NHCHj
A stirred solution of methyl isothiocyanate (93 mg, 1 J7 mmol) in THF, was treated with 61 (295 mg, 1.00 mmol), kept at ambient temperature for 18 h and concentrated in vacuo. The residue was recrystallized from EtOAc-hexane to give 246 mg of 6: mp 158-160 °C: MS m/z 368 (M+). Anal, calcd for C16H21FN40,S: C, 52.16; H, 5.74; N, 15.21. Found: C, 52.20; H. 5.85; N. 15.17. EXAMPLE 7 (S)-cis-N-[[3-[3-Fluoro-4-(tetrahydro-l-oxido-2H-thiopyran-4- yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]ethanethioamide
Step 1: A mixture of (S)J-)-N-[[3-[3-fluoro-4-(3,6-dihydro-2H-thiopyran-4- yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide S-oxide (4.50 g, can be obtained according to the procedures disclosed in International Publication No. WO 97/09328) and platinum oxide (697 mg) in methanol (164 mL) is shaken on the Parr apparatus under a hydrogen atmosphere at 40 psi for 18 hours. The catalyst is then removed by filtration through Celite, and the filtrate is concentrated under reduced pressure and the residue chromatographed on silica gel (230 - 400 mesh, 350 g), eluting with a gradient of methanol/methylene chloride (3/97 - 7/93). Pooling and concentration of those fractions with an Rf = 0.44 by TLC (methanol/chloroform, 10/90) gives (S)- cis-(-)-N-[[3-[3-Fluoro-4-(tetrahydro-l-oxido-2H-thiopyran-4-yl)phenyl] -2-oxo-5- oxazolidinyl] methyl] acetamide, mp 203 - 204°C.
Step 2: A mixture of the compound prepared in Step 1 (2.50 g) and hydroxylamine hydrochloride (2.36 g) in pyridine (30.6 mL) and ethanol (3.4 mL) is stirred in a screw-cap vial at 100°C for 22 hrs and at ambient temperature for 16 hrs, during which additional hydroxylamine hydrochloride (944 mg) and pyridine (4 mL) is added. The reaction mixture is then concentrated under reduced pressure, diluted with saturated aqueous sodium bicarbonate (100 mL) and saline (50 mL), adjusted to pH 11 with solid sodium carbonate and extracted with methanol methylene chloride (10/90, 5 x 100 mL). The combined organic phase is concentrated under reduced pressure, and the crude product is chromatographed on silica gel (230 - 400 mesh, 150 g), eluting with a gradient of methanol/methylene chloride (6/94 - 10/90). Pooling and concentration of those fractions with an Rf = 0.14 by TLC (methanol/chloroform, 10/90) gives (S)-cis-3-[3-fluoro-4-(tetrahydro-l- oxido-2H-thiopyran-4-yl)phenyl]-5-aminomethyl-2-oxazolidinone, mp 159 - 161°C.
Step 3: A solution of ethyl dithioacetate (105 mL, 0.919 mmol) and sodium fluoride (39 mg, 0.919 mmol) in ethanol (9.2 mL) under a nitrogen atmosphere was treated with a mixture of (S)-cis-3-[3-fluoro-4-(tetrahydro-l-oxido-2H-thiopyτan-4- yl)phenyl]-5-aminomethyl-2-oxazolidinone, as prepared in Step 2,(300 mg, 0.919 mmol) and aqueous potassium hydroxide (IM, 0.92 mL) in ethanol (46 mL). The resulting solution was stirred at ambient temperature for 4 hours and was then diluted with methylene chloride (150 mL) and washed with water (50 mL), aqueous potassium hydrogen sulfate (IM, 50 mL) and brine (25 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated in υacuo, and the crude product was triturated with methylene chloride/diethyl ether and filtered to give the title compound, mp 176 - 177°C (dec).
EXAMPLE 8 (S)-cis-[[3-[3-Fluoro-4-(tetrahydro-l-oxido-2H-thiopyran-4- yDphenyl] -2-oxo-5-oxazolidinyl] methyl] thiourea
Step 1: A solution of l,r-thiocarbonyldi-2(lH)-pyridone (235 mg, 1.01 mmol) in anhydrous methylene chloride (10 mL) at 0°C under a nitrogen atmosphere was treated with a solution of (S)-cis-3-[3-fluoro-4-(tetrahydro-l-oxido- 2H-thiopyran-4-yl)phenyl]-5-aminomethyl-2-oxazolidinone, as prepared in Example 7, Step 2, (275 mg, 0.843 mmol) in anhydrous methylene chloride (34 mL) over 30 minutes. The resulting mixture was stirred at 0°C for 30 minutes and at ambient temperature for 1 hour and was then diluted with methylene chloride (40 mL), washed with water (25 mL) and brine (25 mL), dried over anhydrous sodium sulfate and concentrated in υacuo. The crude product was chromatographed on silica gel (70 - 230 mesh, 20 g), eluting with acetonitrile/methylene chloride (40/60), and those fractions with an Rf = 0.07 by TLC (acetonitrile/methylene chloride, 30/70) were pooled and concentrated to give (S)-cis-3-[3-Fluoro-4-(tetrahydro-l-oxido-2H- thiopyran-4-yl)phenyl]-5-isothiocyanatomethyl-2-oxazolidinone, mp 187 - 190°C (dec).
Step 2: A solution of (S)-cis-3-[3-fluoro-4-(tetrahydro-l-oxido-2H-thiopyran-4- yl)phenyl]-5-isothiocyanatomethyl-2-oxazolidinone (Step 1, 290 mg, 0.787 mmol) in anhydrous tetrahydrofuran (39 mL) at 0°C under a nitrogen atmosphere was treated (bubbled) with a stream of ammonia gas for 5 minutes. The reaction pot was sealed, and the resulting mixture was stirred at 0°C for 1 hour. The excess ammonia was then removed under a stream of nitrogen, and the reaction mixture was concentrated in υacuo to give the crude product. Recrystallization from methanol methylene chloride/diethyl ether gave the title compound, mp 206 - 208°C (dec).
EXAMPLE 9 (S)-trans-N-[[3-[3-Fluoro-4-(tetrahydro-l-oxido-2H-thiopyran-4- yl )phenyl] -2-oxo-5-oxazolidinyl] methyl] ethanethioamide
Step 1: (S)-(-)-N-[[3-[3-fluoro-4-(3,6-dihydro-2H-thiopyran-4-yl)phenyl]-2-oxo- 5-ox azolidinyl] methyl] acetamide S-oxide (disclosed in International Publication No. WO 97/09328) may be reduced to the corresponding cis- and trans-sulfoxides by catalytic hydrogenation in the presence of a catalyst and solvent. Alternatively, the sulfide by product of this reduction reaction can be oxidized with an oxidizing agent such NaIO4 or meta-chloroperoxybenzoic acid in solvent to provide the cis- and trans-sulfoxides. Alternatively, the sulfide byproduct acn be oxidized selectively to the trans isomer using t-butyl hydroperoxide and a catalyst such as Ti(OiPr)4 and D-diisopropyl tartrate in a suitable solvent. The isomeric mixture can then be separated by chromatography to isolate the trans-sulfoxide, mp 211 - 212°C (dec). A mixture of the trans-sulfoxide, (S)-trans-(-)-N-[[3-[3-fluoro-4-(tetrahydro-l-oxido- 2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide, (0.90 g) and hydroxylamine hydrochloride (0.85 g) in pyridine ( 11.0 mL) and ethanol (1.2 mL) is stirred in a screw-cap vial at 100°C for 23 hrs and at ambient temperature for 19 hrs, during which additional hydroxylamine hydrochloride (340 mg) and pyridine (1 mL) is added. The reaction mixture is then concentrated under reduced pressure, diluted with saturated aqueous sodium carbonate (50 mL) and saline (50 mL) and extracted with methanol/methylene chloride ( 10/90, 6 x 100 mL). The combined organic phase is concentrated under reduced pressure, and the crude product is chromatographed on silica gel (230 - 400 mesh, 45 g), eluting with a gradient of methanol/methylene chloride (7.5/92.5 - 10/90). Pooling and concentration of those fractions with an Rf = 0J4 by TLC (methanol chloroform, 10/90) gives (S)-trans-3-[3- fluoro-4-(tetrahydro-l-oxido-2H-thiopyτan-4-yl)phenyl]-5-aminomethyl-2- oxazolidinone, mp 138 - 140°C.
Step 2: A solution of ethyl dithioacetate (105 mL, 0.919 mmol) and sodium fluoride (39 mg, 0.919 mmol) in ethanol (9.2 mL) under a nitrogen atmosphere was treated with a mixture of (S)-trans-3-[3-fluoro-4-(tetrahydro-l-oxido-2H-thiopyran-4- yl)phenyl]-5-aminomethyl-2-oxazolidinone, as prepare in Step 1, (300 mg, 0.919 mmol) and aqueous potassium hydroxide (IM, 0.92 mL) in ethanol (46 mL). The resulting solution was stirred at ambient temperature for 17 hours and was then diluted with methylene chloride (150 mL), washed with water (2 x 50 mL) and brine (25 mL), dried over anhydrous sodium sulfate and concentrated in υacuo. The crude product was chromatographed on silica gel (230 - 400 mesh, 35 g), eluting with methanol methylene chloride (3/97), and those fractions with an Rf = 0.56 by TLC (methanol/chloroform, 10/90) were pooled and concentrated and the residue recrystallized from methylene chloride/diethyl ether to give the title compound, mp 193 - 194°C (dec).
EXAMPLE 10 (S)-trans-[[3-[3-Fluoro-4-(tetrahydro-l-oxido-2H- thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl] methyl] thiourea
Step 1: A solution of lJ'-thiocarbonyldi-2(lH)-pyridone (192 mg,
0.827 mmol) in anhydrous methylene chloride (8.3 mL) at 0°C under a nitrogen atmosphere was treated with a solution of (S)-trans-3-[3-fluoro-4-(tetrahydro-l-oxido- 2H-thiopyran-4-yl)phenyl]-5-aminomethyl-2-oxazolidinone, as prepared in Example 9, Step 1, (225 mg, 0.689 mmol) in anhydrous methylene chloride (28 mL) over 30 minutes. The resulting mixture was stirred at 0°C for 30 minutes and at ambient temperature for 40 minutes and was then diluted with methylene chloride (20 mL), washed with water ( 15 mL) and brine ( 15 mL), dried over anhydrous sodium sulfate and concentrated in υacuo. The crude product was chromatographed on silica gel (32 - 63 mm, 40 g), eluting with a gradient of acetonitrile/methylene chloride (30/70 - 60/40) under 15 psi N , and those fractions with an Rf = 0J2 by TLC (acetonitrile/methylene chloride, 30/70) were pooled and concentrated to give (S)- trans-3-[3-Fluoro-4-(tetrahydro-l-oxido-2H-thiopyran-4- yl)phenyl]-5- isothiocyanatomethyl-2-oxazolidinone, mp 165 - 167°C.
Step 2: A solution of (S)-trans-3-[3-fluoro-4-(tetrahydro-l-oxido-2H- thiopyran-4-yl)phenyl]-5-isothiocyanatomethyl-2-oxazolidinone (Step 1, 230 mg, 0.624 mmol) in anhydrous tetrahydrofuran (31.2 mL) at 0°C under a nitrogen atmosphere was treated (bubbled) with a stream of ammonia gas for 5 minutes. The reaction pot was sealed, and the resulting mixture was stirred at 0°C for 1 hour. The excess ammonia was then removed under a stream of nitrogen, and the reaction mixture was concentrated in υacuo to give the crude product. Trituration with methanol/methylene chloride/diethyl ether gave the title compound, mp 209 - 210°C (dec).
EXAMPLE 11 (S)-N-[[3-[3-Fluoro-4-(tetrahydro-lJ-dioxido-2H- thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]ethanethioamide
Step 1: Starting with (S)-cis-(-)-N-[[3-[3-Fluoro-4-(tetrahydro-l-oxido-
2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide as prepared in Example 7, Step 1, and following the general procedure of Step 2, and making non- critical variations by substituting (S)-(-)-N-[[3-[3-fluoro-4-(tetrahydro-2H-thiopyran-4- yl)phenyl]-2-oxo-5-oxazolidinyl] methyl] acetamide S,S-dioxide (disclosed in International Publication No. WO 97/09328) for (S)-cis-(-)-N-[[3-[3-fluoro-4- (tetrahydro-l-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide, the product (S)-(-)-3-[3-Fluoro-4-(tetrahydro-lJ-dioxido-2H-thiopyran-4-yl)phenyl]-5- aminomethyl-2-oxazolidinone is obtained, mp 194°C (dec). Step 2: A solution of ethyl dithioacetate (100 mL, 0.876 mmol) and sodium fluoride (37 mg, 0.876 mmol) in ethanol (8.8 mL) under a nitrogen atmosphere was treated with a mixture of (S)-(-)-3-[3-fluoro-4-(tetrahydro-lJ-dioxido-2H-thiopyran-4- yl)phenyl]-5-aminomethyl-2-oxazolidinone, as prepared in Step 1, (300 mg, 0.876 mmol) and aqueous potassium hydroxide (IM, 0.88 mL) in ethanol (43.8 mL). The resulting mixture was stirred at ambient temperature for 26 hours, during which additional ethyl dithioacetate (50 mL, 0.438 mmol), sodium fluoride (19 mg, 0.438 mmol), aqueous potassium hydroxide (IM, 0.44 mL) and ethanol (3.0 mL) was added, and was then diluted with methylene chloride (150 mL), washed with water (50 mL), aqueous potassium hydrogen sulfate (IM, 50 mL) and brine (25 mL), dried over anhydrous sodium sulfate and concentrated in υacuo. The crude product was recrystallized from methylene chloride/diethyl ether to give the title compound, mp 186 - 187°C (dec).
EXAMPLE 12 (S)-N-[[3-[3-Fluoro-4-(tetrahydro-lJ-dioxido-2H- thiopyran-4-yl)phenyl] -2-oxo-5-oxazolidinyl] methyl] thiourea
Step 1: A solution of l,l'-thiocarbonyldi-2(lH)-pyridone (304 mg, 1.31 mmol) in anhydrous methylene chloride (13 mL) at 0°C under a nitrogen atmosphere was treated with a solution of (S)-(-)-3-[3-fluoro-4-(tetrahydro-lJ-dioxido-2H-thiopyran-4- yl)phenyl]-5-aminomethyl-2-oxazolidinone, as prepared in Example 11, Step 1, (375 mg, 1.09 mmol) in anhydrous methylene chloride (88 mL) over 30 minutes. The resulting mixture was stirred at 0°C for 30 minutes and at ambient temperature for 30 minutes and was then diluted with methylene chloride (40 mL), washed with water (25 mL) and brine (25 mL), dried over anhydrous sodium sulfate and concentrated in υacuo. The crude product was chromatographed on silica gel (230 - 400 mesh, 45 g), eluting with acetonitrile/methylene chloride (7.5/92.5), and those fractions with an Rf = 0.64 by TLC (acetonitrile/methylene chloride, 20/80) were pooled and concentrated to give (S)-3-[3-fluoro-4-(tetrahydro-lJ-dioxido-2H- thiopyran-4-yl)phenyl]-5-isothiocyanatomethyl-2-oxazolidinone, mp 158 - 162orj (dec).
Step 2: A solution of (S)-3-[3-fluoro-4-(tetrahydro-lJ-dioxido-2H- thiopyran-4-yl)phenyl]-5-isothiocyanatomethyl-2-oxazolidinone (Step 1, 380 mg, 0.988 mmol) in anhydrous tetrahydrofuran (49 mL) at 0°C under a nitrogen atmosphere was treated (bubbled) with a stream of ammonia gas for 5 minutes. The reaction pot was sealed, and the resulting mixture was stirred at 0°C for 1 hour. The excess ammonia was then removed under a stream of nitrogen, and the reaction mixture was concentrated in υacuo to give the crude product. Recrystallization from methanol methylene chloride/diethyl ether gave the title compound, mp 196 - 198°C (dec).
EXAMPLE 13: (S)-N-[[3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5- oxazolidinyl]methyl]-thioformamide (7).
A stirred mixture of acetic anhydride (0.23 mL, 0.0024 mol) and 95-97% formic acid (0.10 mL, 0.0027 mL) was warmed, under nitrogen at 50-55 °C for 2 h, cooled to ambient temperature and treated, portionwise during 2 min, with 398 (0.45 g, 0.0015 mol). The suspension was kept at ambient temperature for 4 h and the resulting solution was treated with Et2O (1 mL) and kept at ambient temperature for 18 h. The mixture was diluted with additional Et O ( 10 mL) and the solid was collected by filtration, washed with Et2O and dried to give 0.38 g of 69: MS (ES) m/z 324 (M+HJ, 346 (M+NaJ; Η NMR (300 mHz, CDCL,) d 3.08 (m, 4H), 3.72 (m, 2H), 3.77 (d,d, 1H), 3.89 (m, 4H), 4.04 (t, 1H), 4.80 (m, 1H), 6.33 (s, 1H), 7.05 (m, 2H), 7.45 (d,d, 1H), 8.27 (s, 1H).
A stirred mixture of 6 (0.38 g, 0.00118 mol) in dioxane (20 mL), under nitrogen was treated with 4 (0.51 g, 0.00126 mol), warmed to reflux during 30 min and kept at this temperature for 90 min. It was then evaporated under a stream of nitrogen. The residue was chromatographed on silica gel with 1.25% MeOH-CH2Cl2 and the slightly impure product was rechromatographed on silica gel with 25% EtOAc- CH2C1 . The resulting product was crystallized from EtOAc-methyl tert-butyl ether to give 0.114 g of 7: mp 150-155 °C (dec); IR (DRIFT) 3322, 1752 cm 1; MS(ES) m/z 340 (M+HJ, 362 (M+NaJ; 'HNMR [300 MHz, (CD3)2SO] d 2.94 (m, 4H), 3.72 (m, 4H), 3.77 (d,d, 1H), 3.94 (t, 2H), 4.12 (t, 1H), 4.93 (m, 1H), 7.05 (t, 1H), 7.16 (d,d, 1H), 7.47 (d,d, 1H), 9.33 (d, 1H), 10.59 (s, 1H). Anal, calcd for C15H18FN3O3S: C, 53.08; H, 5.35; N, 12.38. Found: C, 53.02; H, 5.44; N, 12.36.
EXAMPLE 14: (S)-N-[[3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5- oxazolidinyl]methyl]thiopropion-amide (9).
An ice cold, stirred solution of 39 (0.395 g, 0.00134 mol) and triethyl amine (0.186 mL, 0.0027 mol) in CH C12 (20 mL), under nitrogen was treated, dropwise during 2 min, with a solution of propionyl chloride (0J28 mL, 0.00147 mol) in CH2C12 (3 mL). The mixture was kept in the ice bath for 20 min and at ambient temperature for 1 h. It was then diluted with CH2C1 , washed with saturated NaHCO3, water and brine, dried (MgSO4) and concentrated. The residue (8) was used without further purification in the next reaction. 8 9
A stirred mixture of the product (8) from the previous reaction and dioxane (20 mL), under nitrogen, was treated, portionwise during 1 min, with Lawesson's reagent (0.58 g, 0.0014 mol) and refluxed for 2 h; it was then concentrated. The residue was chromatographed on silica gel with 2% MeOH-CHCl3 and the product was crystallized from methyl tert-butyl ether to give 0.259 g of 9: mp 138-139 °C; MS(ES) m/z 368 (M+HJ, 390 (M+NaJ; IR (DRIFT) 3284, 3266, 1748, 1744 cm 1; [α] 4 D +20° (MeOH); 1H NMR[300 MHz, (CD3)2SO] d 1.12 (t, 3H), 2.56 (q, 2H), 2.94 (m, 4H), 3.72 (m, 4H), 3.78 (d,d, 1H), 3.90 (t, 2H), 4.11 (t, 1H), 4.93 (m, 1H), 7.05 (t, 1H), 7.16 (d,d, 1H), 7.47 (d,d, 1H), 10.30 (broad s, 1H). Anal, calcd for C H22FN3O3S: C, 55.57; H, 6.03; N, 11.44. Found: C, 55.68; H, 6.21; N, 11.37.
EXAMPLE 15: (S)-N-[[3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5- oxazolidinyl]methyl]-2-chlorothioacetamide (11).
39 10
A stirred solution of 39 (1.54 g, 5.2 mmol) and triethylamine (750 mg, 7.5 mmol) in CH2C12 (50 mL), under nitrogen, was treated, dropwise, during 15 min with a solution of chloroacetyl chloride (465 mL, 5.8 mmol) in CH C12 (30 mL) and kept at ambient temperature for 18 h. It was then washed with saturated NaHCO3 and dilute NaCl, dried (Na2SO4) and concentrated. The residue was flash chromatographed on silica gel with 20-30% acetone-CH2Cl2 to give 1.49 g of 109 which was used in the next reaction without further purification.
A stirred mixture of 10 (0.371 g, 1.0 mmol) and Lawesson's reagent (0.420 mg, 1.04 mmol) in dioxane (10 mL) was refluxed, under nitrogen for 2 h and concentrated under reduced pressure. The residue was chromatographed on silica gel with 3-10% acetone-CH Cl2 to give 0.143 g of 11: MS (CD mlz 388 (M+HJ; 'H NMR (300 MHz, CDC1,) d 3.07 (m, 4H), 3.77 (d,d, 1H), 3.88 (m, 4H), 4.04 (m, 1H), 4.12 (t, 1H), 4.35 (m, 1H), 4.61 (s, 2H), 4.98 (m, 1H), 6.96 (t, 1H), 7.08 (d,d, 1H), 7.44 (d,d, 1H), 8.69 (s, 1H). Anal, calcd for ClβH19ClFN 03S: C, 49.55; H, 4.94; N, 10.83. Found: C, 49.38; H, 5.20; N, 10.27.
EXAMPLE 16: (S)-N-[[3-[3-Fluoro-4-(4-moropholinyl)phenyl]-2-oxo-5- oxazolidinyl]methyl]-α,α,α-trifluorothioacetamide (13).
An ice cold stirred solution of 39 (0.590 g, 2.0 mmol) and triethylamine (640 mL, 4.6 mmol) in CH C1 (10 mL) was treated with trifluoroacetic anhydride (325 mL, 2.3 mmol) and kept in the ice bath for 10 min and then at ambient temperature. The reaction was followed by TLC on silica gel with 30% acetone-CH2Cl . Additional trifluoroacetic anhydride and triethylamine were added after 3 d (64 mL / 125 mL), 4 d (100 mL / 220 mL) and 6 d (325 mL / 1.0 mL). The reaction was complete 1 h after the last addition; it was mixed with CH2C1 , washed with water and dilute NaCl, dried (Na.,S04) and concentrated. The solid residue was recrystallized from acetone-heptane to give 0.566 g of 12: mp 161-164 °C (dec); MS(EI) m /z 391 (M+). Anal, calcd for C16H17F4N30 : C, 49.11; H, 4.38; N, 10.74. Found: C, 48.99; H, 4.56; N, 10.73.
A stirred mixture of 12 (0.391 g, 1.0 mmol) and Lawesson's reagent (0.422 g, 1.1 mmol) in dioxane (10 mL) was refluxed, under nitrogen for 2 h, cooled slowly to ambient temperature and concentrated in vacuo. The residue was flash
10 chromatographed on silica gel with 5-15% acetone-CH Cl and the product was crystallized from acetone-heptane to give 0.249 g of 13: mp 151-152 °C; MS(EI) m/z 407 (M+), 363, 209, 151, 95; Η NMR (300 MHz, CDC13) d 3.05 (m, 4H), 3.75 (d,d, 1H), 3.87 (m, 4H), 3.95 (m, 1H), 4.14 (t, 1H), 4.32 (m, 1H), 5.01 (m, 1H), 6.92 (t, 1H), 7.05 (d,d, 1H), 7.38 (d,d, 1H), 9.03 (s, 1H). Anal, calcd for C16H17F4N303S: C, 47.17;
15 H, 4.21; N, 10.31. Found: C, 47.09; H, 4.35; N, 10.27.
EXAMPLE 17: (S)-N-[[3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5- oxazolidinyl]methyl]-α-fluorothioacetamide (15).
A stirred, ice cold solution of 39 (0.590 g, 2.0 mmol) and triethylamine (611 mL, 4.4 25 mmol) in CH C1 (10 mL), under nitrogen, was treated, dropwise, with a solution of fluoroacetyl chloride (220 mL, 2.2 mmol) in CH2C12 (5 mL), kept in the ice bath for 10 min and at ambient temperature for 2 h. It was then diluted with CH,C12, washed with water and dilute NaCl, dried (Na2SO4) and concentrated. The residue was chromatographed on silica gel with 10-30% acetone-CH2Cl2 to give 0.180 g of 14: 0 MS(ES) mlz 356 (M+H+), 378 (M+Na+).
A solution of 14 (0J80 g, 0.507 mmol) in dioxane. under nitrogen, was treated with Lawesson's reagent (0.206 g, 0.51 mmol), warmed at 90-100 °C for 1 h and concentrated in vacuo. The residue was chromatographed on silica gel with 15% acetone-CH Cl to give 0.161 g of 15: MS(EI) mlz 371 (MJ; Η NMR (300 MHz, CDCL,) d 3.05 (m, 4H), 3.78 (d,d, IH), 3.87 (m, 4H), 4.03 (m, IH), 4.11 (t, IH), 4.38 (m, IH), 4.98 (m, IH), 5.07 (s, IH), 5.23 (s, IH), 6.93 (t, IH), 7.08 (dd, IH), 7.42 (d,d, IH), 8.42 (s, IH). Anal, calcd for C16H19F,N3O3S: C, 51.74; H, 5.16; N, 11.31. Found: C, 51.79; H, 5.31; N, 11.02.
EXAMPLE 18: (S)-N-[[3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5- oxazolidinyl]methyl]-α,α-difluorothioacetamide (17).
A stirred, ice cold mixture of 39 (0.590 g, 2.0 mmol), difluroacetic acid (190 mL, 2.0 mmol), and 1-hydroxybenzotriazole (0.297 g, 2.2 mmol) in DMF (5 mL) under nitrogen, was treated with l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.843 g, 4.4 mmol) and kept at ambient temperature for 18 h. It was diluted with CH C1 , washed with water and dilute NaCl, dried (Na2S04) and concentrated. The solid residue was crystallized form EtOAc-heptane to give 0.617 g of 16: mp 149-150 °C; IH NMR (300 MHz, CDC13) d 3.05 (m, 4H), 3.66 (m, 2H), 3.85 (m, 5H), 4.08 (t, IH), 4.80 (m, IH), 5.93 (t, J = 53.9 Hz, IH), 6.92 (t, IH), 7.06 (m, 2H), 7.39 (d,d, IH); MS(EI) m /z 373 (M+). Anal, calcd for C16H,BF3N.,O4: C, 51.48; H, 4.86; N, 11.26. Found: C, 51.59; H, 4.91; N, 11.29.
2.
A stirred solution of 16 (0.373 g, 1.00 mmol) in dioxane (10 mL), under nitrogen was treated with Lawesson's reagent (0.404 g, 1.00 mmol), warmed at about 95 °C for 1 h and concentrated in vacuo. Chromatography of the residue on silica gel with 10% acetone-CH2Cl2 and cyrstallization of the product from EtOAc-heptane gave 0.276 g of 17: mp 125-127 °C; MS(EI) mlz 389 (M*), 345, 305, 247, 209, 195, 151, 138, 123, 109, 95; Η NMR (300 MHz, CDC13) d 3.05 (m, 4H), 3.76 (d,d, IH), 3.86 (m, 4H), 4.01 (m, IH), 4.12 (t, IH), 4.30 (m, IH), 4.99 (m, IH), 6.20 (t, J = 55.9 Hz, IH), 6.92 (t, IH), 7.06 (d,d, IH), 7.38 (d,d, IH), 8.78 (broad s, IH) Anal, calcd for C16H18F3N3O3S. C, 49.35; H, 4.66; N, 10.79. Found: C, 49.37; H, 4.71; N, 10.83.
EXAMPLE 19: (S)-N-[t3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5- oxazolidinyI]methyl]-α-cyanothioacetamide (19).
1.
An ice cold, stirred mixture of 39 (0.646 g, 2J9 mmol), cyanoacetic acid (0J79 g, 2J mmol) and 1-hydroxybenzotriazole (0.351 g, 2.6 mmol) in DMF (5 mL), under nitrogen, was treated with l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.997 g, 5.2 mmol) and kept at ambient temperature for 24 h. It was diluted with CH2C12, washed with water and dilute NaCl, dried (Na2SO4) and concentrated. The solid residue was crystallized from EtOAc-heptane to give 0.546 g of 18: mp 172-174 °C: IR (DRIFT) 3316, 2256, 1754, 1684 cm l; MS(EI) m lz 362 (M*). Anal, calcd for C17H19FN4O4: C, 56.35; H, 5.28; N, 15.46. Found: C, 56.33; H, 5.30; N, 15.36.
2.
A stirred solution of 18 (0.453 mg, 1.25 mmol) in dioxane ( 10 mL), under nitrogen, was treated with Lawesson's reagent (0.505 g, 1.25 mmol) and warmed at about 100 °C. When the reaction was over (TLC with 30% acetone-CH Cl2) the mixture was cooled and concentrated in vacuo. Chromatography of the residue on silica gel with 10-20% acetone-CH Cl and crystallization of the product from EtOAc-heptane gave 0J10 g of 19: mp 186-187 °C (dec); MS(ES) m /z 379 (M+HJ, 401 (M+NaJ; Η NMR (300 MHz, CDCL,) d 3.05 (m, 4H), 3.81 (d,d, IH), 3.86 (m, 4H), 3.89 (s, 2H), 4.09 (t, IH), 4.14 (m, 2H), 5.01 (m, IH), 6.92 (t, IH), 7.05 (d,d, IH), 7.34 (d,d, IH), 9.15 (s, IH); IR (DRIFT) 3244, 2260, 1754 cm 1. Anal, calcd for C17H19FN40 S: C, 53.96; H, 5.06; N, 14.81. Found: C, 53.88; H, 5.39; N, 14.61.
EXAMPLE 20: (S)-N-[[3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5- oxazolidinyl]methyl]-α,α-dichlorothioacetamide (21).
A stirred, ice cold solution of 39 (0.885 g, 3.00 mmol) and triethylamine (975 mL, 7 mmol) in CH2C12 (15 mL), under nitrogen was treated, dropwise with a solution of dichloroacetic anhydride (555 mL, 3.5 mmol) in CH2C12 (5 mL) and kept in the ice bath for 15 min and at ambient temperature for 18 h. It was diluted with CH2C12, washed with water, saturated NaHCO3 and dilute NaCl, dried (Na2S04) and concentrated. Chromatography of the residue on silica gel with 10% acetone-CH2Cl2 and crystallization of the product from acetone-heptane gave 0.463 g of 20: mp 197- 198 °C (dec); MS(ES) mlz 406 (M+HJ, 428 (M+NaJ; 'H NMR (300 MHz, CDCL,) d 3.05 (m, 4H), 3.75 (m, 3H), 3.86 (m, 4H), 4.07 (t, IH), 4.83 (m, IH), 5.94 (s, IH), 6.92 (t, IH), 7.06 (m, 2H), 7.41 (d,d, IH).
A stirred solution of 20 (0.305g, 0.75 mmol) in dioxane (5 ml), under nitrogen, was treated with Lawesson's reagent (0.202g, 0.5 mmol), warmed at about 90°C for 1 hour, cooled and concentrated in vacuo. Chromatography of the residue on silica gel first with 30% acetone-heptane and then with 10% acetone-methylene chloride and crystallization of rh product form methylene chloride - heptane gave 0.203g with 21: mp 143-144°cd.; HR17S (ED calculated for C16H18cl, F N, 03 S(M) 421.0431. Anal, calcd for C16H18cl2 F N3 O3 S, C, 45.51; H, 4.30; N, 9.95. Found: C, 45.47; H, 4.24; H, 9.88.
EXAMPLE 21: (S)-N-[[3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5- oxazolidinyl]methyl]-α-(methoxycarbonyl)thioacetamide (23).
A stirred solution of 39 (0.955 g, 3.2 mmol) and triethylamine (650 mL, 4.5 mmol) in CH2C12 (50 mL), under nitrogen, was treated, dropwise during 15-20 min with a solution of methyl malonyl chloride (475 mL, 4.3 mmol) in CH2C12 (10 mL) and kept at ambient temperature for 3 days. It was then washed with water and dilute NaCl, dried and concentrated. The residue was flash chromatographed on silica gel with 15-30% acetone-CH2Cl2 and the product was crystallized form acetone-hexane to give 0.873 g of 22: mp 150-151 °C; Η NMR (300 MHz, CDCL,) d 3.03 (m, 4H), 3.34 is, 2H), 3.67 (s, 3H), 3.69 (m, 2H), 3.76 (d,d, IH), 3.85 (m, 4H), 4.00 (t, IH), 4.78 (m, IH), 6.90 (t, IH), 7.06 (d,d, IH), 7.41 (d,d, IH), 7.57 (t, IH); MS(ES) m /z 396 (M+H+), 418 (M+NaJ; HRMS (FAB) calcd for C18H2 FN30B (M+HJ 396.1571, found 396.1579. Anal, calcd for C18H22FN 06: C, 54.68; H, 5.61; N, 10.63. Found: C, 54.69; H, 5.68; N, 10.58.
A stirred solution of 22 (0.395 g, 1.0 mmol) in dioxane ( 10 mL), under nitrogen, was treated with Lawesson's reagent (0.202 g, 0.5 mmol) and kept at ambient temperature for 4 h 10 min and at 80-90 °C for 1.5 h. The reaction was followed by TLC on silica gel with 10% MeOH-CHCl ,. At this time a new, less polar product had begun to form. It was kept at ambient temperature for 18 h and at 80 °C for 2 h; additional Laewsson's reagent (40 mg, 0.099 mmol) was added and warming at 80 °C was continued for 2 h; some starting material still remained. The mixture was concentrated and the residue was chromatographed on silica gel with 15% acetone- CH C1 to give 0.348 g of 23: Η NMR (300 MHz, CDCL,) d 3.05 tm, 4H), 3.71 (s, 3H), 3.81 (d,d, IH), 3.86 (m, 4H), 3.88 (s, 2H), 4.07 (t, IH), 4.19 (m, 2H), 4.99 (m, IH), 6.91 (t, IH), 7.07 (d,d, IH), 7.42 (d,d, IH), 9.52 (s, IH); IR (DRIFT) 3269, 1743 cm 1; MS(EI) mlz 411 (MJ. Anal, calcd for C18H FN 05S: C, 52.54; H, 5.39; N, 10.21. Found: C, 52.58; H, 5.43; N, 10.14.
EXAMPLE 22: (S)-N-[[3-[4-[l-[l,2,4]Triazolyl]phenyl]-2-oxo-5- oxazolidinyl]methyl]thioacetamide (25).
A stirred mixture of 24 (0J50 g, 0.470 mmol) and dioxane (12.5 mL), under nitrogen, was treated with Lawesson's reagent (0.20 g, 0.50 mmol), refluxed for 1.5 h, kept at ambient temperature for 18 h and concentrated in vacuo. Flash chromatography of the residue on silica gel with 5% MeOH-CHCl3 gave the product which was crystallized from MeOH to give 0J00 g (63.4%) of 25: mp 161-163 °C; Η NMR [300 MHz, (CD3)2SO] d 2.43 (s, 3H), 3.87 (m, 3H), 4.22 (t, IH), 4.99 (m, IH), 7.51 (d, IH), 7.77 (m, 2H), 8.26 (s, IH), 8.97 (d, IH), 10.35 (broad s, IH); IR (mull) 3259, 3226, 3044, 1752 cm 1; MS(ES) m lz 336 (M+HJ, 358 (M+NaJ. Anal, calcd for C14H14FN50 S: C, 50.14; H, 4.21; N, 20.88. Found: C, 50.18; H, 4.26; N, 20.94.
EXAMPLE 23: (S)-N-[[3-[4-[l-[l,2,4]Triazolyl]phenyl]-2-oxo-5- oxazolidinyl]methyl]thioacetamide (25).
A stirred mixture of 26 (0.26 g, 0.938 mmol), ethyl dithioacetate (0J2 g, 0.998 mmol), sodium fluoride (0.040 g, 0.953 mmol) and absolute EtOH (10 mL), under nitrogen, was treated during 5 min with a solution of 0.97 M KOH (1.03 mL) in EtOH and kept at ambient temperature for 2 h. It was then diluted with CH2CL2 (75mL), washed with water, IM KHS04, water and brine and evaporated. The residue was flash chromatographed on silica gel with 5% MeOH-CHCL, and the product was crystallized from MeOH to give 0J18 g, mp 164-165°C (dec) and 0.026 g, mp 162-163°C (dec) of 25.
EXAMPLE 24: (S)-N-[[3-[l-(Hydroxyacetyl)-5-indolinyl]-2-oxo-5- oxazolidinyl]methyl]thioacetamide (28).
1.
A stirred, ice cold solution of 52 (8.80 g, 0.0240 mol) in CH2C12 (25 mL) was treated during 20 min with a solution of trifluoroacetic acid (25 mL) in CH2C12 (10 mL). The mixture was kept in the ice bath for 2 h 15 min and concentrated under reduced pressure. A solution of the residue in CH C1 was washed with saturated NaHCO3 and dilute NaCl, dried (Na2SO4) and concentrated. The residue was used in the next reaction without further purification. A sample of this material (53) had: !H NMR (300 MHz, CDCL,) d 3.00 (t, 2H), 3.54 (t, 2H), 3.85 (broad s, IH), 5.17 (s, 2H), 6.59 (d, IH), 6.66 (broad s, IH), 6.91 (d, IH), 7.23 (s, IH), 7.36 (m, 5H); MS m/z 269 (M+H+).
NHCbz
416.48
268.22
Cl6Hi6N2θ2 25H24N2°4
54 53 An ice cold, stirred mixture of 53 (crude product from the previous reaction), acetone (200 mL), saturated NaHC03 (200 mL) and water (30 mL) was treated, dropwise during 20 min, with a solution of benzyloxyacetyl chloride (4.70 mL, 0.030 mol) in acetone (55 mL), warmed slowly to ambient temperature and kept for 18 h. Additional benzyloxytacetyl chloride (1.0 mL) in acetone 35 mL) was added dropwise and the mixture was kept at ambient temperature for an additional 3 h and diluted with EtOAc and water. A solid was collected by filtration and dried to give 4.00 g of crude product. The EtOAc solution was dried (Na2SO4) and concentrated to give 5.36 g of additional crude product. Crystallization of the product from EtOAc gave a total of 6.35 g of 5414, mp 157-159.5°C. The analytical sample had: mp 158-159.5°C; Η NMR (300 MHz, CDCLJ δ 3J6 (t,2H), 4.01(t,2H), 4.21 is, 2H), 4.69 (s, 2H), 5J9 is, 2H), 6.67 (s, IH), 6.97 (d, IH), 7.36 (m, 10H), 7.50 (braod s, IH), 8J5 (d, IH); MS(EI) m /z (relative intensity) 416 (M+, 9), 310 (8), 202 (10), 133 (8), 92 (8), 91 (99), 79 (7), 77 (9), 65 ( 12), 51 (6); IR (mull) 2381, 1722, 1659, 1608, 1558 cm 1. Anal. calcd for C25H24N O4: C, 72.10; H, 5.81; N, 6.73. Found: C, 72.05; H, 5.86; N, 6.68.
A stirred suspension of 54 (1.16 g, 2.78 mmol) in THF (42 mL) was cooled, under nitrogen, to -78°C and treated, dropwise, during 5 min with 1.6 M n-BuLi in hexane (1.83 mL). It was kept at -78°C for 50 min, treated, dropwise, during 5 min with a solution of (R)-(J-glycidyl butyrate (0.500 g, 3.47 mmol) in THF (2 mL), allowed to warm to ambient temperature during 3 h and kpet for 18 h. It was then diluted with EtOAc, washed with saturated NH4C1, water and brine, dried (MgS04) and concentrated. Chromatography of the residue on silica gel with 3% MeOH-0.2% NH4OH-CHCL, gave 0.60 g (56%) of 5514: Η NMR [300 MHz, (CD )2SO] δ 3J4 (t, 2H), 3.59 (m, 2H), 3J9 (d,d, IH), 4.03 (m, 3H), 4.29 (s, 2H), 4.58 (s, 2H), 4.65 (m, IH), 5.20 (t, IH), 7.31 (m, 6H), 7.55 (s, IH), 8.03 (d, IH); MS(ES) m lz 383 (M+HJ, 405 (M+NaJ. 4.
BzO-CH2 BzO-CH2
An ice cold, stirred mixture of 55 (0.60 g, 1.57 mmol), triethylamine (2.2 mL), and CH2C12 (12 mL), under nitrogen, was treated with 3-nitrobenzenesulfonyl chloride (0.44 g, 1.99 mmol) and kept in the ice bath for 30 min and at ambient temperature for 60 min. It was then diluted with CH2C12, washed with water and brine, dried (Na2S04) and concentrated. Chromatography of the residue on silica gel with 15% CH3CN-CH2C12 gave 0.70 g of 56: Η NMR (300 MHz, CDCL,) d 3.19 (t, J = 8.3 Hz, 2H), 3.88 (d,d, IH), 4.04 (t, J = 8.4 Hz, 2H), 4.14 (t, IH), 4.23 (s, 2H), 4.42 (m, 2H), 4.70 (s, 2H), 4.84 (m, IH), 6.97 (m, IH), 7.34 (m, 5H), 7.58 is, IH), 7.81 (t, IH), 8.22 (m, 2H), 8.53 (m, IH), 8.73 (m, IH); MS(ES) m /z 568 (M+HJ, 590 (M+Na+).
5.
BzO- CH2
A stirred mixture of 56 (crude product from 0.00314 mol of 55), acetonitride (70 mL), isopropanol (70 mL) and 29% ammonium hydroxide (70 mL) was warmed at 40-44 °C for 7h and kept at ambient temperature for 18 h. It was concentrated in vacuo to an aqueous residue with was extracted with CH2C12. The extract was washed with water and brine, dried (Na2SO4) and concentrated. Chromatography of the residue on silica gel with 8% MeOH-0.5% NH4OH-CHCl3 gave 1.05 g of 57: 'H NMR [300 MHz, (CD3)2SO] d 2.78 (m, 2H), 3.13 (t, 2H), 3.82 (d,d, IH), 4.01 (m, 3H), 4.29 (s, 2H), 4.58 (s, 2H), 4.58 (m, IH), 7.31 (m, 6H), 7.54 (broad s, IH), 8.03 (d, IH); MS(ES) m /z 382 (M+HJ, 404 (M+NaJ. 6.
A mixture of 57 (0.46 g, 1.21 mmol), MeOH (150 mL), 1 M HCl (1.2 mL) and 5% palladium-on-carbon catalyst (250 mg) was hydrogenated at an initial pressure of 49 psi for 5 h. Additional IM HCl (0.5 mL) and catalyst (100 mg) were added and hydrogenation was continued for 18 h. The catalyst was removed by filtration and the filtrate was concentrated to give 0.34 g of 27: Η NMR [300 MHz, (CD3)2SO] δ 3J5 (t, 2H), 3.22 (broad s, 2H), 3.84 (d,d, IH), 4.00 (t, 2H), 4.15 (s, 2H), 4.15 (m, IH), 4.92 (m, IH), 7.24 (q, IH), 7.50 (d, IH), 8.03 (d, IH), 8.37 (broad s, 3H); MS(ES) mlz 2.92 (M+H+).
7.
A suspension of 27 (0J0 g, 0.34 mmol) in a mixture of EtOH (15 mL) and 0.97 M KOH (0.7 mL) was added, under nitrogen to a stirred mixture of ethyl dithioacetate (0.0412 g, 0.343 mmol) and sodium fluoride (0.0137 g, 0.326 mmol) in EtOH (5 mL) and the mixture was kept at ambient temperature for 2h 15 min. Additional 0.97 M KOH (0.2 mL), sodium iodide (6 mg) and ethyl dithioacetate (20 mg) were added and the mixture was stirred for 2 h, mixed with CH C12 ( 150 mL), washed with water, IM KHS04 and brine, dried (Na2S04) and concentrated. The residue was crystallized from acetone to give 0.0404 g of 28: mp 175-176 °C (dec); MS (FAB) mlz 350 (M+HJ, 349 (MJ, 331, 316, 205, 73; HR MS (FAB) calcd for C16H20N,O4S (M+HJ 350.1174, found 350.1183: Η NMR [300 MHz, (CD ),SO] d 2.42 (s, 3H), 3J4 (t, 2H), 3.79 (d,d, IH), 3.89 (t, 2H), 4.00 (t, 2H), 4.12 (m, 3H), 4.83 (t, IH), 4.90 (m, IH), 7.25 (d, IH), 7.50 (s, IH), 8.03 (d, IH), 10.35 (s, IH); IR (DRIFT) 3255, 3223, 3068, 1747, 1639, 1614 cm 1.
EXAMPLE 25: (S)-N-[[3-[3-Fluoro-4-[4-(hydroxyacetyl)-l- piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] thioacetamide (30).
58 59
A mixture of 58 (3.00 g, 7.00 mmol), THF (60 mL), absolute EtOH (100 mL) and 10% palladium-on-carbon catalyst (415 mg) was hydrogenated at an initial pressure of 58 psi for 2 h 50 min. The catalyst was removed by filtration and the filtrate was concentrated in vacuo to give 2.67 g of 59 which was used without further purification in the next reaction: Η NMR (300 MHz, CDCL,) d 2J6 (broad s), 3.02 (m, 8H), 3.73 (d,d, J = 3.9, 12.6 Hz, IH), 3.96 (m, 3H), 4.72 (m, IH), 6.92 (t, J = 9.2 Hz, IH), 7.11 (m, IH), 7.43 (d,d, J = 2.6, 14.3 Hz, IH); MS(ES) mlz 296 (M+H+).
60
59
A stirred, ice cold mixture of 59 (2.67 g from the previous reaction), acetone (190 mL) and saturated NaHCO., (70 mL) was treated, dropwise during 2-3 min with a solution of benzyloxyacetyl chloride (1.34 mL, 8.61 mmol) in acetone (25 mL), kept in the ice bath for 1 h and diluted with EtOAc. The aqueous layer was extracted with EtOAc and the combined organic solution was washed with dilute NaCl, dried and concentrated. Chromatography of the residue on silica gel with 30% acetone-CH2CL> gave 2.64 g of 60: 'H NMR (300 MHz, CDCL,) d 2.28 (broad s, IH), 3.00 (m, 4H), 3.66 (m, 2H), 3.77 (m, 3H), 3.96 (m, 3H), 4.22 (s, 2H), 4.61 (s, 2H), 4.74 (m, IH), 6.88 (t, J = 9.2 Hz, IH), 7J2 (m, IH), 7.35 is, 5H), 7.46 (d,d, J = 2.6, 14.2 Hz, IH); IR (mull) 3406, 1748. 1647 cm 1; HRMS(EI) calcd for C,.,H 6FN.,05 (MJ 443.1856, found 443.1842.
3.
A stirred, ice cold mixture of 60 (2.64 g, 6.00 mmol) and triethylamine (1J4 mL, 8J6 mmol) in CH2C12 (200 mL), under nitrogen, was treated with 3- nitrobenzenesulfonyl chloride (1.78 g, 8.04 mmol), warmed to ambient temperature and kept for 5 h 20 min. Additional 3-nitrobenzenesulfonyl chlroide (180 mg) and triethylamine (0.20 mL) were added and the mixture was kept at ambient temperature for 18 h, diluted with CH2C1 and washed with water and dilute NaCl, dried (Na2SO4) and concentrated. Chromatography of the residue on silica gel with 40-60% acetone-hexane gave 3.36 g of 77: Η NMR (300 MHz, CDCL,) d 3.02 (broad s, 4H), 3.66 (broad s, 2H), 3.78 (broad s, 2H), 3.87 (d,d, J = 5.9, 9.1 Hz, IH), 4.09 (t, J = 9.2 Hz, IH), 4.22 (s, 2H), 4.41 (m, 2H), 4.61 (s, 2H), 4.84 (m, IH), 6.88 (t, J = 9J Hz, IH), 7.02 (m, IH), 7.35 (m, 6H), 7.82 (t, J = 8.0 Hz, IH), 8.23 (m, IH), 8.53 (m, IH), 8.73 (m, IH); MS(ES) mlz 629 (M+H+).
4.
77 61
A solution of 77 (3.36 g, 5.34 mmol) in a mixture of acetonitrile (90 mL), isopropanol (90 mL) and concentrated ammonium hydroxide (90 mL) was warmed at 40-45 °C for 18 h, treated with additional ammonium hydroxide (30 mL), warmed at 40-45 °C for 8 h, treated with additional ammonium hydroxide (25 mL) and warmed at 45 °C for 18 h. It was then mixed with water and extracted with CH2C12. The extract was washed with dilute NaCl, dried (Na2S04) and concentrated. Chromatography of the residue on silica gel with 5% MeOH-0.5% NH4OH-CHCL, gave 2.44 g of 61: Η NMR (300 MHz, CDCL,) d 1.50 (broad s), 3.04 (m, 6H), 3.65 (broad s, 2H), 3.81 (m, 3H), 3.99 (t, IH). 4.21 (s, 2H), 4.61 (s, 2H), 4.66 (m. IH), 6.88 (t. IH), 7.12 (m, IH), 7.33 (m, 5H), 7.47 (d,d, IH); MS(ES) m/z 443 (M+HJ.
5.
A solution of 61 (1.45 g, 3.3 mmol) and 1.0 N HCl (3.65 mL) in 95% EtOH (150 mL) was treated with 5% palladium-on-carbon catalyst (500 mg) and hydrogenated at an initial pressure of 54 psi for 20 h 15 min. Additional 1.0 N HCl (0.5 mL) and catalyst (100 mg) were added and hydrogenation was continued for 20 h 30 min at an initial pressure of 60 psi. The reaction was compete by TLC; it was neutralized with concentrated NH4OH, filtered and concentrated in vacuo to give 1.18 g of 29: Η NMR [300 MHz, (CD3) SO] d 2.94 (broad s, 4H), 3.19 (m, 2H), 3.48 (broad s, 2H), 3.60 (broad s, 2H), 3.84 (m, IH), 4.14 (m, 3H), 4.66 (broad s, IH), 4.93 (m, IH), 7.07 (t, IH), 7.16 (d,d, IH), 7.48 (d,d, IH), 8.04 (broad s); IR (mull) 3420, 3099, 3040, 3008, 1755, 1641 cm'1; MS(ES) m/z 353 (M+H+). Anal, calcd for C16H22ClFN4O4: C, 49.42; H, 5.70; Cl, 9.12; N, 14.41. Found: C, 48.16; H, 5.82; Cl, 10.00; N, 14.28.
6.
A stirred mixture of ethyl dithioacetate (180 mL, 1.56 mmol), sodium fluoride (72 mg, 1.7 mmol), 29 (500 mg, 1.29 mmol) and EtOH (70 mL) under nitrogen, was treated with 0.97M KOH (1.46 mL, 1.42 mmol) and the resulting solution was kept at ambient temperature for 3 h 35 min, diluted with CHCl.,, washed with water and dilute NaCl, dried (Na SO4) and concentrated. Chromatography of the residue on silica gel with 5% MeOH-0.5% NH4OH-CHCL, and crystallization of the resulting product from absolute EtOH gave 0.238 mg (44.9%) 30: mp 163-165 °C; lH NMR (300 MHz, CDCL,) d 2.60 (s, 3H), 3.06 (m, 4H), 3.45 (m, 2H), 3.61 (m, IH), 3.82 (m, 3H), 4.07 (m, 2H), 4.25 (m, 3H), 4.97 (m, IH), 6.91 (t, IH), 7.07 (m, IH), 7.45 (d,d, IH), 7.91 (broad s, IH); MS(FAB) m/z (relative intensity) 411 (M+H+, 100), 410 (M+, 66.5), 266 (3.1); IR 3292, 1733, 1653 cm 1. Anal, calcd for C18H23FN404S: C, 52.67; H, 5.65; N, 13.65. Found: C, 52.76; H, 5.58; N, 13.64. EXAMPLE 26 (S)-N-[[3-[3-Fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5- oxazolidinyl]methyl]thio-acetamide (32).
An ice cold, stirred mixture of 31 (0 38 g, 0.0012 mol) and triethylamine (0 38 mL, 0.0027 mol) in THF (12 mL), under nitrogen, was treated with ethyl dithioacetate (0 16 mL, 0 0014 mol) and then kept at ambient temperature for 24.5 h and concentrated in vacuo A solution of the residue in CH C12 was washed with saturated NaHCO ,, water and brine, dried (MgS04) and concentrated. Crystallization of the residue from EtOAc-hexane gave 0 355 g of 32. mp 155-156 °C; MS(ES) m/z 370 (M+HJ, 392 (M+Na+); IR (DRIFT) 3206, 3042, 1759, 1738 cm 1, Η NMR (300 MHz, CDCL,) d 2.60 (s, 3H), 2.95 (s, 4H), 3.43 (m, 4H), 3 82 (d, d, IH), 4.08 (m, 2H), 4.27 (m, IH), 4.98 (m, IH), 7.06 (m, IH), 7.33 (broad s, IH), 7 51 (d, IH), 8 03 (broad s, IH). Anal, calcd for C16H20FN3O2S2 C, 52.01, H, 5.46; N, 11.37. Found: C, 51.86; H, 5.43, N, 11.20.
EXAMPLE 27 (S)-N-[[3-[3-Fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5- oxazolidinyl]methyl]thio-acetamide, thiomorpholine S-oxide (34).
1.
An ice cold, stirred mixture of sodium metaperiodate (1 08 g, 5 05 mmol) and water (12 mL), under nitrogen, was treated with 62 (1 5 g, 4 8 mmol) and MeOH (17 mL) and kept at 6 °C for 18 h and at 4 °C for 3 h It was then treated with additional sodium metaperiodate (0 1 g), kept at 4°C for 3 h and extracted with CHC1, The extract was dried (MgSO ) and concntrated to give 1 4 g of 63 Η NMR [300 MHz, (CD ) SO] d 2 84 (m, 2H), 3 01 (m, 2H), 3 16 (m, 2H), 3 50 (m, 3H), 3 65 (m, IH), 3 77 (d,d, IH), 4 03 (t, IH), 4 66 (m, IH), 5 18 (t, IH), 7 16 (m, 2H), 7 52 (m, IH), MS(ES) m lz 329 (M+HJ, 351 (M+NaJ.
An ice cold, stirred mixture of 63 (1.27 g, 3.87 mmol) and triethylamine (0.732 mL, 5.25 mmol) in CH2C12 (130 mL), under nitrogen, was treated with m- nitrobenzenesulfonyl chloride (1.15 g, 5J9 mmol) and kept at ambient temperature for about 24 h. It was diluted with CH2C12, washed with water and brine, dried (Na2SO4) and concentrated to give 78 which was used in the next reaction without purification.
78 33
A stirred mixture of the product (78) from the previous reaction, acetonitrile (70 mL) and isopropanol (70 mL) was treated with concentrated ammonium hydroxide (70 mL, 29.9% NH3) and kept at 40 °C for 2 h, at ambient temperature for 18 h and at 40-45 °C for 4 h; it was concentrated to about 50 mL, diluted with water and extracted with CH2C1 . The extracts were washed with water and brine, dried (MgSO4) and concentrated. Chromatography of the residue on silica gel with 5% MeOH-CHCl3 gave 0.58 g of 33: MS(ES) m lz 328 (M+HJ, 350 (M+NaJ; Η NMR [300 MHz, (CD.,)2SO] d 2.81 (m, 4H), 3.01 (m, 2H), 3J6 (m, 2H), 3.30 (broad s), 3.49 (m, 2H), 3.80 (d,d, IH), 4.01 (t, IH), 4.58 (m, IH), 7J9 (m, 2H), 7.51 (m, IH).
4.
33 34 A stirred suspension of 33 (3.7 g, 0.011 mol) and triethylamine (3.5 mL, 0.025 mol) in THF ( 120 mL) was cooled, in an ice bath, under nitrogen, treated, dropwise during 2 min, with a solution of ethyl dithioacetate (1.47 mL, 0.0128 mol) in THF (2 mL) and kept at ambient temperature for 22 h. The resulting solution was concentrated and the residue crystallized from acetonitrile to give 3.61 g of 34: mp 176-177 °C ; Η NMR [300 MHz, (CD3)2SO] d 2.42 (s, 3H), 2.85 (m, 2H), 3.01 (m, 2H), 3.18 (m, 3H), 3.50 (m, 2H), 3.78 (d,d, IH), 3.89 (broad s, 2H), 4.12 (t, IH), 4.92 (m, IH), 7.18 (m, 2H), 7.49 (m, IH), 10.33 (s, IH); IR (DRIFT) 3186, 3102, 1741 cm 1; MS(ES) m /z 386 (M+H+), 408 (M+NaJ. Anal, calcd for C16H20FN O3S2 0.5 H2O: C, 48.71; H, 5.37; N, 10.65; S, 16.26; H2O, 2.38. Found: C, 48.75; H, 5.17; N, 10.72; S, 16.07; H2O, 1.72.
EXAMPLE 28: (S)-N-[[3-[3-Fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5- oxazolidinyl]methyl]thio-acetamide, thiomorpholine S, S-dioxide (36).
1.
A stirred mixture of 62 (0.399 g, 0.00128 mol) in 25% water/acetone (12 mL), under nitrogen was treated with N-methylmorpholine, N-oxide (0.45 g, 0.00384 mol) and 0J mL of a 2.5 wt% solution of osmium tetroxide in tert-butanol. It was kept at ambient temperature for 18 h, mixed with saturated NaHSO., (50 mL) and extracted with CH C1 . The extract was washed with saturated NaHS03 and brine, dried (Na2SO4) and concentrated. The residue was mixed with 3.5% MeOH-CH Cl2 and filtered; the solid was dissolved in 15% MeOH-CH2Cl2 and concentrated to give 0.29 g of 64. The filtrate was chromatographed on silica gel with 3.5% MeOH-CH2Cl2 to give 0J of additional 64: MS(ES) m lz 345 (M+HJ, 367 (M+NaJ; 'H NMR [300 MHz, (CD.,) SO] d 3.26 (m, 4H), 3.44 (m, 4H), 3.60 (m, 2H), 3.80 (d,d, IH), 4.05 (t, IH), 4.69 (m, IH), 7.22 (m, 2H), 7.54 (d, IH).
A stirred mixture of 64 (0.39 g, 0.00113 mol) and triethylamine (0.214 mL, 0.00154 mol) in CH C12 (37 mL) was cooled, under nitrogen, in an ice bath and treated, portionwise during 5 min, with 3-nitrobenzenesulfonyl chloride (0.335 g, 0.00151 mol). The mixture was kept in the ice bath for 20 min and at ambient temperature for 18 h and concentrated in vacuo. A stirred solution of the residue in 2-propanol (25 mL) and acetonitrile (25 mL), under nitrogen, was treated with 30% NH4OH (25 mL), warmed at 50-55 °C for 6 h and kept at ambient temperature for 48 h. It was concentrated to remove the organic solvents, diluted with water and extracted with CH2C12. The extract was washed with water and brine, dried (MgSO4) and concentrated. Flash chromatography of the residue on silica gel with 6% MeOH- 0.4% NH4OH-CHCl3 gave 0.29 g of 35: Η NMR [300 MHz, (CD3)2SO] d 1.59 (broad s, 2H), 2.78 (m, 2H), 3.24 (m, 4H), 3.43 (m, 4H), 3.81 (d,d, IH), 4.01 (t, IH), 4.57 (m, IH), 7.18 (m, 2H), 7.52 (m, IH); MS(ES) m/z 344 (M+HJ, 366 (M+Na+).
A stirred, ice cold suspension of 35 (0.28 g, 0.85 mmol) in a mixture of Et.,N (0.26 mL, 1.9 mmmol) and THF (10 mL) was treated with ethyl dithioacetate (0.11 mL, about 6 drops) and kept in the ice bath for 20 min and then at ambient temperature; the reaction was followed by TLC. After 20 h there was still a suspension and only partial reaction; additional THF (10 mL) and ethyl dithioacetate (3 drops) were added. After an additional 48 h the reaction was still incomplete; the suspension was treated with CH,C12 (10 mL) and kept for 72 h. At this time almost complete solution and an almost complete conversion to product had been obtained. An additional drop of ethyl dithioacetate was added and the mixture was kept at ambient temperature for 5 d and concentrated in vacuo. The residue was mixed with EtOAc, washed with saturated NaHC03, water and brine, dried (MgS0 ) and concentrated. Crystallization of the residue from MeOH-EtOAc gave 0.209 g of 36: mp 197-198 °C; Η NMR [300 MHz, (CD3)2SO] d 2.42 is, 3H), 3.24 (m, 4H), 3.43 (m, 4H), 3.78 (d,d, IH), 3.88 (m, 2H), 4J2 (t, IH), 4.92 (m, IH), 7J8 (m, 2H), 7.50 (m, IH), 10.37 (broad s, IH); IR (mull) 3300, 3267, 1743 cm 1; MS(ES) m/z 424 (M+NaJ. Anal, calcd for C1BH,0FN.,O4S2: C, 47.87; H, 5.02; N, 10.47. Found: C, 47.84; H, 5.23; N, 10.28.
EXAMPLE 29: (S)-N-[[3-[3,5-Difluoro-4-[4-(hydroxyacetyl)-l- piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]thioacetamide (38).
1.
A stirred mixture of 65 (1.8 g, 0.00396 mol), pyridine (30 mL) and absolute EtOH (3 mL), under nitrogen, was treated with hydroxylamine hydrochloride (1.44 g, 0.0207 mol), warmed to the reflux temperature during 2 h, refluxed for 3.5 h, kept at ambient temperature for 18 h and at reflux for 4 h. It was concentrated in vacuo and the residue was mixed with water, adjusted to pH 11 with saturated NaHCO3 and extracted with Et O. The extracts were washed with brine, dried (Na2SO4) and concentrated. Chromatography of the residue on silica gel with 5% MeOH-0.35% NH4OH-CHCl3 gave 0.75 g of recovered 65 and 0.72 g of 66: Η NMR [300 MHz, (CD3) SO] d 1.40 (s, 9H), 1.72 (broad s, 2H), 2.78 (m, 2H), 2.97 (m, 4H), 3.40 (m, 4H), 3.80 (d,d, IH), 4.00 (t, IH), 4.59 (m, IH), 7.27 (d, 2H); MS(ES) m /z 413 (M+HJ, 435 (M+Na+).
66
An ice cold, stirred mixture of 66 (0.75 g, 0.0018 mol) and triethylamine (0.315 mL, 0.00225 mol) in THF ( 12 mL), under nitrogen, was treated, dropwise with benzyl chloroformate (0.29 mL, 0.0020 mol), kept in the ice bath for 15 min and at ambient temperature for 2 h and concentrated in vacuo. The residue was mixed with CH2C12 and washed with saturated NaHC0 , water and brine, dried (Na2S04) and concentrated. This residue was mixed with Et2O and filtered to give 0.939 g of 67: mp 116-118 °C; Η NMR (300 MHz, CDC13) d 1.48 (s, 9H), 3.08 (m, 4H), 3.53 (m, 4H), 3.60 (m, 2H), 3.73 (m, IH), 3.96 (t, IH), 4.76 (m, IH), 5.10 (s, 2H), 5.21 (m, 1H),7.07 (d, 2H), 7.31 (s, 5H); MS(ES) m lz 547 (M+HJ, 569 (M+NaJ.
67 68
Compound 67 (0.805 g, 0.00147 mol) was added with stirring, portionwise during 5 min, under nitrogen, to ice cold trifluoroacetic acid (9 mL). The resulting solution was kept in the ice bath for 1 h and then concentrated under a stream of nitrogen.
The residue was mixed with ice and saturated NaHCO3 and extracted with CH2C12; the extract was washed with water and brine, dried (Na2SO4) and concentrated to give 0.63 g of product. The combined aqueous layer was reextracted with EtOAc; the extracts were washed with water and brine, dried (Na2SO4) and concntrated to give additional product. The combined product amounted to 0.68 g of 68 which was used in the next reaction without further purification.
4.
An ice cold, stirred mixture of 68 (0.68 g, 0.00152 mol), saturated NaHCO3 (15.2 mL) and acetone (40 mL), under nitrogen was treated, dropwise during 15 min, with a solution of benzyloxyacetyl chloride (0.29 mL, 0.0019 mol) in acetone (5 mL), kept at ambient temperature for 6 h, diluted with EtOAc and washed with water and brine. The extract was dried (MgS0 ) and concentrated in vacuo to give 0.72 g of 69: MS(ES) m lz 395 (M+HJ, 617 (M+Na+); Η NMR (300 MHz, CDCL,) d 3.12 (m, 4H), 3.59 (m, 4H), 3.74 (m, 3H), 3.96 (t, IH), 4.22 (s, 2H), 4.62 (s, 2H), 4.75 (broad s, IH), 5.10 (s, 2H), 5.22 (m, IH), 7.08 (d, 2H), 7.33 (m, 10H).
5.
69 37
A mixture of 69 (0.72 g, 0.0012 mol), MeOH and 5% palladium-on-carbon catalyst (0.4 g) was hydrogenated at an initial pressure of 45 psi for 4 h. By TLC (8% MeOH-0.5% NH4OH-CHCl3) the starting material had been reduced and two products formed. IM Hydrochloric acid (1.34 mL) was added and hydrogenation was continued at an initial pressure of 40 psi for 21 h. By TLC only the more polar product remained. The catalyst was removed by filtration and the filtrate was concentrated to give 0.40 g of 37: MS(ES) m/z 371 (M+HJ, 393 (M+Na+); Η NMR [300 MHz, (CD3)2SO] d 3.02 is, 4H), 3.20 (m, 2H), 3.43 (s, 2H), 3.56 (s, 2H), 3.84 (m, IH), 3.84 (broad s), 4.10 (s, 2H), 4.14 (t, IH), 4.96 (m, IH), 7.26 (d, 2H), 8.41 (broad s, 3H).
6.
x HCl 38
37
A stirred suspension of 37 (0.38 g) in a solution of Et3N (0.31 mL) and THF (10 mL), under nitrogen, was treated with ethyl dithioacetate (0J3 mL, about 7 drops) and kept at ambient temperature for 7 d; the reaction was followed by TLC (8% MeOH- 0.5% NH4OH-CHCl ). Additional ethyl dithioacetate (2 drops) was added after 24 h; after 30 h CH2C12 (10 mL) and ethyl dithioacetate (3 drops) were added; after 48 h additional triethylamine (0.3 mL) was added. The mixture was concentrated in vacuo and the residue was mixed with ice and saturated NaHCO an extracted with CH,C12. The extract was washed with water and brine, dried (MgSO ) and concentrated. The residue was chromatographed on silica gel with 2.5% MeOH- CH2C12 and the product was crystallized from MeOH to give 0J82 g of 38: mp 110- 111 °C (dec); MS(ES) m/z 429 (M+HJ, 451 (M+NaJ; HRMS (FAB) calcd for C18H 3F N404S (M+HJ 429.1408, found 429.1415; IR (DRIFT) 1760, 1652, 1639 cm'
[α'4 D 8° (MeOH).
EXAMPLE 30: (S)-N-[[3-[4-[l-[l,2,4]Triazolyl]phenyl]-2-oxo-5- oxazolidinyl]methyl]thiourea (44).
1.
A solution of 26 (0J90 g, 0.685 mmol) in CH2C12 (20 mL) was added, dropwise during 20 min, under nitrogen, to an ice cold, stirred solution of l,l<Z-thiocarbonyldi- 2(lH)-pyridone (0.193 g, 0.831 mmol) in CH2C12 (7 mL). The mixture was kept in the ice bath for 20 min and at ambient temperature for 2 h, diluted with CH2C12, washed with water and brine, dried (MgS04) and concentrated. Chromatography of the residue on silica gel with 10-15% CH3CN-CH2C12 gave 0.11 g of 79 which was used in the next reaction without further purification: MS(ES) m I z 320 (M+H+), 342 (M+Na+).
44
79
A stirred, ice cold solution of 79 (0J0 g, 0.31 mmol) in THF (15 mL) was treated with excess anhydrous ammonia and kept in the ice bath for 90 min. It was then evaporated under a stream of nitrogen to a volume of about 5 mL to give a solid which was collected by filtration and washed with cold THF to give 0J05 g of 44: mp 214-215 °C; Η NMR [300 MHz, (CD3),SO] d 3.82 (m, 3H), 4.18 (t, IH), 4.89 (broad s, IH), 7.20 (broad s, 2H), 7.50 (d, IH), 7.79 (m, 2H), 7.93 (t, IH), 8.26 is, IH), 8.97 is, IH); MS(ES) m/z 337 (M+HJ, 359 (M+NaJ. Anal, calcd for C13H13FN6O2S: C, 46.42; H, 3.90; N, 24.99. Found: C, 46.22; H, 3.98; N, 24.55. EXAMPLE 31: (S)-N-[[3-[3-Fluoro-4-[4-(hydroxyacetyl)-l- piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]-methyl]thiourea (45).
An ice cold, stirred solution of l,l(Z-thiocarbonyl-2(lH)-dipyridone (0.123 g, 0.530 mmol) in CH2C12 (5 mL), under nitrogen, was treated with a suspension of 29 (0.17 g, 0.4 mmol) in CH2C12 (20 mL) and then during 10 min with a solution of triethylamine (0.111 mL, 0.8 mmol) in CH2C12 (10 mL). It was kept in the ice bath for 30 min, at ambient temperature for 2 h and at < 0 °C for 18 h. It was then diluted with CH C12, washed with water and brine, dried (MgSO4) and concentrated. The residue (80) was used without further purification in the next reaction. A sample of 80 that was purified by flash chromatography on silica gel with 10-20% acetonitrile-CH2Cl2 had: Η NMR (300 MHz, CDCL,) d 1.60 (broad s), 3.07 (m, 4H), 3.45 (m, 2H), 3.85 (m, 4H), 3.97 (d,d, IH), 4.16 (t, IH), 4.21 (s, 2H), 4.82 (m, IH), 6.95 (t, IH), 7.13 (d,d, IH), 7.47 (d,d, IH); MS mlz 395 (M+H+); 417 (M+Na+).
2.
80 45
Excess anhydrous ammonia was bubbled into a stirred, ice cold solution of 80 (crude product from the previous reaction) in THF (25 mL) and the mixture was kept in the ice bath for 90 min and concentrated under a stream of nitrogen. The residue was chromatographed on silica gel with 5% MeOH-0.4% NH4OH-CHCl3 and the product was crystallized from acetonitrile to give 0.0544 g of 45: mp 209-210 °C; Η NMR [300 MHz, (CD3)2SO] d 294 (broad s, 4H), 3.47 (broad s, 2H), 3.60 (broad s, 2H), 3.78 (broad s, 3H), 4.07 (t, IH), 4.10 (d, J = 5.5 Hz, 2H), 4.63 (t, J = 5.5 Hz, IH), 4.81 (broad s, IH), 7.05 (t, IH), 7.16 (d,d, IH), 7.15 (broad s, 2H), 7.49 (d,d, IH), 7.91 (t, IH); IR (mull) 3443, 3403, 3321, 3202, 3081, 1753, 1655, 1648 cm 1; HRMS (FAB) calcd for C17H23FN5O4S (M+HJ 412.1454, found 412.1447. Anal, calcd for C17H22FN5O4S: C, 49.63; H, 5.39; N, 17.02. Found: C, 49.63; H, 5.48; N, 16.99.
EXAMPLE 32: (S)-N-[[3-[l-(Hydroxyacetyl)-5-indolinyl]-2-oxo-5- oxazolidinyl]methyl]thiourea (46).
An ice cold, stirred solution of l,lø-thiocarbonyldi-2(lH)-pyridone (0.096 g, 0.41 mmol) in CH2C12 (5 mL) was treated with a suspension of 27 (0J0 g, 0.34 mmol) in CH2C12 (15 mL) and then with 0.05 mL (0.36 mmol) of triethylamine. It was kept in the ice bath for 30 min and at ambient temperature for 2 h, diluted with CH2C12, washed with water and brine, dried (MgSO4) and concentrated. Chromatography ofthe residue on silica gel with 20-40% CH3CN-CH2C12 gave 0.04 g of 81. 2.
HOCHj HOCH-2 -C-^O
Excess anhydrous ammonia was bubbled into an ice cold solution of 81 (0.04 g) in THF (30 mL) and the mixture was kept in the ice bath for 80 min and concentrated under a stream of nitrogen. The residue was crystallized from CH3CN to give
0.0151 g of 46: mp 214-215 °C (dec); MS (FAB) m lz 351 (M+H*), 350 (MJ, 319, 304, 147; HRMS (FAB) calcd for C15H19N4O4S (M+H*) 351.1127, found 351.1130; IR (DRIFT) 3329, 3296, 3196, 1746, 1655, 1626 cm'1.
EXAMPLE 33: (S)-N-[[3-[3-Fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5- oxazolidinyl]methyl]thiourea, thiomorpholine S-oxide (47).
33 82
A suspension of 33 (0.30 g, 0.92 mmol) in CH2C12 (7 mL) was added, during 20 min, 0 to an ice cold, stirred mixture of l,l(Z-thiocarbonyldi-2(lH)-pyridone (0.258 g, 1.11 mmol) and CH2C12 (20 mL). The mixture was kept in the ice bath for 20 min and at ambient temperature for 2 h, mixed with CH2C12 (50 mL), washed with water and brine, dried (MgS04) and concentrated. Chromatography of the product on silica gel with 20-50% CH3CN-CH C12 gave 0.27 g of 82 which was used in the next reaction: 5 MS(ES) m/z 370 (M+HJ, 392 (M+Na+).
2.
82 4
A stirred, ice cold solution of 82 (0.27g , 0.73 mmol) in THF (15 mL), under nitrogen, was treated with excess anhydrous ammonia, kept in the ice bath for 1 h and 5 concentrated; crystallization of the residue from MeOH gave 0J75 g of 47; mp 212- 213 °C; Η NMR [300 MHz, (CD3)2SO] d 2.83 (m, 2H), 3.01 (m, 2H), 3.17 (m, 2H), 3.50 (t, 2H), 3.78 (broad s, 3H), 4.08 (t, IH), 4.80 (broad s, IH), 7.17 (m, 2H), 7.17 (broad s, 2H), 7.50 (d, IH), 7.90 (t, IH); MS(ES) mlz 409 (M+Na+); IR (mull) 3335, 3284, 3211, 3175, 3097, 1750, 1630 cm'1. Anal, calcd for C15H19FN4O3S2: C, 46.62; H, 0 4.95; N, 14.50. Found: C, 46.50; H, 4.95; N, 14.40.
EXAMPLE 34: (S)-N-[[3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5- oxazolidinyl]methyl-S-methyldithiocarbamate (48).
48 An ice cold, stirred mixture of 39 (0.59 g, 0.0020 mol), EtOH (1.5 mL), water (2 drops) and triethylamine (0.613 mL, 0.00440 mol), under nitrogen, was treated with carbon disulfide (0.066 mL, 0.0011 mol) and kept in the ice bath for 2 h and at ambient temperature for 18 h. (A solution was obtained after the addition of carbon disulfide; a white precipitate began to form soon after the mixture was warmed to ambient temperature.) The thick suspension was treated, dropwise during 2 min, with a solution of methyl iodide (0J37 mL, 0.00220 mol) in EtOH (2 mL) and the mixture was kept at ambient temperature for 1.5 h and concentrated in vacuo. A solution of the residue in EtOAc was washed with saturated NaHCO3, water and brine, dried (MgSO4) and concentrated. The residue was chromatographed on silica gel with 1.8% MeOH-CH2Cl2 and the product was crystallized from EtOAc to give 0J97 g of 48: mp 154-155 °C; IR (mull) 3354, 3346, 1726 cm 1. Anal, calcd for C16H20FN,O3S2: C, 49.85; H, 5.23; N, 10.90. Found: C, 49.73; H, 5.25; N, 10.82.
EXAMPLE 35: (S)-N-[[3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5- oxazolidinyl]methyl-O-methylthiocarbamate (50).
SO
48
A stirred mixture of 48 (0.200 g, 0.518 mmol), sodium methoxide (0.003 g, 0.06 mmol) and MeOH (5 mL), under nitrogen, was refluxed for 4 h and kept at ambient temperature for 18 h. It was found that the starting material and product had similar mobilities on TLC. the reaction was therefore followed by MS(ES). Starting material was still present. The mixture was refluxed for 3 h, additional sodium methoxide (0.005 g) was added and reflux was continued for 2 h. It was kept at ambient temperature for 18 h, refluxed for 1 h, kept at ambient temperature 1.5 h and concentrated in vacuo. The residue was mixed with ice, the pH was adjusted to 9-10 with IM KHSO4 and saturated NaHCO3 and the mixture was extracted with CH2C1 . The extract was washed with water and brine, dried (MgSO4) and concentrated. The residue was chromatographed on silica gel with 5% acetone- CH2C1, and the product was crystallized from EtOAc-hexane to give 0J07 g of 50: mp 128-129 °C; MS(ES) mlz 370 (M+HJ, 392 (M+NaJ; IR (DRIFT) 3282, 3251, 1753, 1735 cm"1; Η NMR [300 MHz, (CD3)2SO] d 2.94 (m, 4H), 3.47, 374 (m,m, 7H), 3.86, 3.91 (s,s, 3H), 4J0 (m, IH), 4.73, 4.86 (m,m, IH), 7.05 (t, IH), 7J6 (d,d, IH), 7.47 (d,d, IH), 9.41, 9.50 (s,s, IH). Anal, calcd for C16H20FN3O4S: C, 52.02; H, 5.46; N, 11.38. Found: C, 51.97; H, 5.49; N, 11.35.
When in the procedure of Example 35 an appropriate amount of sodium ethoxide was substituted for sodium methoxide, the compound of Example 36 below in Table A was obtained.
When in the procedure of Example 1 an appropriate amount of (S)-N-[[3-[3-fluoro- 4-morpholinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]isopropylcarboxamide, (S)-N-[[3-[3- fluoro-4-mo holinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]cyclopropylcarboxamide, or (S)-N-[[3-[3,5-difluoro-4-morpholinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide was substituted for (S)-N-[[3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]- methyl]acetamide (Compound 11) and the general procedures of Example 1 was followed, the compounds of Examples 37, 38 and 39 respectively as set forth below in Table A were obtained. The isopropylcarboxamide and the cyclopropylcarboxamide are obtained by following the procedure in Example 5 of U.S. Patent No. 5,688,792 only substituting isobutyric anhydride and cyclopropane carbonyl chloride respectively for acetic anhydride in step 7. The acetamide is obtained as described in U.S. Patent No. 5,688,792 at Example 4.
When in the procedure of Example 5, step B, an excess amount of dimethylamine in THF is substituted for anhydrous ammonia, the compound of Example 40 set forth below in Table A is obtained.
TABLE A
Example No. Compound R, R'
36 (S)-N-[[3-[3-Fluoro-4-(4-morpholinyl)- R = H, R' = OC2H5 phenyl]-2-oxo-5- oxazolidinyl]methyl]-O- ethylthiocarbamate; mp 120 °C. MS(ES) m z 384 (M+H+). Anal, calcd for C17H22FN3O4S: C. 53.25: H, 5.78; N, 10.96. Found: C. 53.23; H, 5.82; N, 10.92. Example No Compound R. R" 37 (S)-N-[[3-[3-Fluoro-4-(4-moφholinyD- R = H. R' = CH(CH- 2 phenyl]-2-oxo-5-oxazohdιnyl]methyl]-2- methylpropanethioamide; mp 152- 153 °C (dec); Anal, calcd for C18H24FN OιS: C, 56 67; H, 6J4, N, 1 1.02. Found: C, 56.58: H, 6.41 ; N, 10.81
38 (S)-N-[[3-[3-Fluoro-4-(4-morphohnyl)- H, R' = -^ phenyl]-2-oxo-5-oxazohdinyl]methyl]- cyclopropane-carbothioamide; mp 155-156 °C; Anal, calcd for C*8H22FN O,S: C, 56.98; H, 5.84; N. 1 1.07. Found: C, 56.98; H, 5.85; N, 10.97
39 (5)-N-[[3-[3.5-Difluoro-4-(4-moφholinyD- R = F. R' = CHi phenyl]-2-oxo-5-oxazolidinyl]methyl]- thioacetamide
40 (S)-N-[[3-[3-Fluoro-4-(4-moφholinyl)- R = H. R' = N(CH3)2 phenyl]-2-oxo-5-oxazolidinyl]methyl]-N',N'- dimethylthiourea
PREPARATION Z Methyl Dithiopropionate
1) CH3CH2MgBr cs. →- CH3CH2-C-SCH3
2) CH3I
(a)
A stirred mixture of magnesium turnings ( 12.6 g, 0.520 g atom) and THF ( 100 mL) under nitrogen is treated with a crystal of iodine and about 5% of a solution of bromoethane (30.0 mL. 0.40 mol) in THF (200 mL). When the reaction starts, the remainder of the bromoethane solution is added, dropwise at a rate sufficient to maintain a gentle reflux. After the addition, stirring is continued for 1 hour; the resulting solution is cooled to -20 °C and treated, during 10 minutes with carbon disulfide (24.0 mL. 0.40 mol). The mixture is warmed to 15 °C, treated with methyl iodide (28.0 mL, 0.45 mol) and kept at 60 °C for 1 hour. It is then cooled in an ice bath, treated with ice and extracted with Et2O. The extract is washed with brine, dried (MgSO4) and concentrated. Distillation of the residue gives 34.0 g of the titled product, bp 48-52 °C ( 12 mmHg). The following methyl dithio compounds were obtained when the appropπate alkyl magnesium bromide was substituted for ethyl magnesium bromide in the above procedure:
TABLE B
Rs-C — SCH,
Rs =
(c) ϊ>- (i) C^
( ) CH, (1)
CH CH CH" ~CH2-
(g) (CH3),C-CH2- (m)
CH,
When following the general procedure of Example 27, step 4. an appropriate amount of the amine listed below is reacted with the dithio compound listed below the respective compounds. Examples 41 to 61 of Table C are obtained.
When following the general procedure of Example 25, step 6, an appropπate amount of the amine listed below is reacted with the dithio compound listed below, the respective compounds, Examples 62 to 67, of Table C are obtained.
TABLE C
Example Compound Amine Dithio Compound
No. (from Preparation Z) 41 (S)-N-[[3-[3-Fluoro-4- Z (a) (4-thiomoφholinyl)- o=s -t NM phenyl]-2-oxo-5- oxazolidinyljmethyl]- propanethioamide, thiomoφholine S-oxide; mp 196-197°C; Anal, calcd for 51.1 1 ; H, 5.55; N, 10.52; S, 16.05. Found: C, 50.99; H, 5.60; N, 10.55: S. 15.75
42 S)-N-[[3-[3-Fluoro-4-(4- Same as above Z (b) thiomoφholinyl)- phenyl]-2-oxo-5- oxazolidinyl]methyl]-2- methylpropanethio- amide, thiomoφholine S-oxide; mp 195-196°C; Anal, calcd for C|8H24FN3O3S2: C, 52.28; H, 5.85; N, 10.16; S, 15.51. Found: C, 52.24; H, 5.97; N, 10.16: S, 15.28
43 (S)-N-[[3-[3-Fluoro-4- Same as above Z (c)
(4-thiomoφholinyl)- phenyl]-2-oxo-5- oxazolidinyl]methyl]- cyclopropanecarbothio- amide, thiomoφholine S-oxide; mp 109-1 10°C: Anal, calcd for C|8H22FN3O3S2: C, 52.54; H, 5J9; N, 10.21 : S, 15.58. Found: C, 52.48; H, 5.51 ; N, 10.28: S, 15.29 Example Compound Amine Dithio Compound No. (from Preparation Z)
44 (S)-N-[[3-[3-Fluoro-4- Same as above Z (d)
(4-thiomoφholinyl)- phenyl]-2-oxo-5- oxazolidinyl]methyl]- butanethioamide. thiomoφholine S-oxide
45 (S)-N-[[3-[3-Fluoro-4- Same as above Z (e)
(4-thiomoφholinyl)- phenyl]-2-oxo-5- oxazolidinyl]methyl]-3- methylbutanethioamide, thiomoφholine S-oxide
46 (S)-N-[[3-[3-Fluoro-4- Same as above Z (f)
(4-thiomoφholinyl)- phenyl]-2-oxo-5- oxazolidinyl]methyl]-2- methylbutanethioamide, thiomoφholine S-oxide
47 (S)-N-[[3-[3-Fluoro-4- Same as above Z (g)
(4-thiomoφholinyl)- phenyl]-2-oxo-5- oxazolidinyljmethyl]- 3J-dimethylbutanethio- amide, thiomoφholine S-oxide
48 (S)-N-[[3-[3-Fluoro-4- Same as above Z (h)
(4-thiomoφholinyl)- phenyl]-2-oxo-5- oxazolidinyljmethyl]- cyclobutanecarbothio- amide, thiomoφholine S-oxide
49 (S)-N-[[3-[3-Fluoro-4- Same as above Z (i)
(4-thiomoφholinyl)- phenyl]-2-oxo-5- oxazolidinyl]methyl]- l- cyclopentanecarbothio- amide. thiomoφholine S-oxide Example Compound Amine Dithio Compound
No. (from Preparation Z)
50 (S)-N-[[3-[3-Fluoro-4- Same as above Z (j)
(4-thiomoφholinyl)- phenyl]-2-oxo-5- oxazolidinyl]methyl]- cyclohexanecarbothio- amide, thiomoφholine
S-oxide
51 (S)-N-[[3-[3-Fluoro-4- Same as above Z (k)
(4-thiomoφholinyl)- phenyl]-2-oxo-5- oxazolidinyl]methyl]-2- cyclopropylethanethio- amide, thiomoφholine
S-oxide
52 (S)-N-[[3-[3-Fluoro-4- Same as above Z (l)
(4-thiomoφholinyl)- phenyl]-2-oxo-5- oxazolidinyl]methyl]-2- cyclobutylethanethio- amide, thiomoφholine S-oxide
53 (S)-N-[[3-[3-Fluoro-4- Same as above Z (m)
(4-thiomoφholinyl)- phenyl]-2-oxo-5- oxazolidinyl]methyl]-2- cyclopentylethanethio- amide, thiomoφholine S-oxide
54 (S)-N-[[3-[3,5-Difluoro- Ethyl dithioacetate
4-(4-thiomoφholinyl)- ρhenyl]-2-oxo-5- oxazolidinyljmethyl]- thioacetamide, thiomoφholine S-oxide
55 (S)-N-[[3-[3J-Difluoro- Same as above Z (a)
4-(4-thiomoφholinyl)- phenyl]-2-oxo-5- oxazolidinyl]methyl]- propanethioamide, thiomoφholine S-oxide Example Compound Amine Dithio Compound
No. (from Preparation Z
56 (S)-N-[[3-[3.5-Difluoro- Same as above Z (b)
4-(4-thiomoφholinyl)- phenyl]-2-oxo-5- oxazolidinyl]methyl]-2- methylpropanethio- amide, thiomoφholine
S-oxide
57 (S)-N-[[3-[3.5-Difluoro- Same as above Z (c)
4-(4-thiomoφholinyl)- phenyl]-2-oxo-5- oxazolidinyljmethyl]- cyclopropanecarbothio- amide, thiomoφholine S-oxide
58 (S)-N-[[3-[4-(4- Ethyl dithioacetate thiomoφholinyl)- phenyl]-2-oxo-5- oxazolidinyl]methyl]- thioacetamide, thiomoφholine S-oxide
59 (S)-N-[[3-[4-(4- Same as above Z (a) thiomoφholinyl)- phenyl]-2-oxo-5- oxazolidinyl]methyl]- propanethioamide, thiomoφholine S-oxide
60 (5)-N-[[3-[4-(4- Same as above Z (b) thiomoφholinyl)- phenyl]-2-oxo-5- oxazolidinyl]methyl]-2- methylpropanethio- amide, thiomoφholine S-oxide
61 (5)-N-[[3-[4-(4- Same as above Z (c) thiomoφholinyl)- phenyl]-2-oxo-5- oxazolidinyl]methyl]- cyclopropanecarbothio- amide, thiomoφholine S-oxide Example Compound Amine Dithio Compound No. (from Preparation Z) 62 (S)-N-[[3-[3,5-Difluoro- F 0 Z (a)
4-(4-hydroxyacetyl)-l- HOCH2-C-N N-Q-N piperazinyl]phenyl]-2- F
NH, oxo-5-oxazolidinyl]- t*" methyl]propanethio- amide
63 (S)-N-[[3-[3,5-Difluoro- Same as above Z (b) 4-(4-hydroxyacety 1)- 1 - piperazinyl]phenyl]-2- oxo-5-oxazolidinyl]- methyl]-2-methyl- propanethioamide
64 (S)-N-[[3-[3,5-Difluoro- Same as above Z (c) 4-(4-hydroxyacetyl)- 1 - piperazinyl]phenyl]-2- oxo-5-oxazolidinyl]- methyl]cyclopropane- thioamide
65 (S)-N-[[3-[3-[4- O
(hydroxyacetyl)-l- HOCH2-C-N .A. Z (a) piperazinyl]phenyl]-2- oxo-5-oxazolidinyl]- t- methyl]propanethio- amide
66 (5)_N-[[3-[3-[4- Same as above Z (b) (hydroxyacetyl)-l- piperazinyl]phenyl]-2- oxo-5-oxazolidinyl]- methyl]-2-methyl- propanethioamide
67 (S)-N-[[3-[3-[4- Same as above Z (c) (hydroxyacetyl)-l- piperazinyl]phenyl]-2- oxo-5-oxazolidinyl]- methyl]cyclopropane- carbothioamide
When following the procedure of Example 28. step 3, an appropriate amount of the amine listed below is reacted with the dithio compound listed below, the respective compounds. Examples 68 to 78 of Table D are obtained. TABLE D
Example Compound Amine Dithio Compound No. (see Preparation Z)
68 (S)-N-[[3-[3-Fluoro-4- Z (a)
(4-thiomoφholinyl)- phenyl]-2-oxo-5- oxazolidinyl]methyl]- propanethioamide, thiomoφholine S.S- dioxide
69 (S)-N-[[3-[3-FIuoro-4- Same as above Z (b)
(4-thiomoφholinyl)- phenyl]-2-oxo-5- oxazolidinyl]methyl]-2- methylpropanethio- amide, thiomoφholine S,S-dioxide
70 (S)-N-[[3-[3-Fluoro-4- Same as above Z (c)
(4-thiomoφholinyl)- phenyl]-2-oxo-5- oxazolidinyl]methyl]- cyclopropanecarbothio- amide, thiomoφholine S,S-dioxide
71 (S)-N-[[3-[3,5- Difluoro- Ethyl dithioacetate
4-(4-thiomoφholinyl)- phenyl]-2-oxo-5- oxazolidinyl]- methyljthioacetamide, thiomoφholine S,S- dioxide
72 (S)-N-[[3-[3,5- Difluoro- Same as above Z (a)
4-(4-thiomoφholinyl)- phenyl]-2-oxo-5- oxazolidinyljmethyl]- propanethioamide, thiomoφholine S,S- dioxide Example Compound Amine Dithio Compound
No. (see Preparation Z)
73 (S)-N-[[3-[3J- Difluoro- Same as above Z (b)
4-(4-thiomoφholinyl)- phenyl]-2-oxo-5- oxazolidinyl]methyl]-2- methylpropanethio- amide. thiomoφholine
S,S-dioxide
74 (S)-N-[[3-[3,5- Difluoro- Same as above Z (c)
4-(4-thiomoφholinyl)- phenyl]-2-oxo-5- oxazolidinyl]methyl]- cyclopropanecarbothio- amide. thiomoφholine S,S-dioxide
75 (S)-N-[[3-[4-(4-thio- o Ethyl dithioacetate moφholinyl)phenyl]-2- o9s N-v V-N .A' "o. oxo-5-oxazolidinyl]- methyl]thioacetamide, f ■— NHH, thiomoφholine S,S- dioxide
76 (S)-N-[[3-[4-(4-thio- Same as above Z (a) moφholinyl)phenyl]-2- oxo-5-oxazolidinyl]- methyljpropanethio- amide. thiomoφholine S.S-dioxide
77 (S)-N-[[3-[4-(4-thio- Same as above Z (b) moφholinyl)phenyl]-2- oxo-5-oxazolidinyl]- methyl]-2-methyl- propanethioamide, thiomoφholine S,S- dioxide
78 (S)-N-[[3-[4-(4-thio- Same as above Z (c) moφholinyl)phenyl]-2- oxo-5-oxazolidinyl]- methyl]cyclopropane- carbothioamide, thiomoφholine S.S- dioxide When following the procedure of Example 26. an appropriate amount of the amine listed below is reacted with the dithio compound listed below the respective compounds. Examples 79 to 99 of Table E are obtained.
TABLE E
Example Compound Amine Dithio Compound
No. (See Preparation Z)
79 (S)-N-[[3-[3-Fluoro-4- Z (a)
(4-thiomoφholinyl)- phenyl]-2-oxo-5- oxazolidinyl]methyl]- propanethioamide
80 (S)-N-[[3-[3-Fluoro-4- Same as above Z (b)
(4-thiomoφholinyl)- phenyl]-2-oxo-5- oxazolidinyl]methyl]-2- methylpropanethioamide
81 (S)-N-[[3-[3-Fluoro-4- Same as above Z (c)
(4-thiomoφholinyl)- phenyl]-2-oxo-5- oxazolidinyljmethyl]- cyclopropanecarbothio- amide
82 (S)-N-[[3-[3-Fluoro-4- Same as above Z (d)
(4-thiomoφholinyl)- phenyl]-2-oxo-5- oxazolidinyl]methyl]- butanethioamide
83 (S)-N-[[3-[3-Fluoro-4- Same as above Z (e)
(4-thiomoφholinyl)- phenyl]-2-oxo-5- oxazolidinyl]methyl]-3- methylbutanethioamide
84 (5)-N-[[3-[3-FIuoro-4- Same as above Z (f)
(4-thiomoφholinyl)- phenyl]-2-oxo-5- oxazolidinyl]methyl]-2- methvlbutanethioamide Example Compound Amine Dithio Compound No. (See Preparation Z)
85 (S)-N-[[3-[3-Fluoro-4- Same as above Z (g)
(4-thiomoφholinyl)- phenyl]-2-oxo-5- oxazolidinyl]methyl]-
3J-dimethylbutanethio- amide
86 (S)-N-[[3-[3-Fluoro-4- Same as above Z (h)
(4-thiomoφholinyl)- phenyl]-2-oxo-5- oxazolidinyl]methyl]- cyclobutanecarbothio- amide
87 (S)-N-[[3-[3-Fluoro-4- Same as above Z (i)
(4-thiomoφholinyl)- phenyl]-2-oxo-5- oxazolidinyljmethyl]- cyclopentanecarbothio- amide
88 (S)-N-[[3-[3-Fluoro-4- Same as above Z O)
(4-thiomoφholinyl)- phenyl]-2-oxo-5- oxazolidinyljmethyl]- cyclohexanecarbothio- amide
89 (S)-N-[[3-[3-5 Fluoro-4- Same as above Z (k)
(4-thiomoφholinyl)- phenyl]-2-oxo-5- oxazolidinyl]methyl]-2- cyclopropylethanethio- amide
90 (S)-N-[[3-[3-Fluoro-4- Same as above Z (l)
(4-thiomoφholinyl)- phenyl]-2-oxo-5- oxazolidinyl]methyl]-2- cyclobutylethanethio- amide Example Compound Amine Dithio Compound No. (See Preparation Z)
(S)-N-[[3-[3-Fluoro-4- Same as above Z (m)
(4-thiomoφholinyl)- phenyl]-2-oxo-5- oxazolidinyl]methyl]-2- cyclopentylethanethio- amide
92 (S)-N-[[3-[3,5-Difluoro- Ethyl dithioacetate
4-(4-thiomoφholinyl)- phenyl]-2-oxo-5- oxazolidinyljmethyl]- thioacetamide
93 (S)-N-[[3-[3,5-Difluoro- Same as above Z (a)
4-(4-thiomoφholinyl)- phenyl]-2-oxo-5- oxazolidinyl]methyl]- propanethioamide
94 (S)-N-[[3-[3,5-Difluoro- Same as above Z (b) 4-(4-thiomoφholinyl)- phenyl]-2-oxo-5- oxazolidinyl]methyl]-2- methylpropanethioamide
95 (S)-N-[[3-[3,5-Difluoro- Same as above Z (c) 4-(4-thiomoφholinyl)- phenyl]-2-oxo-5- oxazolidinyljmethyl]- cyclopropanecarbothio- amide
96 (S)-N-[[3-[4-(4-thio- Ethyl dithioacetate moφholinyl)phenyl]-2- oxo-5-oxazolidinyl]- methyl]thioacetamide
97 (S)-N-[[3-[4-(4-thio- Same as above Z (a) moφholinyl)phenyl]-2- oxo-5-oxazolidinyl]- methyljpropanethio- amide Example Compound Amine Dithio Compound No (See Preparation Z)
98 (S)-N-[[3-[4-(4-thιo- Same as above Z (b) moφhohnyl)phenyl]-2- oxo-5-oxazohdιnyl]- methyl]-2-methyl- propanethioamide
99 (5)-N-[[3-[4-(4-thιo- Same as above Z (c) moφhohnyl)phenyl]-2- oxo-5-oxazohdιnyl]- methyljcyclopropane- carbothioamide
The amine utilized in Examples 41 to 53 is prepared as described in Example 27, step 3 The amine utilized in Examples 54 to 57 is prepared by the procedure of Example 27, steps 1 to 3 by substituting the appropriate (S)-N-[[3-[3.5-dιfluoro-4-(4-thιo- moφholιnyl)phenyl]-2-oxo-5-oxazohdιnyl]methanol for compound 62 in step 1 of Example 27
The amine utilized in Examples 58 to 61 is prepared by the procedure of Example 27, steps 1 to 3 by substituting the appropriate (S)-N-[[3-[4-(4-thιomoφhohnyl)phenyl]-2- oxo-5-oxazolιdιnyl]methanol for compound 62 in Example 27. step 1 The appropriate oxazolidinyl methanol compound is obtained by following the procedure of Example 1 in U S Patent 5 688,792, steps 1 through 3 only substituting 4-fluoronιtrobenzene for 3,4- difluoronitrobenzene in step 1 thereof
The amine utilized in Examples 62 to 64 is prepared as compound 37 in Example 29 from the amide. 65, which is prepared as described in Example 32 of U S Patent No 5,700,799 The amine utilized in Examples 65 to 67 is prepared by the general procedure of Example 29 from the following amide, the preparation of which is decπbed in Example 3 of U S Patent 5.700,799
The amine utilized in Examples 68 to 70 is prepared as described in step 2 of Example 28 above
The amine utilized in Examples 71 to 74 is prepared as described in Example 28 by substituting (S)-N-[[3-[3,5-dιfluoro-4-(4-thιomoφholιnyl)phenyl]-2-oxo-5- oxazolidinyljmethanol for compound 62 in step 1 and lollowing the procedure of steps 1 and 2 The appropriate oxazolidinyl methanol compound is prepared by following the general procedure of Example 4 of U S Patent No 5,688,792, steps 1 through 4, only substituting thiomoφhohne tor moφhohne in step 1 thereot
The amine utilized in Examples 75 to 78 is prepared as described in Example 28, step 1, above by substituting (S)-N-[3-[4-(4-thιomoφhohnyl)phenyl]-2-oxo-5- oxazo dinyljmethanol for compound 62 in step 1 The appropriate oxazolidinyl methanol is obtained by following the procedure of Example 1 in U S Patent No 5,688.792, steps 1 through 3, only substituting 4-fluoronιtrobenzene tor 3,4-dιfluoromtrobenzene in step 1 thereof The amine utilized in Examples 79 to 91 is prepared as described in Example 1, step
4, of U S Patent No 5,688,792 The amine utilized in Examples 92 to 95 is prepared as described in Example 4 of U S Patent No 5,688,792 only substituting thiomoφhohne for moφhohne in step 1 thereof The amine utilized in Examples 96 to 99 is prepared by the procedure of Example 1 of U S Patent No 5,688,792, only substituting 4-fluoronιtro- benzene for 3,4-dιfluoronιtrobenzene in step 1 thereof
EXAMPLE 100 (S)-N-[[3-[3-Fluoro-4-(4-thιomoφhohnyl)phenyl]-2-oxo-5- oxazohdinyl]methylJ-0-methylthiocarbamate, thiomorphohne S-oxide
A solution of 201 mg (0 554 mmol) of (S)-N-[[3-[3-fluoro-4-(4-thιomoφhohnyl)- phenyl]-2-oxo-5-oxazolιdιnyl]methyl]ιsothιocyanate, thiomoφhohne s-oxide compound 82 from Example 33. step 1. in methanol ( 10 mL) is refluxed, under nitrogen tor 18 hours and cooled The solid is collected by filtration to give 0 138 g ot the titled product m p 208- 209°C Anal calcd for C16H2oFN-,O4S2 C, 47 87, H, 5 02 N 10 47 Found C, 47 81. H, 5 04 N, 10 49 When in the procedure ot Example 100 the thioisocyanate listed below is substituted compound 82 the products listed below as Examples 101 to 109 are obtained
TABLE F
Isothiocyanate
Re Ra Rb Example Compound No
OS 101 (5)-N-[[3-[3,5-Dιfluoro-4-(4- thιomoφhohnyl)phenyl]-2-oxo-5- oxazohdinylJmethylJ-O-methylthio- carbamate, thiomoφhohne S-oxide
OS H H 102 (S)-N-[[3-[4-(4-thιomoφhohnyl)phenyl]-2- oxo-5-oxazohdιnyl]methyl]-O-methylthιo- carbamate, thiomoφholine S-oxide
O.S H 103 (S)-N-[[3-[3-Fluoro-4-(4-thιomoφhohnyl)- phenyl]-2-oxo-5-oxazohdιnyl]methyl]-O- methylthiocarbamate. thiomoφholine S,S- dioxide
O-.S F 104 (5)-N-[[3-[3,5-Dιfluoro-4-(4- thιomoφhohnyl)phenylJ-2-oxo-5- oxazohdιnyl]methyl]-O-methylthιo- carbamate, thiomoφhohne S,S-dιoxιde
O,S H H 105 (S)-N-[[3-[4-(4-thιomorphohnyl)phenyl]-2- oxo-5-oxazolιdιnyl]methylJ-0-methylthιo- carbamate, thiomoφhohne S,S-dιoxιde
H 106 (S)-N-[[3-[3-Fluoro-4-(4-thιomoφhohnyl)- phenylJ-2-oxo-5-oxazohdιnyl]methyl]-O- methylthiocarbamate
107 (S)-N-[[3-[3J-Dιfluoro-4J4-thιomoφh- olιnyl)phenyl]-2-oxo-5-oxazohdιnylJ- methylJ-O-methylthiocarbamate Rc Ra Rb Example Compound No
H H 108 (S)-N-[[3-[4-(4-thιomoφhohnyl)phenylJ-2- oxo-5-oxazolιdιnyl]methyl]-O-methylthιo- carbamate o II H H 109 (S)-N-[[3-[3-Fluoro-4-(4-(hydroxyacetyl)-l
HOCH2CN pιperazιnyl]phenyl]-2-oxo-5-oxazohdιnylJ- methyl]-0-methylthiocarbamate
When in the procedure of Example 100 an appropriate amount of ethanol and isopropyl alcohol were substituted for methanol, the following respective compounds were obtained EXAMPLE 1 10 (S)-N-[[3-[3-Fluoro-4-(4-thιomorphohnyl)phenylJ-2-oxo-5- oxazohdιnγl]methylJ-O-ethylthιocarbamate, thiomoφhohne S-oxide m.p. 198-199°C,
Anal, calcd for Cι7H22FN3O4S2 C, 49.14; H, 5.34, N, 10 1 1 Found. C. 49.06, H, 5.27; N,
10.10.
EXAMPLE 1 1 1 : (S)-N-[[3-[3-Fluoro-4-(4-thιomoφholmyl)phenylJ-2-oxo-5- oxazolidinyl Jmethyl]-O-ιsopropylthιocarbamate, thiomoφholine S-oxide. m.p. 180-181°C;
Anal, calcd for C 18H24FN3O4S2 C, 50.33, H, 5.63; N, 9 78 Found. C, 50.29; H, 5.69; N,
9.82.
When in the procedure of Example 1 14 an appropriate amount of (S)-N-[[3-[3- fluoro-4-(4-thιomoφhohnyl)phenyl]-2-oxo-5-oxazohdιnyl]ιsothιocyanate is substituted for compound 82 and ethanol or isopropyl alcohol is substituted for methanol, the following respective products are obtained:
EXAMPLE 1 12 (S)-N-[[3-[3-Fluoro-4-(4-thιomoφhohnyl)phenyl]-2-oxo-5- oxazohdιnylJmethyl]-O-ethylthιocarbamate;
EXAMPLE 1 13 (S)-N-[[3-[3-Fluoro-4-(4-thιomoφholιnyl)phenylJ-2-oxo-5- oxazohdιnyl]methyl]-O-ιso-propylthιocarbamate,
EXAMPLE 1 14 (S)-N-[[3-[3-Fluoro-4-(4-thιomoφhohnyl)phenyl]-2-oxo-5- oxazohdιn\ l]methylJ-N-methylthιourea, thiomoφhohne S-oxide
A stirred suspension of 240 mg (0 650 mmol) of compound 82 from Example 33. step 1 in THF (5 mL) at 0 °C is treated with a 2M solution of methyiamine in THF (042 mL, 0 845 mmol) and kept at ambient temperature for 18 hours The solid is collected by filtration to give 0J21 g ot the titled product Following the procedure ot Example 1 14, only substituting an appropπate amount of dimethylamine and azetidine for methylamine, the following compounds are obtained EXAMPLE 115 (5)-N-[[3-[3-Fluoro-4-(4-thιomorphoIιnyl)phenyl]-2-oxo-5- oxazohdinylJmethylJ-N' N'-dimethylthioureα. thiomoφhohne S-oxide, Anal Calcd for C|7H23FN4O.S2, C 49 26. H, 5 59, N, 13 52 Found C, 49 1 1 , H, 5 57. N 13 40, mp 180- 182°C
EXAMPLE 1 16 (S)-N-[[3-[3-Fluoro-4-(4-thιomoφhohnyl)phenyl]-2-oxo-5- oxazolιdιnyl]methylJ- l-azetιdιnecαrbothιoamιde, thiomoφholine S-oxide, Anal Calcd for C,8H2 FN4O3S2, C, 50 69, H, 5 43, N, 13 14 Found C, 50 79, H, 5 45, N. 12 82, mp 213- 214°C
When in the procedure of Example 1 14 an appropriate amount of (S)-N-[[3-[3- fluoro-4-(4-thιomoφhohnyl)phenyl]-2-oxo-5-oxazolιdιnyl]methylJιsothιocyanate is substituted for compound 82. the following compound is obtained EXAMPLE 1 17 (S)-N-[[3-[3-Fluoro-4-(4-thιomoφhohnyl)phenyl]-2-oxo-5- oxazohdιnyl]methylJmethyl-N'-methylthιourea
When in the procedure of Example 1 17 an appropriate amount of dimethylamine and azetidine are substituted for methylamine, the following respective products are obtained EXAMPLE 1 18 (S)-N-[[3-[3-Fluoro-4-(4-thιomoφhohnyl)phenylJ-2-oxo-5- oxazolιdιnylJmethyl]-N',N'-dιmethylthιourea,
EXAMPLE 1 19 (S)-N-[[3-[3-Fluoro-4-(4-thιomoφhohnyl)phenyl]-2-oxo-5- oxazohdinyljmethylj- 1 -azetidinecarbothioamide
When in the procedure of Example 33 an appropriate amount of compound 31 from Example 26 is substituted for compound 33 and the general procedure ot steps 1 and 2 of Example 33 are followed, the following compound is obtained
EXAMPLE 120 (S)-N-[[3-[3-Fluoro-4-(4-thιomoφhohnyl)phenyl]-2-oxo-5- oxazohdinyljmethyljthiourea
EXAMPLE 121 (S)-N-[[3-[3-Fluoro-4-[4-(hydroxyacetyl)-l-pιperazιn\ l]phenyl-2- oxo-5-oxazohdιnyl]methylJpropanethιoamιde
A stirred mixture of 200 mg (0.514 mmol) of 29 methyl dithiopropionate (247 mg, 2.06 mmol), triethylamine (0.58 mL, 4J 1 mmol), THF (5.4 mL) and methylene chloride (5.4 mL) is kept, under nitrogen, for 3 days, diluted with water and extracted with methylene chloride. The extracts are dried (MgSO4) and concentrated. Chromatography of the residue on silica gel and crystallization of the product from methanol gives 0J32 g of the titled product, m.p. 190-191°C; Anal, calcd for C, 53.76; H, 5.94; N, 13.20; S, 7.55. Found: C, 53.66; H, 5.94; N, 13.20; S, 7.37.
Following the procedure of Example 121 only substituting dithio compounds Z (b) to Z (m) from Preparation Z above for methyl dithiopropionate, the following compounds are obtained.
TABLE G
Example No. Compound
122 (S)-N-[[3-[3-Fluoro-4-[4-(hydroxy- R = CH(CH- 2 acetyl)-l-piperazinylJphenyl]-2-oxo-5- oxazolidinyl]methyl]-2-methylpropane- thioamide; Anal, calcd for C20H27FN4O4S: C, 54.78; H, 6.21 ; N, 12.78; S, 7.31. Found: C, 54.67; H. 6.34; N, 12.41 ; S, 7J5 Example No. Compound 123 (S)-N-[[3-[3-Fluoro-4-[4-(hydroxy- R =→3 acetyl)- l-piperazinylJphenyl]-2-oxo-5- oxazolidinyljmethyljcyclopropane- carbothioamide: mp 179- 181 °C; Anal, calcd for C20H25FN4O4S: C, 55.03; H, 5.77; N, 12.84; S, 7.34. Found: C, 55.15; H, 5J2: N, 12.76; S, 7.09
124 (S)-N-[[3-[3-Fluoro-4-[4-(hydroxy- R = CH.-CH.-CH. acetyl)- 1 -piperazinyl]phenyl]-2-oxo-5- oxazolidinyljmethyljbutanethioamide
125 (S)-N-[[3-[3-Fluoro-4-[4-(hydroxy- CH, acetyl)-l-piperazinyl]phenylJ-2-oxo-5- FI = CH2-CH-CH3 oxazolidinyl]methyl]-3-methylbutane~ thioamide
126 (S)-N-[[3-[3-Fluoro-4-[4-(hydroxy- CH, I acetyl)- 1 -piperazinyl]phenyl]-2-oxo-5- R = CH-CH2-CH3 oxazolidinyl]methyl]-2-methylbutane- thioamide
127 (S)-N-[[3-[3-Fluoro-4-[4-(hydroxy- R = CH2-C(CH3)3 acetyl)- 1 -piperazinyl]phenylJ-2-oxo-5- oxazolidinyl]methyl]-3J-dimethyl- butanethioamide
128 (S)-N-[[3-[3-Fluoro-4-[4-(hydroxy- acetyl)-l-piperazinyl]phenyl]-2-oxo-5- :-0 oxazolidinyljmethyljcyclobutane- carbothioamide
129 (S)-N-[[3-[3-Fluoro-4-[4-(hydroxy- acetyl)- 1 -piperazinylJphenyl]-2-oxo-5- oxazolidinyljmethyljcyclopentane- --o carbothioamide
130 (S)-N-[[3-[3-Fluoro-4-[4-(hydroxy- acetyl)-l-piperazinyl]phenyl]-2-oxo-5- oxazolidinyl]methyl]cyclohexane- -o carbothioamide
131 (S)-N-[[3-[3-Fluoro-4-[4-(hydroxy- R = CH2-<] acetyl)-l-piperazinylJphenyl]-2-oxo-5- oxazolidinyl]methyl]-2-cyclopropyl- ethanethioamide Example No Compound
132 (S)-N-[[3-[3-Fluoro-4-[4-(hydroxy- R = CH _/\ acetyl)- l-pιperazιnyl]phenylJ-2-oxo-5- oxazohdιnyl]methylJ-2-cyclobutyl- ethanethioamide
133 (S)-N-[[3-[3-Fluoro-4-[4-(hydroxy- R acetyl )-l-pιperazιnyl]phenyl]-2-oxo-5- oxazohdιnyl]methylJ-2-cyclopentyl- ethanethioamide
When in the procedure of Example 100 an appropriate amount of compound 80 from Example 31 is substituted for compound 82, and ethanol or isopropyl alcohol is substituted for methanol, the following respective compounds are obtained EXAMPLE 134 (S)-N-[[3-[3-Fluoro-4-[4-(hydroxyacetyl)- l-pιperazιnyl]phenyl]-2- oxo-5-oxazohdιnyl]methyl]-O-ethylthιocarbamate,
EXAMPLE 135 (S)-N-[[3-[3-Fluoro-4-[4-(hydroxyacetyl)-l-pιperazιnyl]phenyl]-2- oxo-5-oxazolιdιnyl]methyl]-O-/.rø-propylthιocarbamate,
EXAMPLE 136 (S)-N-[[3-[3-Fluoro-4-[4-(hydroxyacetyl)- l-pιperazιnyl]phenylJ-2- oxo-5-oxazolιdιnyl]methyl]-N'-methylthιourea
When in the procedure of Example 1 14 an appropriate amount of compound 80 from Example 31 is substituted for compound 82, the title compound is obtained
Following the procedure of Example 1 14 only substituting an appropriate amount of compound 80 from Example 31 for compund 82 and substituting an appropriate amount of dimethylamine and azetidine for methylamine, the following compounds. Examples 137 and 138, are obtained
EXAMPLE 137 (S)-N-[[3-[3-Fluoro-4-[4-(hydroxyacetyl)- l-pιperazιnyl]phenyl]-2- oxo-5-oxazolιdιnylJmethylJ-N' N'-dimethylthiourea,
EXAMPLE 138 (S)-N-[[3-[3-Fluoro-4-[4-(hydroxyacetyl)- l-pφerazιnyl]phenvl]-2- oxo-5-oxazolιdιnylJmethyl J- 1 -azetidinecarbothioamide
EXAMPLE 139 (S)-N-[[3-[3J-Dιfluoro-4-[4-(hydroxyacetyl)-l -pιperazιnylJphenylJ-
2-oxo-5-oxazohdιnylJmethyl]-0-rnethylthιocarbamate
Part A Following the procedure of Example 33, step 1, only substituting an appropriate amount of compound 37 from Example 29 step 5 tor compound 33 (5)-N- [[3,5-[3-difluoro-4-[4-(hydroxyacetyl)- l-piperazinyl]phenyl]-2-oxo-5-oxazolidinylJ- methyljisothiocyanate is obtained.
Part B: Upon substitution of an appropriate amount of (S)-N-[[3-[3,5-difluoro-4-[4- (hydroxyacetyl)- l-piperazinylJphenylJ-2-oxo-5-oxazolidinyl]methylJisothiocyanate for compound 82 in the general procedure of Example 100, the title compound is obtained.
EXAMPLE 140: (S)-N-[[3-[4-[4-(hydroxyacetyl)- l-piperazinyl]phenyl]-2-oxo-5- oxazolidinyl]methyl]-O-methylthiocarbamate
Part A: Following the procedure of Example 33, step 1, only substituting an appropriate amount of (S)-N-[[3-[4-[4-(hydroxyacetyl)- 1 -piperazinylJphenyl]-2-oxo-5- oxazolidinyljmethyljamine for compound 33, (S)-N-[[3-[4-[4-(hydroxyacetyl)-l- piperazinyl]phenylJ-2-oxo-5-oxazolidinyl]methyl]isothiocyanate is obtained.
Part B: Upon substituting an appropriate amount of (S)-N-[[3-[4-[4-(hydroxy- acetyl)- l-piperazinyl]phenylJ-2-oxo-5-oxazolidinylJmethyl]isothiocyanate for compound 82 in the general procedure of Example 100, the title compound is obtained.
EXAMPLE 141 : (S)-N-[[3-Fluoro-4-(4-acetyl-l-piperazinyl)phenylJ-2-oxo-5- oxazolidinyljmethyljthioacetamide Step 1
58 85
An ice cold, stirred solution of 30.4 g (70.8 mmol) of starting material 58 from
Example 25, step 1), and triethylamine ( 15.4 mL, 1 10 mmol) in methylene chloride (2570 mL) is treated with /w-nitrobenzenesulfonyl chloride (18.8 g, 84.9 mmol) and kept, under nitrogen, at ambient temperature (24 °C) for 24 hours. Additional m-nitrobenzenesulfonyl chloride (1.88 g) and triethylamine (1.54 mL) are added and the mixture is kept for one additional day at ambient temperature, washed with water, saturated sodium bicarbonate and brine, dried (Na2SO4) and concentrated to give an oily product, 85. The alcohol, 58 is prepared according to the procedures of Brickner (J. Med. Chem. 1996, 39, 673-679), see compound 5a therein.
Step 2
85 86
A stirred mixture of 85, acetonitrile ( 1270 mL), isopropanol ( 1270 mL) and ammonium hydroxide ( 1270 mL) is kept at ambient temperature for 3 days and concentrated in vacuo. Chromatography of the residue on silica gel with 0.5% NHJ,OH- 1 % MeOH-CH2Cl2 gives 22.4 g of the amine. 86. Step 3
86 87
An ice cold, stirred solution of the amine 86 in THF (650 mL) is treated, during 20 mintues with a solution of di-tert-butyl dicarbonate ( 12.0 g, 55J mmol) in THF (90 mL). The mixture is kept at ambient temperature for 18 hours and concentrated in vacuo. The residue, dissolved in methylene chloride, is washed with dilute sodium bicarbonate, dried (MgSO4) and concentrated. Crystallization of the residue from methanol-ethyl acetate gives 20.0 g of the Boc protected amine. Additional product (4J g) is obtained by chromatographing the mother liquors on silica gel with 1-2% methanol-methylene chloride. Step 4
87 88
A solution of the protected amine, 87, (5.00 g, 9.46 mmol) in ethanol (150 mL) is treated with 10% palladium-on-carbon catalyst (1.0 g) and hydrogenated at an initial pressure of 30 psi for 3 hours. The catalyst is removed by filtration through Celite and the filtrate was concentrated to give 3.66 g of compound 88. Step 5
88 89
A stirred solution of compound 88 (1J0 g, 2.79 mmol) in pyridine ( 10 mL) is treated with acetic anhydride (289 μL, 3.07 mmol), kept at ambient temperature for 2 hours and concentrated in vacuo. A solution of the residue in methylene chloride is washed with dilute hydrochloric acid, dried (MgSO4) and concentrated to give 1 J3 g of compound 89: MS m/z 436 (M+). Step 6
An ice cold, stirred 4N solution of HCl in dioxane ( 10 mL) is treated with compound 89 (1J0 g, 2.52 mmol). The mixture is kept in the ice bath for 30 minutes and at ambient temperature for 1 hour. It was then mixed with methylene chloride and concentrated. The residue is triturated with methylene chloride to give 1.03 g of the amine hydrochloride. Step 7
P-90
A stirred mixture of compound P-90 (250 mg), triethylamine (0.75 mL, 5J6 mmol), ethyl dithioacetate (307 μL, 2.68 mmol), methylene chloride (7.4 mL) and THF (1.4 mL) is kept at ambient temperature for 1 day, concentrated and chromatographed on silica gel with mixtures of methanol-methylene chloride containing 1-2% methanol. Crystallization of the product from ethyl acetate-heptane gives 0J60 g of the titled product: Anal, calcd for
C18H23FN4O3S: C, 54.81 ; H, 5.88; N, 14.20; S, 8J3. Found: C 54.92; H, 5.95; N, 14.08; S. 7.94; mp 158°C.
When in the general procedure of Example 141 an appropriate amount of
is substituted for compound 58 and the procedure of steps 1 through 6 are followed, the respective amine compounds P-91 and P-92 listed below are obtained:
The alcohols above designated as x and y are prepared according to the procedures of Bπckner (J Med Chem , 1996, 39, 673-679), by substituting an appropπate amount of 2,6-dιfluoro-4-nιtrobenzene (tπfluoromethane) sulfonate and 4-fluoronιtrobenzene respectively for 3,4-dιfluoronιtrobenzene in the preparation of 2a therein
When in the procedure of Example 141 an appropriate amount of \ or y is substituted for compound 58 and the procedures of steps 1 through 4 are followed, the following Boc protected compounds listed below are obtained
When in the procedure of Example 141, step 5, an appropriate amount ot compound
88, compound x-b or compound y-b is treated with the reagent listed below and the general procedures of step 5 and step 6 are followed, the amines listed below as Preparation P-93 through P- 128 are obtained
The amine compound set forth below as P- 129 is obtained by refluxing tor 6 days a solution of compound 88 ( 1 00 g, 2 54 mmol), sultamide (305 mg, 3 18 mmol) and 1,2- dimethyoxyethane (6 mL) The solid which precipitates is collected by filtration and chromatographed on silica gel with 5% methanol-methylene chloride Crystallization of the product from methanol-methylene chloride gives 0 551 g of the sulfamoyl derivative, which is used in step 6 of Example 141 to gι\e P- 129 When compounds x-b and y-b are substituted for compound 88 and this general procedure is followed. Preparations P- 130 and P- 131 respectively set forth below are obtained.
Following the general procedures of steps 5 and 6 of Example 141 only in step 5 substituting chloroacetonitrile or 2-fluoroethyl bromide respectively for acetic anhydride and using potassium carbonate in acetonitrile, and using either compound 88, compound x- b or compound y-b, the respective amines set forth below as Preparations P- 132 to P-137 are obtained.
The amine compound set forth below as Preparation P- 138 is obtained by combining compound 88 ( 1 J0 g, 2J5 mmol) set forth in step 5 of Example 141 with N- formylbenzotriazole (493 mg, 3J5 mmol) in THF (30 mL) and the mixture is kept at ambient temperature for 18 hours. The mixture is concentrated and the residue in methylene chloride is washed with IN sodium hydroxide and dilute sodium chloride, dried (MgS0 ). concentrated, and chromatographed on silica gel with mixtures of methanol and methylene chloride containing 1-2% methanol to give 1.09 g of the N-formyl derivative which is utilized in the general procedure of step 6 of Example 141 to give Preparation P- 138. When in this foregoing procedure compound x-b or compound y-b is substituted for compound 88, Preparations P- 139 and and P- 140 as set forth below are obtained.
Reagent Boc R R ' K Preparation Compound No.
methoxyacetylchloride 88 O H F P-93 x-b II CH3OCH2C F F P-94 y-b H H P-95
cyanoacetyl chloride 88 O H F P-96 x-b II NCCH2C — F F P-97 y-b H H P-98
acetoxyacetyl chloride 88 O O H F P-99 x-b II II H3C--0-CH F F P- 100 y-b H H P-101 Reagent Boc R R' Preparation Compound No.
benzyloxyacetyl chloride 88 O H F P-102 x-b PhCH2OCH2c— F F P-103 y-b H H P-104
methyl chloroformate 88 0 H F P-105 x-b II CH3OC— F F P-106 y-b H H P-107
methanesultonyl chloride 88 CH3S02— H F P-108 x-b F F P-109 y-b H H P-110 ethanesulfonyl chloride 88 H F P-lll y-b H H P-113 chloromethanesulfonyl 88 H F P-114 chloride x-b CICH2SO2- F F P-115 y-b H H P-116
cyanomethanesulfonyl 88 H F P-117 chloride x-b NCCH2SO2- F F P-118 y-b H H P-119
N-methylsulfamoyl 88 H F P-120 chloride x-b CH3NHSO2- F F P-121 y-b H H P-122
N,N-dimethylsulfamoyl 88 H F P-123 chloride x-b (CH 2NSO2- F F P-124 y-b H H P-125
ethyl chloroformate 88 0 H F P-126 x-b II CH3CH2OC- F F P-127 y-b H H P-128
sulfamide 88 H F P-129 y-b H H P-131
chloroacetonitrile 88 H F P-132 x-b NCCH2- F F P-133 y-b H H P-134 Reagent Boc R I Preparation Compound No.
2-fluoroethyl bromide 88 H F P- 135 x-b FCH2CH2- F F P-136 y-b H H P-137
N-formylbenzotriazole 88 O H F P-138 x-b I I H C— F F P-139 y-b H H P-140
EXAMPLES 142-161 :
When following the general procedures of Example 141 , step 7, an appropriate amount of the amine listed below and the dithio compound from Preparation Z listed below are utilized, the respective products designated as Examples 142 to 400 in Table H are obtained.
TABLE H
Example Dithio
No. Product Amine Compound
142 (S)-N-[[3-[3-Fluoro-4-(4-acetyl-l-piperazinyl)phenylJ- P-90 Z (a) 2-oxo-5-oxazolidinyl]methyl]propanethioamide; mp
161-162°C; Anal, calcd for C19H25FN4O3S: C, 55.87; H, 6.17; N, 13.72; S, 7.85. Found: C, 55.79; H, 6.26; N, 13.60; S, 7.71
143 (S)-N-[[3-[3-Fluoro-4-(4-acetyl- l-piperazinyl)phenyl]- P-90 Z (b) 2-oxo-5-oxazolidinyl]methyl]-2-methylpropane- thioamide
144 (S)-N-[[3-[3-Fluoro-4-(4-acetyl- l-piperazinyl)phenylJ- P-90 Z (c) 2-oxo-5-oxazolidinyl]methyl]cyclopropanecarbo- thioamide; mp 159- 160°C; Anal, calcd for C20H25FN4O3S: C. 57.13; H, 5.99; N, 13.32; S, 7.62. Found: C, 57.05; H, 6.01 ; N, 13.15; S, 7.45.
145 (S)-N-[[3-[3-Fluoro-4-(4-acetyl- l -piperazinyl)phenylJ- P-90 Z (d) 2-oxo-5-oxazolidinyl]methyl]butanethioamide
146 (S)-N-[[3-[3-Fluoro-4-(4-acetyl- l -piperazinyl)phenyl]- P-90 Z (e) 2-oxo-5-oxazolidinyl]methyl]-3-methylbutane- thioamide Example Dithio No. Product Amine Compound
147 (S)-N-[[3-[3-Fluoro-4-(4-acetyl- 1 -piperazinyDphenylJ- P-90 Z (f)
2-oxo-5-oxazolidinylJmethyl]-2-methyibutane- thioamide
148 (S)-N-[[3-[3-Fluoro-4-(4-acetyl- 1 -piperazinyDphenylJ- P-90 Z (g)
2-oxo-5-oxazolidinyl]methyl]-3J-dimethylbutane- thioamide
149 (S)-N-[[3-[3-Fluoro-4-(4-acetyl-l-piperazinyl)phenylJ- P-90 Z (h)
2-oxo-5-oxazolidinylJmethyl]cyclobutanecarbo- thioamide
150 (S)-N-[[3-[3-Fluoro-4-(4-acetyl-l-piperazinyl)phenyiJ- P-90 Z (i)
2-oxo-5-oxazolidinylJmethyl]cyclopentanecarbo- thioamide
151 (S)-N-[[3-[3-Fluoro-4-(4-acetyl-l-piperazinyl)phenylJ- P-90 Z (j) 2-oxo-5-oxazoIidinyl]methyl]cyclohexanecarbo- thioamide
152 (S)-N-[[3-[3-Fluoro-4-(4-acetyl-l-piperazinyl)phenylJ- P-90 Z (k) 2-oxo-5-oxazolidinyl]methyl]-2-cyclopropylethane- thioamide
153 (S)-N-[[3-[3-Fluoro-4-(4-acetyl-l-piperazinyl)phenyl]- P-90 Z (l) 2-oxo-5-oxazolidinylJmethyl]-2-cyclobutylethane- thioamide
154 (S)-N-[[3-[3-Fluoro-4-(4-acetyl- l-piperazinyl)phenylJ- P-90 Z (m) 2-oxo-5-oxazolidinylJmethylJ-2-cyclopentylethane- thioamide
155 (5)-N-[[3-[3,5-Difluoro-4-(4-acetyl- l-piperazinyl)- P-91 Ethyl phenylJ-2-oxo-5-oxazolidinylJmethyl]thioacetamide dithioacetate
156 (5)-N-[[3-[3.5-Difluoro-4-(4-acetyl- 1 -piperazinyl)- P-91 Z (a) phenyl]-2-oxo-5-oxazolidinylJmethylJpropane- thioamide
157 (5)-N-[[3-[3J-Difluoro-4-(4-acetyl-l-piperazinyl)- P-91 Z (b) phenyl]-2-oxo-5-oxazolidinyl]methylJ-2-methyl- propanethioamide Example Dithio No. Product Amine Compound
158 (S)-N-[[3-[3.5-Difluoro-4-(4-acetyl- 1 -piperazinyl)- P-91 Z (c) phenyl]-2-oxo-5-oxazolidinylJmethyl]cyclopropane- carbothioamide
159 (S)-N-[[3-[4-(4- Acetyl- 1 -piperazinyl)phenylJ-2-oxo-5- P-92 Ethyl oxazolidinyljmethyljthioacetamide dithioacetate
160 (S)-N-[[3-[4-(4- Acetyl- 1 -piperazinyl)phenyl]-2-oxo-5- P-92 Z (a) oxazolidinyljmethyljpropanethioamide
161 (S)-N-[[3-[4-(4- Acetyl- 1 -piperazinyl)phenyl]-2-oxo-5- P-92 Z (b) oxazolidinylJmethylJ-2-methylpropanethioamide
162 (S)-N-[[3-[4-(4- Acetyl- 1 -piperazinyl)phenyl]-2-oxo-5- P-92 Z (c) oxazolidinyljmethyljcyclopropanecarbothioamide
163 (S)-N-[[3-[3-Fluoro-4-[4-(methoxyacetyl)-l- P-93 Ethyl piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methylJ- dithiothioacetamide acetate
164 (S)-N-[[3-[3-Fluoro-4-[4-(methoxyacetyl)- 1 - P-93 Z (a) piperazinyl]phenylJ-2-oxo-5-oxazolidinyl]methylJ- propanethioamide
165 (S)-N-[[3-[3-Fluoro-4-[4-(methoxyacetyl)- 1 - P-93 Z (b) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2- methylpropanethioamide
166 (S)-N-[[3-[3-Fluoro-4-[4-(methoxyacetyl)- 1 - P-93 Z (c) piperazinyl]phenylJ-2-oxo-5-oxazolidinylJmcthyl]- cyclopropanecarbothioamide
167 (S)-N-[[3-[3-Fluoro-4-[4-(methoxyacetyl)- 1 - P-93 Z (d) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methylJ- butanethioamide
168 (S)-N-[[3-[3-Fluoro-4-[4-(methoxyacetyl)- l- P-93 Z (e) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-3- methylbutanethioamide
169 (S)-N-[[3-[3-Fluoro-4-[4-(methoxyacetyl)-l- P-93 Z (f) piperazinyl]phenylJ-2-oxo-5-oxazolidinyl]methyl]-2- methylbutanethioamide Example Dithio No. Product Amine Compound
170 (S)-N-[[3-[3-Fluoro-4-[4-(methoxyacetyl)-l- P-93 Z (g) piperazinyl]phenyl]-2-oxo-5-oxazolidinylJmethylJ-3J- dimethylbutanethioamide
171 (S)-N-[[3-[3-Fluoro-4-[4-(methoxyacetyl)-l- P-93 Z (h) piperazinyl]phenylJ-2-oxo-5-oxazolidinyl]methyl]- cyclobutanecarbothioamide
172 (S)-N-[[3-[3-Fluoro-4-[4-(methoxyacetyl)-l- P-93 Z (i) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyIJ- cyclopentanecarbothioamide
173 (S)-N-[[3-[3-Fluoro-4-[4-(methoxyacetyl)-l- P-93 Z O) piperazinylJphenyl]-2-oxo-5-oxazolidinyl]methyl]- cyclohexanecarbothioamide
174 (S)-N-[[3-[3-Fluoro-4-[4-(methoxyacetyl)-l- P-93 Z (k) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2- cyclopropylethanethioamide
175 (S)-N-[[3-[3-Fluoro-4-[4-(methoxyacetyl)-l- P-93 Z (l) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2- cyclobutylethanethioamide
176 (S)-N-[[3-[3-Fluoro-4-[4-(methoxyacetyl)-l- P-93 Z (m) piperazinylJphenyl]-2-oxo-5-oxazolidinyl]methylJ-2- cyclopentylethanethioamide
177 (5)-N-[[3-[3J-Difluoro-[4-[4-(methoxyacetyl)-l- P-94 Ethyl piperazinyl]phenyl]-2-oxo-5-oxazolidinylJmethyl]- dithiothioacetamide acetate
178 (S)-N-[[3-[3,5-Difluoro-[4-[4-(methoxyacetyl)- 1 - P-94 Z (a) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methylJ- propanethioamide
179 (5)-N-[[3-[3J-Difluoro-[4-[4-(methoxyacetyl)- 1 - P-94 Z (b) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methylJ-2- methylpropanethioamide
180 (5)-N-[[3-[3J-Difluoro-[4-[4-(methoxyacetyl)-l- P-94 Z (c) piperazinylJphenyl]-2-oxo-5-oxazolidinylJmethyl]- cyclopropanecarbothioamide
14 - Example Dithio
No Product Amine Compound
181 (S)-N-[[3-[4-[4-(methoxyacetyl)- 1 -piperazinyljphenylj- P-95 Ethyl 2-oxo-5-oxazohdιnylJmethylJthιoacetamιde dithioacetate
182 (S)-N-[[3-[4-[4-(methoxyacetyl)- 1 -piperazinyljphenylj- P-95 Z (a) 2-oxo-5-oxazohdιnyl]methylJpropanethιoamιde
183 (S)-N-[[3-[4-[4-(methoxyacetyl)- 1 -piperazinyljphenylj- P-95 Z (b)
2-oxo-5-oxazohdιnyl]methyl]-2-methylpropane- thioamide
184 (S)-N-[[3-[4-[4-(methoxyacetyl)-l -piperazmyljphenylj- P-95 Z (c) 2-OXO-5- oxazohdinyljmethyljcyclopropanecarbothioamide
185 (5)-N-[[3-[3-Fluoro-4-[4-(cyanoacetyl)- l-pιperazιnylJ- P-96 Ethyl phenylJ-2-oxo-5-oxazolιdιnyl]methyl]thιoacetamιde dithioacetate
186 (S)-N-[[3-[3-Fluoro-4-[4-(cyanoacetyl)-l -piperazinyl]- P-96 Z (a) phenylJ-2-oxo-5-oxazohdinyl]methyl]propanethιo- amide
187 (S)-N-[[3-[3-Fluoro-4-[4-(cyanoacetyl)-l -piperazinyl]- P-96 Z (b) phenyl]-2-oxo-5-oxazolιdιnyl]methylJ-2-methyl- propanethioamide
(S)-N-[[3-[3-Fluoro-4-[4-(cyanoacetyl)- l-pιperazιnylJ- P-96 Z (c) phenylJ-2-oxo-5-oxazohdιnylJmethyl]cyclopropane- carbothioamide
189 (5)-N-[[3-[3,5-Dιfluoro-4-[4-(cyanoacetyl)-l- P-97 Ethyl pιperazιnylJphenylJ-2-oxo-5-oxazohdιnylJ- dithiomethyljthioacetamide acetate
190 (S)-N-[[3-[3.5-Dιfluoro-4-[4-(cyanoacetylM- P-97 Z (a) piperazinyl Jphenyl]-2-oxo-5-oxazohdιnylJ- methyljpropanethioamide
191 (5)-N-[[3-[3,5-Dιfluoro-4-[4-(cyanoacetyl)- l- P-97 Z (b) pιperazιnylJphenyl]-2-oxo-5-oxazohdιnyIJmethyl]-2- methylpropanethioamide
192 (S)-N-[[3-[3,5-Dιfluoro-4-[4-(cyanoacetyl)- P-97 Z (c) piperaziny I Jphenyl J-2-oxo-5-oxazolιdιnylJ- methyljcyclopropanecarbothioamide
15 Example Dithio
No. Product Amine Compound
193 (S)-N-[[3-[4-[4-(Cyanoacetyl)-l-piperazinyl]phenyl]-2- P-98 Ethyl oxo-5-oxazolidinyl]methyl]thioacetamide dithioacetate
194 (S)-N-[[3-[4-[4-(Cyanoacetyl)- l-piperazinyl]phenyl]-2- P-98 Z (a) oxo-5-oxazolidinylJmethylJpropanethioamide
195 (S)-N-[[3-[4-[4-(Cyanoacetyl)- l-piperazinylJphenylJ-2- P-98 Z (b) oxo-5-oxazolidinyl]methyl]-2-methylpropanethioamide
196 (S)-N-[[3-[4-[4-(Cyanoacetyl)-l-piperazinyl]phenyl]-2- P-98 Z (c) oxo-5-oxazolidinylJmethylJcycopropanecarbothio- amide
197 (S)-N-[[3-[3-Fluoro-4-[4-(acetoxyacetyl)-l- P-99 Ethyl piperazinyl]phenylJ-2-oxo-5-oxazolidinyl]methyl]- dithiothioacetamide acetate
198 (S)-N-[[3-[3-Fluoro-4-[4-(acetoxyacetyi)-l- P-99 Z (a) piperazinyl]phenylJ-2-oxo-5-oxazolidinyl]methylJ- propanethioamide
199 (S)-N-[[3-[3-Fluoro-4-[4-(acetoxyacetyl)-l- P-99 Z (b) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methylJ-2- methylpropanethioamide
200 (S)-N-[[3-[3-Fluoro-4-[4-(acetoxyacetyl)- 1 - P-99 Z (c) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- cyclopropanecarbothioamide
201 (S)-N-[[3-[3-Fluoro-4-[4-(acetoxyacetyl)-l- P-99 Z (d) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- butanethioamide
202 (S)-N-[[3-[3-Fluoro-4-[4-(acetoxyacetyl)-l- P-99 Z (e) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-3- methylbutanethioamide
203 (S)-N-[[3-[3-Fluoro-4-[4-(acetoxyacetyl)-l- P-99 Z (f) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2- methylbutanethioamide
204 (S)-N-[[3-[3-Fluoro-4-[4-(acetoxyacetyl)-l- P-99 Z (g) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-3J- di ethylbutanethioamide Example Dithio No. Product Amine Compound
205 (S)-N-[[3-[3-Fluoro-4-[4-(acetoxyacetyl)- l- P-99 Z (h) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- cyclobutanecarbothioamide
206 (S)-N-[[3-[3-Fluoro-4-[4-(acetoxyacetyl)- l- P-99 Z (i) piperazinyl]phenyI]-2-oxo-5-oxazoIidinyl]methyI]- cyclopentanecarbothioamide
207 (S)-N-[[3-[3-Fluoro-4-[4-(acetoxyacetyl)- 1 - P-99 Z fj) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- cyclohexanecarbothioamide
208 (S)-N-[[3-[3-Fluoro-4-[4-(acetoxyacetyl)-l- P-99 Z (k) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2- cyclopropylethanethioamide
209 (S)-N-[[3-[3-Fluoro-4-[4-(acetoxyacetyl)- l- P-99 Z (l) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2- cyclobutylethanethioamide
210 (S)-N-[[3-[3-Fluoro-4-[4-(acetoxyacetyl)-l- P-99 Z (m) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2- cyclopentylethanethioamide
21 1 (S)-N-[[3-[3,5-Difluoro-4-[4-(acetoxyacetyl)- 1 - P-100 Ethyl piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- dithiothioacetamide acetate
212 (S)-N-[[3-[3,5-Difluoro-4-[4-(acetoxyacetyl)J- P-100 Z (a) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- propanethioamide
213 (S)-N-[[3-[3,5-Difluoro-4-[4-(acetoxyacetyl)- l- P-100 Z (b) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2- methylpropanethioamide
214 (S)-N-[[3-[3.5-Difluoro-4-[4-(acetoxyacetyl)- l- P-100 Z (c) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- cyclopropanecarbothioamide
215 (S)-N-[[3-[4-[4-(Acetoxyacetyl)- l-piperazinyl]phenyl]- P-101 Ethyl 2-oxo-5-oxazolidinyl]methyl]thioacetamide dithioacetate
216 (S)-N-[[3-[4-[4-(Acetoxyacetyl)- l-piperazinyl]phenyl]- P- 101 Z (a) 2-oxo-5-oxazolidinyl]methyl]propanethioamide
17 - Example Dithio No Product Amine Compound
217 (S)-N-[[3-[4-[4-( Acetoxyacetyl)- 1 -pιperazιnyl]phenyl]- P- 101 Z (b)
2-oxo-5-oxazohdinyl]methyl]-2-methylpropane- thioamide
218 (S)-N-[[3-[4-[4-(Acetoxyacetyl)- l-pιperazιnyl]phenyl]- P- 101 Z (c) 2-oxo-5-oxazohdιn> l]methyl]cyclopropanecarbo- thioamide
219 (S)-N-[[3-[3-Fluoro-4-[4-(benzyloxyacetyl)-l- P-102 Ethyl pιperazιnyl]phenyl]-2-oxo-5-oxazohdιnyl]methyl]- dithiothioacetamide acetate
220 (S)-N-[[3-[3-Fluoro-4-[4-(benzyloxyacetyl)- 1 - P-102 Z (a) pιperazιnyl]phenyl]-2-oxo-5-oxazohdιnyl]methyl]- propanethioamide
221 (S)-N-[[3-[3-Fluoro-4-[4-(benzyloxyacetyl)- 1 - P- 102 Z (b) pιperazιnyl]phenyl]-2-oxo-5-oxazohdιnyl]methyI]-2- methylpropanethioamide
222 (S)-N-[[3-[3-Fluoro-4-[4-(benzyloxyacetyl)-l- P-102 Z (c) pιperazιnyl]phenyl]-2-oxo-5-oxazohdιnyl]methyl]- cyclopropanecarbothioamide
223 (S)-N-[[3-[3,5-Dιfluoro-4-[4-(benzyloxyacetyl)- 1 - P-103 Ethyl pιperazιnyl]phenyl]-2-oxo-5-oxazohdιnyl]methyl]- dithiothioacetamide acetate
224 (S)-N-[[3-[3.5-Dιfluoro-4-[4-(benzyloxy acetyl)- 1 - P- 103 Z (a) pιperazιnyl]phenyl]-2-oxo-5-oxazohdιnyl]methyl]- propanethioamide
225 (S)-N-[[3-[3,5-Dιfluoro-4-[4-(benzyloxyacetyl)- 1 - P-103 Z (b) pιperazιnyl]phenyl]-2-oxo-5-oxazohdιnyl]methyl]-2- methylpropanethioamide
226 (S)-N-[[3-[3J-Dιfluoro-4-[4-(benzyloxyacetyl)- 1 - P- 103 Z (c) pιperazιnyl]phenyl]-2-oxo-5-oxazohdιnyl]methyl]- cyclopropanecarbothioamide
227 (S)-N-[[3-[3-Fluoro-4-[4-(methoxycarbonyl)- l- P-105 Ethyl pιperazιnyl]phenyl]-2-oxo-5- dithiooxazohdιnyl]methyl]thιoacetamιde acetate
- n Example Dithio
No. Product Amine Compound
228 (S)-N-[[3-[3-Fluoro-4-[4Jmethoxycarbonyl)- l - P-105 Z (a) piperazinyl]phenyI]-2-oxo-5-oxazolidinyl]methyl]- propanethioamide
229 (S)-N-[[3-[3-Fluoro-4-[4-(methoxycarbonyl)-l- P-105 Z (b) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]J -?. methylpropanethioamide
230 (S)-N-[[3-[3-Fluoro-4-[4-(methoxycarbonyl)-l- P-105 Z (c) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- cyclopropanecarbothioamide
231 (5)-N-[[3-[3-Fluoro-4-[4-(methoxycarbonyl)-l- P- 105 Z (d) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- butanethioamide
232 (S)-N-[[3-[3-Fluoro-4-[4-(methoxycarbonyl)- l- P-105 Z (e) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-3- methylbutanethioamide
233 (5)-N-[[3-[3-Fluoro-4-[4-(methoxycarbonyl)-l- P-105 Z (f) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2- methylbutanethioamide
234 (S)-N-[[3-[3-Fluoro-4-[4-(methoxycarbonyl)-l- P- 105 Z (g) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-3J- dimethylbutanethioamide
235 (S)-N-[[3-[3-Fluoro-4-[4Jmethoxycarbonyl)-l- P- 105 Z (h) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- cyclobutanecarbothioamide
236 (S)-N-[[3-[3-Fluoro-4-[4-(methoxycarbonyl)-l- P- 105 Z (i) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- cyclopentanecarbothioamide
237 (S)-N-[[3-[3-Fluoro-4-[4-(methoxycarbonyl)-l- P-105 Z 0) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- cyclohexanecarbothioamide
238 (S)-N-[[3-[3-Fluoro-4-[4-(methoxycarbonyl)-l- P- 105 Z (k) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2- cyclopropylethanethioamide Example Dithio No. Product Amine Compound
239 (S)-N-[[3-[3-Fluoro-4-[4-(methoxycarbonyl)- 1 - P-105 Z (l) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2- cyclobutylethanethioamide
240 (S)-N-[[3-[3-Fluoro-4-[4-(methoxycarbonyl)- 1 - P-105 Z (m) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2- cyclopentylethanethioamide
241 (S)-N-[[3-[3,5-Difluoro-4-[4-(methoxycarbonyl)- 1 - P-106 Ethyl piperazinyl]phenyI]-2-oxo-5-oxazolidinyl]methyl]- dithiothioacetamide acetate
242 (S)-N-[[3-[3.5-Difluoro-4-[4-(methoxycarbonyl)-l- P-106 Z (a) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- propanethioamide
243 (S)-N-[[3-[3J-Difluoro-4-[4-(methoxycarbonyl)-l- P-106 Z (b) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2- methylpropanethioamide
244 (S)-N-[[3-[3,5-Difluoro-4-[4-(methoxycarbonyl)J- P-106 Z (c) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- cyclopropanecarbothioamide
245 (S)-N-[[3-[4-[4-(methoxycarbonyl)-l- P-107 Ethyl piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- dithiothioacetamide acetate
246 (S)-N-[[3-[4-[4-(methoxycarbonyl)-l- P- 107 Z (a) piperazιnyl]phenyl]-2-oxo-5-oxazoiidinyl]methyl]- propanethioamide
247 (S)-N-[[3-[4-[4-(methoxycarbonyl)-l- P- 107 Z (b) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2- methylpropanethioamide
248 (S)-N-[[3-[4-[4-(methoxycarbonyl)- 1 - P- 107 Z (c) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- cyclopropanecarbothioamide
249 (5)-N-[[3-[3-Fluoro-4-[4-(methanesulfonyl)- l- P-108 Ethyl piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- dithiothioacetamide mp 197- 198°C; Anal, calcd for acetate C17H23FN4O4S2: C, 47.43; H, 5.39: N. 13.01 : S. 14.89. Found: C, 47.25; H, 5.40; N. 12.82; S. 14.56. Example Dithio No. Product Amine Compound
250 (S)-N-[[3-[3-Fluoro-4-[4-(methanesulfonyl)- 1 - P-108 Z (a) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- propanethioamide; mp 207-208°C; Anal, calcd for C18H25FN4O4S2: C 48.63; H, 5.67; N. 12.60; S, 14.42. Found: C. 48.51 ; H, 5.59; N, 12.52; S, 14.09.
251 (S)-N-[[3-[3-Fluoro-4-[4-(methanesulfonyl)-l- P- 108 Z (b) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2- methylpropanethioamide; mp 204-206°C; Anal, calcd for C|9H27FN4O4S2: C, 49.76; H, 5.93; N, 12.22: S, 13.98. Found: C, 49.63; H, 5.92; N, 14.14; S, 13.91.
252 (S)-N-[[3-[3-Fluoro-4-[4-(methanesulfonyl)-l- P-108 Z (c) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- cyclopropanecarbothioamide; Anal, calcd for C19H25FN4O4S2: C, 49.98; H, 5.52; N, 12.27; S, 14.04. Found: C, 49.42; H, 5.50; N, 12.08; S, 13.80.
253 (S)-N-[[3-[3,5-Difluoro-4-[4-(methanesulfonyl)-l- P-109 Ethyl piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- dithiothioacetamide acetate
254 (S)-N-[[3-[3,5-Difluoro-4-[4-(methanesulfonyl)- 1 - P-109 Z (a) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- propanethioamide
255 (S)-N-[[3-[3,5-Difluoro-4-[4-(methanesulfonyl)- 1 - P-109 Z (b) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2- methylpropanethioamide
256 (5)-N-[[3-[3,5-Difluoro-4-[4-(methanesulfonyl)-l- P-109 Z (c) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- cyclopropanecarbothioamide
257 (S)-N-[[3-[4-[4-(methanesulfony 1)- 1 - P-110 Ethyl piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- dithiothioacetamide acetate
258 (S)-N-[[3-[4-[4-(methanesulfonyl)- l- P-1 10 Z (a) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- propanethioamide
259 (S)-N-[[3-[4-[4-(methanesulfonyl)- l- P- 1 10 Z (b) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyI]-2- methylpropanethioamide Example Dithio No. Product Amine Compound
260 (S)-N-[[3-[4-[4-(methanesulfonyl)-l- P-1 10 Z (c) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- cyclopropanecarbothioamide
261 (S)-N-[[3-[3-Fluoro-4-[4-(ethanesulfonyl)- 1 - P-11 1 Ethyl piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- dithiothioacetamide acetate
262 (S)-N-[[3-[3-Fluoro-4-[4-(ethanesulfonyl)-l- P-111 Z (a) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- propanethioamide
263 (S)-N-[[3-[3-Fluoro-4-[4-(ethanesulfonyl)-l- P-111 Z (b) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2- methylpropanethioamide
264 (S)-N-[[3-[3-Fluoro-4-[4-(ethanesulfonyl)-l- P-111 Z (c) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- cyclopropanecarbothioamide
265 (S)-N-[[3-[3,5-Difluoro-4-[4-(ethanesulfonyl)- 1 - P-1 12 Ethyl piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- dithiothioacetamide acetate
266 (S)-N-[[3-[3,5-Difluoro-4-[4-(ethanesulfonyl)- 1 - P-1 12 Z (a) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- propanethioamide
267 (S)-N-[[3-[3,5-Difluoro-4-[4-(ethanesulfonyl)- 1 - P-1 12 Z (b) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2- methylpropanethioamide
268 (S)-N-[[3-[3,5-Difluoro-4-[4-(ethanesulfonyl)- l- P-1 12 Z (c) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- cyclopropanecarbothioamide
269 (S)-N-[[3-[4-[4-(ethanesulfonyl)- 1 -piperazinyl]phenyl]- P- 113 Ethyl 2-oxo-5-oxazolidinyl]methyl]thioacetamide dithioacetate
270 (S)-N-[[3-[4-[4-(ethanesulfonyl)- 1 -piperazinyl]phenyl]- P-1 13 Z (a) 2-oxo-5-oxazolidinyl]methyl]propanethioamide
271 (S)-N-[[3-[4-[4-(ethanesulfonyl)- l-piperazinyl]phenyl]- P- 1 13 Z (b) 2-oxo-5-oxazolidinyl]methyl]-2-methylpropane- thioamide Example Dithio No. Product Amine Compound
272 (S)-N-[[3-[4-[4-(ethanesulfonyl)- 1 -piperazinyl]phenyl]- P-113 Z (c)
2-oxo-5-oxazolidinyl]methyI]cyclopropanecarbothio- amide
273 (S)-N-[[3-[3-Fluoro-4-[4-(chloromethanesulfonyl)- P-114 Ethyl piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- dithiothioacetamide acetate
274 (S)-N-[[3-[3-Fluoro-4-[4-(chloromethanesulfonyl)- 1 - P-1 14 Z (a) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- propanethioamide
275 (S)-N-[[3-[3-Fluoro-4-[4-(chloromethanesulfonyl)- 1 - P-1 14 Z (b) piperazinyI]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2- methylpropanethioamide
276 (S)-N-[[3-[3-Fluoro-4-[4-(chloromethanesulfonyl)- 1 - P-1 14 Z (c) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- cyclopropanecarbothioamide
277 (S)-N-[[3-[3,5-Difluoro-4-[4-(chloromethanesulfonyl)- P-115 Ethyl l-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- dithiothioacetamide acetate
278 (S)-N-[[3-[3,5-Difluoro-4-[4-(chloromethanesulfonyl)- P-115 Z (a) l-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- propanethioamide
279 (S)-N-[[3-[3,5-Difluoro-4-[4-(chloromethanesulfonyl)- P-1 15 Z (b) l-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2- methylpropanethioamide
280 (S)-N-[[3-[3,5-Difluoro-4-[4-(chloromethanesulfonyl)- P-1 15 Z (c) l-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- cyclopropanecarbothioamide
281 (S)-N-[[3-[4-[4-(chloromethanesulfonyl)- l- P-1 16 Ethyl piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- dithio- thioacetamide acetate
282 (S)-N-[[3-[4-[4-(chloromethanesulfonyl)-l- P- 1 16 Z (a) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- propanethioamide Example Dithio No. Product Amine Compound
283 (S)-N-[[3-[4-[4-(chloromethanesulfonyl)-l- P-1 16 Z (b) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2- methylpropanethioamide
284 (S)-N-[[3-[4-[4-(chloromethanesulfonyl)-l- P-116 Z (c) piperazinyI]phenyl]-2-oxo-5-oxazolidinyl]methyl]- cyclopropanecarbothioamide
285 (S)-N-[[3-[3-Fluoro-4-[4-(cyanomethane-sulfonyl)-l- P-1 17 Ethyl piperazinyl]phenyl]-2-oxo-5- dithiooxazolidinyl]methyl]thioacetamide acetate
286 (S)-N-[[3-[3-Fluoro-4-[4-(cyanomethane-sulfonyl)- 1 - P-1 17 Z (a) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- propanethioamide
287 (S)-N-[[3-[3-Fluoro-4-[4-(cyanomethane-sulfonyl)-l- P-117 Z (b) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2- methylpropanethioamide
288 (S)-N-[[3-[3-Fluoro-4-[4-(cyanomethane-sulfonyl)-l- P-1 17 Z (c) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- cyclopropanecarbothioamide
289 (S)-N-[[3-[3,5-Difluoro-4-[4-(cyanomethane-sulfonyI)- P- 1 18 Ethyl l-piperazinyl]phenyl]-2-oxo-5- dithiooxazolidinyl]methyl]thioacetamide acetate
290 (S)-N-[[3-[3,5-Difluoro-4-[4-(cyanomethane-sulfonyl)- P-118 Z (a) l-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]- methyl]propanethioamide
291 (S)-N-[[3-[3,5-Difluoro-4-[4-(cyanomethane-sulfonyD- P-1 18 Z (b) l-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2- methylpropanethioamide
292 (S)-N-[[3-[3,5-Difluoro-4-[4-(cyanomethane-sulfonyl)- P- 1 18 Z (c) l-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- cyclopropanecarbothioamide
293 (S)-N-[[3-[4-[4-(Cyanomethanesulfonyl)- l- P-1 19 Ethyl piperazinyl]phenyl]-2-oxo-5- dithiooxazolidinyl]methyl]thioacetamide acetate Example Dithio
No. Product Amine Compound
294 (S)-N-[[3-[4-[4-(Cyanomethanesulfonyl)- 1 - P-119 Z (a) pipεrazinyl]phenyl]-2-oxo-5- oxazolidinyl]methyl]propanethioamide
295 (S)-N-[[3-[4-[4-(Cyanomethanesulfonyl)- 1 - P-1 19 Z (b) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2- methylpropanethioamide
296 (S)-N-[[3-[4-[4-(Cyanomethanesulfonyl)-l- P- 119 Z (c) piperazinyl]phenyl]-2-oxo-5- oxazolidinyl]methyl]cyclopropanecarbothioamide
297 (S)-N-[[3-[3-Fluoro-4-[4-(N-methylsulfamoyl)- l- P-120 Ethyl piperazinyl]phenyl]-2-oxo-5- dithiooxazolidinyl]methyl]thioacetamide acetate
298 (S)-N-[[3-[3-Fluoro-4-[4-(N-methylsulfamoyI)-l- P- 120 Z (a) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- propanethioamide
299 (S)-N-[[3-[3-Fluoro-4-[4-(N-methylsulfamoyl)-l- P- 120 Z (b) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2- methylpropanethioamide
300 (S)-N-[[3-[3-Fluoro-4-[4-(N-methylsulfamoyl)- 1 - P-120 Z (c) piperazinyI]phenyl]-2-oxo-5-oxazolidinyl]methyl]- cyclopropanecarbothioamide
301 (S)-N-[[3-[3J-Difluoro-4-[4-(N-methylsulfamoyl)-l- P-121 Ethyl piperazinyl]phenyl]-2-oxo-5- dithiooxazolidinyl]methyl]thioacetamide acetate
302 (S)-N-[[3-[3,5-Difluoro-4-[4-(N-methylsulfamoyl)- l- P- 121 Z (a) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- propanethioamide
303 (S)-N-[[3-[3,5-Difluoro-4-[4-(N-methylsulfamoyl)-l - P- 121 Z (b) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2- methylpropanethioamide
304 (5)-N-[[3-[3J-Difluoro-4-[4-(N-methylsulfamoyl)-l- P- 121 Z (c) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- cyclopropanecarbothioamide Example Dithio
No. Product Amine Compound
305 (S)-N-[[3-[4-[4-(N-methylsulfamoyl)- 1 - P- 122 Ethyl piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- dithiothioacetamide acetate
306 (S)-N-[[3-[4-[4-(N-methylsulfamoyl)-l- P-122 Z (a) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- propanethioamide
307 (S)-N-[[3-[4-[4-(N-methylsulfamoyl)- 1 - P-122 Z (b) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2- methylpropanethioamide
308 (S)-N-[[3-[4-[4-(N-methylsulfamoyl)-l- P-122 Z (c) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- cyclopropanecarbothioamide
309 (S)-N-[[3-[3-Fluoro-4-[4-(N,N-dimethylsulfamoyl)- l- P-123 Ethyl piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- dithiothioacetamide acetate
310 (S)-N-[[3-[3-Fluoro-4-[4-(N,N-dimethylsulfamoyl)- 1 - P-123 Z (a) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- propanethioamide
31 1 (S)-N-[[3-[3-Fluoro-4-[4-(N,N-dimethylsulfamoyl)-l- P-123 Z (b) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2- methylpropanethioamide
312 (S)-N-[[3-[3-Fluoro-4-[4-(N,N-dimethylsulfamoyl)- l- P- 123 Z (c) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- cyclopropanecarbothioamide
313 (S)-N-[[3-[3,5-Difluoro-4-[4-(N.N-dimethylsulfamoyl)- P-124 Ethyl l-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- dithiothioacetamide acetate
314 (S)-N-[[3-[3J-Difluoro-4-[4-(N,N-dimethylsulfamoyl)- P- 124 Z (a) l-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- propanethioamide
315 (S)-N-[[3-[3,5-Difluoro-4-[4-(N.N-dimethylsulfamoyl)- P- 124 Z (b) l-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2- methylpropanethioamide Example Dithio No. Product Amine Compound
316 (S)-N-[[3-[3,5-Difluoro-4-[4-(N.N-dimethylsulfamoyl)- P-124 Z (c) l-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- cyclopropanecarbothioamide
317 (S)-N-[[3-[4-[4-(N,N-dimethylsulfamoyl)- l- P-125 Ethyl piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- dithiothioacetamide acetate
318 (S)-N-[[3-[4-[4-(N,N-dimethylsulfamoyl)-l- P-125 Z (a) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- propanethioamide
319 (S)-N-[[3-[4-[4JN,N-dimethylsulfamoyl)-l- P-125 Z (b) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2- methylpropanethioamide
320 (S)-N-[[3-[4-[4-(N,N-dimethylsulfamoyl)- 1 - P-125 Z (c) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- cyclopropanecarbothioamide
321 (S)-N-[[3-[3-Fluoro-4-[4-(ethoxycarbonyl)-l- P-126 Ethyl piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- dithiothioacetamide acetate
322 (S)-N-[[3-[3-Fluoro-4-[4-(ethoxycarbonyl)-l- P-126 Z (a) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- propanethioamide
323 (S)-N-[[3-[3-Fluoro-4-[4Jethoxycarbonyl)-l- P- 126 Z (b) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2- methylpropanethioamide
324 (S)-N-[[3-[3-Fluoro-4-[4-(ethoxycarbonyl)- l- P-126 Z (c) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- cyclopropanecarbothioamide
325 (S)-N-[[3-[3-Fluoro-4-[4-(ethoxycarbonyl)-l- P-126 Z (d) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- butanethioamide
326 (S)-N-[[3-[3-Fluoro-4-[4-(ethoxycarbonyl)- 1 - P-126 Z (e) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-3- methylbutanethioamide Example Dithio No. Product Amine Compound
327 (S)-N-[[3-[3-Fluoro-4-[4-(ethoxycarbonyl)- l- P-126 Z (f) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2- methylbutanethioamide
328 (S)-N-[[3-[3-Fluoro-4-[4-(ethoxycarbonyl)- l- P- 126 Z (g) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-3J- dimethylbutanethioamide
329 (S)-N-[[3-[3-Fluoro-4-[4-(ethoxycarbonyl)-l- P-126 Z (h) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- cyclobutanecarbothioamide
330 (S)-N-[[3-[3-Fluoro-4-[4-(ethoxycarbonyl)-l- P-126 Z (i) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- cyclopentanecarbothioamide
331 (S)-N-[[3-[3-Fluoro-4-[4-(ethoxycarbonyl)-l- P-126 Z O) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- cyclohexanecarbothioamide
332 (S)-N-[[3-[3-Fluoro-4-[4-(ethoxycarbonyl)-l- P-126 Z (k) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2- cyclopropylethanethioamide
333 (S)-N-[[3-[3-Fluoro-4-[4-(ethoxycarbonyl)-l- P-126 Z (l) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2- cyclobutylethanethioamide
334 (S)-N-[[3-[3-Fluoro-4-[4-(ethoxycarbonyl)-l- P-126 Z (m) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2- cyclopentylethanethioamide
335 (5)-N-[[3-[3,5-Difluoro-4-[4-(ethoxycarbonyl)-l- P- 127 Ethyl piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- dithiothioacetmide acetate
336 (S)-N-[[3-[3J-Difluoro-4-[4-(ethoxycarbonyl)- 1 - P- 127 Z (a) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- propanethioamide
337 (S)-N-[[3-[3J-Difluoro-4-[4-(ethoxycarbonyl)- l- P-127 Z (b) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2- methylpropanethioamide Example Dithio No. Product Amine Compound
338 (S)-N-[[3-[3,5-Difluoro-4-[4-(ethoxycarbonyl)- l- P- 127 Z (c) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- cyclopropanecarbothioamide
339 (S)-N-[[3-[4-[4-(ethoxycarbonyl)- 1 -piperazinyl]- P-128 Ethyl phenyl]-2-oxo-5-oxazolidinyl]methyl]thioacetamide dithioacetate
340 (S)-N-[[3-[4-[4-(ethoxycarbonyl)-l-piperazinyl]- P-128 Z (a) phenyl]-2-oxo-5-oxazolidinyl]methyl]- propanethioamide
341 (S)-N-[[3-[4-[4-(ethoxycarbonyl)- 1 -piperazinyl]- P-128 Z (b) phenyl]-2-oxo-5-oxazolidinyl]methyl]-2- methylpropanethioamide
342 (S)-N-[[3-[4-[4-(ethoxycarbonyl)-l-piperazinyl]- P-128 Z (c) phenyl]-2-oxo-5-oxazolidinyl]methyl]cyclopropane- carbothioamide
343 (S)-N-[[3-[3-Fluoro-4-(4-sulfamoyl- 1 -piperazinyl)- P-129 Ethyl phenyl]-2-oxo-5-oxazolidinyl]methyl]thioacetamide dithioacetate
344 (S)-N-[[3-[3-Fluoro-4-(4-sulfamoyl- 1 -piperazinyl)- P-129 Z (a) phenyl]-2-oxo-5-oxazolidinyl]methyl]- propanethioamide
345 (S)-N-[[3-[3-Fluoro-4-(4-sulfamoyl- 1 -piperazinyl)- P-129 Z (b) phenyl]-2-oxo-5-oxazolidinyl]methyl]-2- methylpropanethioamide
346 (5)-N-[[3-[3-Fluoro-4-(4-sulfamoyl- l-piperazinyl)- P-129 Z (c) phenyl]-2-oxo-5-oxazolidinyl]methyl]- cyclopropanecarbothioamide
347 (S)-N-[[3-[3-Fluoro-4-(4-sulfamoyl- 1 - P- 129 Z (d) piperazinyl)phenyl]-2-oxo-5- oxazolidinyl]methyl]butanethioamide
348 (5)-N-[[3-[3-Fluoro-4-(4-sulfamoyl- 1 - P- 129 Z (e) piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-3- methylbutanethioamide Example Dithio No. Product Amine Compound
349 (S)-N-[[3-[3-Fluoro-4-(4-sulfamoyl- l- P-129 Z (f) piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyI]-2- methylbutanethioamide
350 (S)-N-[[3-[3-Fluoro-4-(4-sulfamoyl- l- P-129 Z (g) piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-3J- dimethylbutanethioamide
351 (S)-N-[[3-[3-Fluoro-4-(4-sulfamoyl- l- P-129 Z (h) piperazinyl)phenyl]-2-oxo-5- oxazolidinyl]methyl]cyclobutanecarbothioamide
352 (S)-N-[[3-[3-Fluoro-4-(4-sulfamoyl-l- P-129 Z (i) piperazinyl)phenyl]-2-oxo-5- oxazolidinyl]methyl]cyclopentanecarbothioamide
353 (S)-N-[[3-[3-Fluoro-4-(4-sulfamoyl-l- P-129 Z (j) piperazinyl)phenyl]-2-oxo-5- oxazolidinyl]methyl]cyclohexanecarbothioamide
354 (S)-N-[[3-[3-Fluoro-4-(4-sulfamoyl-l- P- 129 Z (k) piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-2- cyclopropylethanethioamide
355 (S)-N-[[3-[3-Fluoro-4-(4-sulfamoyl- 1 - P-129 Z (l) piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-2- cyclobutylethanethioamide
356 (5)-N-[[3-[3-Fluoro-4-(4-sulfamoyl-l- P-129 Z (m) piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-2- cyclopentylethanethioamide
357 (S)-N-[[3-[3J-Difluoro-4-(4-sulfamoyl-l- P-130 Ethyl piperazinyl)phenyl]-2-oxo-5- dithiooxazolidinyl]methyl]thioacetamide acetate
358 (S)-N-[[3-[3.5-Difluoro-4-(4-sulfamoyl-l- P-130 Z (a) piperazinyl)phenyl]-2-oxo-5- oxazolidinyl]methyl]propanethioamide
359 (S)-N-[[3-[3.5-Difluoro-4-(4-sulfamoyl-l- P-130 Z (b) piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-2- methylpropanethioamide Example Dithio No. Product Amine Compound
360 (S)-N-[[3-[3.5-Difluoro-4-(4-sulfamoyl- l- P- 130 Z (c) piperazinyl)phenyl]-2-oxo-5- oxazolidinyl]methyl]cyclopropanecarbothioamide
361 (S)-N-[[3-[4-(4-sulfamoyl-l-piperazinyl)phenyl]-2-oxo- P-131 Ethyl 5-oxazolidinyl]methyl]thioacetamide dithioacetate
362 (S)-N-[[3-[4-(4-suIfamoyl-l-piperazinyl)phenyl]-2-oxo- P- 131 Z (a) 5-oxazolidinyl]methyl]propanethioamide
363 (S)-N-[[3-[4-(4-sulfamoyl- l-piperazinyl)phenyl]-2-oxo- P-131 Z (b) 5-oxazolidinyl]methyl]-2-methylpropanethioamide
364 (S)-N-[[3-[4-(4-sulfamoyl-l-piperazinyl)phenyl]-2-oxo- P-131 Z (c) 5-oxazolidinyI]methyl]cyclopropanecarbothioamide
365 (S)-N-[[3-[3-Fluoro-4-[4-(cyanomethyl)- 1 - P-132 Ethyl piperazinyl]phenyl]-2-oxo-5- dithiooxazolidinyl]methyl]thioacetamide acetate
366 (S)-N-[[3-[3-Fluoro-4-[4-(cyanomethyl)-l- P-132 Z (a) piperazinyl]phenyl]-2-oxo-5- oxazolidinyl]methyl]propanethioamide
367 (S)-N-[[3-[3-Fluoro-4-[4-(cyanomethyl)-l- P-132 Z (b) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2- methylpropanethioamide
368 (S)-N-[[3-[3-Fluoro-4-[4-(cyanomethyl)-l- P- 132 Z (c) piperazinyl]phenyl]-2-oxo-5- oxazolidinyl]methyl]cyclopropanecarbothioamide
369 (S)-N-[[3-[3,5-Difluoro-4-[4-( cyanomethyl)-l- P-133 Ethyl piperazinyI]phenyl]-2-oxo-5- dithiooxazolidinyl]methyl]thioacetamide acetate
370 (S)-N-[[3-[3,5-Difluoro-4-[4-( cyanomethyl)- l- P- 133 Z (a) piperazinyl]phenyl]-2-oxo-5- oxazolidinyl]methyl]propanethioamide
371 (S)-N-[[3-[3,5-Difluoro-4-[4 cyanomethyl)-l- P-133 Z (b) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2- methylpropanethioamide Example Dithio
No. Product Amine Compound
372 (S)-N-[[3-[3,5-Difluoro-4-[4-(cyanomethyl)- 1 - P-133 Z (c) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- cyclopropanecarbothioamide
373 (S)-N-[[3-[4-[4-(cyanomethyl)-l-piperazinyl]phenyl]-2- P-134 Ethyl oxo-5-oxazolidinyl]methyl]thioacetamide dithioacetate
374 (S)-N-[[3-[4-[4-(cyanomethyl)-l-piperazinyl]phenyl]-2- P-134 Z (a) oxo-5-oxazolidinyl]methyl]propanethioamide
375 (S)-N-[[3-[4-[4-(cyanomethyl)- l-piperazinyl]phenyl]-2- P-134 Z (b) oxo-5-oxazolidinyl]methyl]-2-methylpropanethioamide
376 (S)-N-[[3-[4-[4-( cyanomethyl)- 1 -piperazinyl]phenyl]- P-134 Z (c)
2-oxo-5-oxazolidinyl]methyl]cyclopropane- carbothioamide
377 (S)-N-[[3-[3-Fluoro-4-[4-(2-fluoroethyl)-l- P-135 Ethyl piperazinyl]phenyl]-2-oxo-5- dithiooxazolidinyl]methyl]thioacetamide acetate
378 (S)-N-[[3-[3-Fluoro-4-[4-(2-fluoroethyl)- 1 - P-135 Z (a) piperazinyl]phenyl]-2-oxo-5- oxazolidinyl]methyl]propanethioamide
379 (S)-N-[[3-[3-Fluoro-4-[4-(2-fluoroethyl)-l- P-135 Z (b) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2- methylpropanethioamide
380 (S)-N-[[3-[3-Fluoro-4-[4-(2-fluoroethyl)- 1 - P-135 Z (c) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- cyclopropanecarbothioamide
381 (S)-N-[[3-[3,5-Difluoro-4-[4-(2-fluoroethyl)- l- P-136 Ethyl piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- dithiothioacetamide acetate
382 (S)-N-[[3-[3.5-Difluoro-4-[4-(2-fluoroethyl)- 1 - P-136 Z (a) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- propanethioa ide
383 (S)-N-[[3-[3.5-Difluoro-4-[4-(2-fluoroethyl)- 1 - P- 136 Z (b) piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2- methylpropanethioamide Example Dithio No. Product Amine Compound
384 (S)-N-[[3-[3,5-Difluoro-4-[4-(2-fluoroethyl)- l- P-136 Z (c) piperazinyI]phenyl]-2-oxo-5-oxazolidinyl]methyl]- cyclopropanecarbothioamide
385 (S)-N-[[3-[4-[4-(2-fluoroethyl)- 1 -piperazinyl]phenyl]- P- 137 Ethyl 2-oxo-5-oxazolidinyl]methyl]thioacetamide dithioacetate
386 (S)-N-[[3-[4-[4-(2-fluoroethyl)- l-piperazinyl]phenyl]- P-137 Z (a) 2-oxo-5-oxazolidinyl]methyI]propanethioamide
387 (S)-N-[[3-[4-[4-(2-Ωuoroethyl)- l-piperazinyl]phenyl]- P- 137 Z (b) 2-oxo-5-oxazolidinyl]methyl]-2- methylpropanethioamide
388 (S)-N-[[3-[4-[4-(2-fluoroethyl)- l-piperazinyl]phenyl]- P- 137 Z (c) 2-oxo-5-oxazolidinyl]methyl]cyclopropane- carbothioamide
389 (S)-N-[[3-[3-Fluoro-4-(4-formyl-l-piperazinyl)phenyl]- P-138 Ethyl 2-oxo-5-oxazolidinyl]methyl]thioacetamide; Anal calcd dithiofor C,7H2|FN4O3S: C, 53.67; H, 5.56; N, 14.73; S, acetate 8.43. Found: C, 53.14; H, 5.42; N, 14.25; S, 8.18.
390 (S)-N-[[3-[3-Fluoro-4-(4-formyl-l-piperazinyl)phenyl]- P-138 Z (a) 2-oxo-5-oxazolidinyl]methyl]propanethioamide; mp 166-167°C; Anal, calcd for C18H23FN4O3S: C, 54.81;
H, 5.88; N, 14.20; S, 8J3. Found: C, 54.83; H, 6.00; N, 14.12; S, 7.96.
391 (S)-N-[[3-[3-Fluoro-4-(4-formyl-l-piperazinyl)phenyl]- P- 138 Z (b) 2-oxo-5-oxazolidinyl]methyl]-2-methylpropane- thioamide; mp 157-158°C: Anal, calcd for C19H25FN4O3S: C, 55.87, H, 6.17; N, 13.72; S, 7.85. Found: C, 55.67; H, 6.19; N, 13.50; S, 7.70.
392 (5)-N-[[3-[3-Fluoro-4-(4-formyl- l-piperazinyl)phenyl]- P- 138 Z (c) 2-oxo-5-oxazolidinyl]methyl]cyclopropane- carbothioamide; mp 178-179°C; Anal, calcd for C19H23FN4O3S: C, 56.14; H, 5.70; N, 13.78; S, 7.89. Found: C. 56.13; H, 5.64; N, 13.64; S. 7.75.
393 (S)-N-[[3-[3,5-Difluro-4-(4-formyl-l-piperazinyl)- P-139 Ethyl phenyl]-2-oxo-5-oxazolidinyl]methyl]thioacetamide dithioacetate Example Dithio
No. Product Amine Compound
394 (S)-N-[[3-[3,5-Difluro-4-(4-formyl- l-piperazinyl)- P-139 Z (a) phenyl]-2-oxo-5-oxazolidinyl]methyl]- propanethioamide
395 (S)-N-[[3-[3J-Difluro-4-(4-formyl-l-piperazinyl)- P-139 Z (b) phenyl]-2-oxo-5-oxazolidinyl]methyl]-2-methyl- propanethioamide
396 (S)-N-[[3-[3,5-Difluro-4-(4-formyl-l-piperazinyl)- P-139 Z (c) phenyl]-2-oxo-5-oxazolidinyl]methyl]cyclo- propanecarbothioamide
397 (S)-N-[[3-[4-(4-formyl- 1 -piperazinyl)phenyl]-2-oxo-5- P- 140 Ethyl oxazolidinyl]methyl]thioacetamide dithioacetate
398 (S)-N-[[3-[4-(4-formyl-l-piperazinyl)phenyl]-2-oxo-5- P-140 Z (a) oxazolidinyl]methyl]propanethioamide
399 (S)-N-[[3-[4-(4-formyl- 1 -piperazinyl)phenyl]-2-oxo-5- P-140 Z (b) oxazolidinyl]methyl]-2-methylpropanethioamide
400 (S)-N-[[3-[4-(4-formyl- 1 -piperazinyl)phenyl]-2-oxo-5- P-140 Z (c) oxazolidinyl]methyl]cyclopropane-carbothioamide
When in the general procedure of Example 31 , step 1 , an appropriate amount of the amine listed below is substituted for compound 33, the isothiocyanate corresponding to the amines P-90, P-93, P-99, P-105, P-126 and P-129 are obtained.
When in the general procedure of Example 1 14 an appropriate amount of the isothiocyanate and the amine listed below are substituted for compound 82 and methylamine, the respective products listed below are obtained.
TABLE I
Isothiocyanate
Example Corresponding
No. Product to Amine No. Amine
401 (S)-N-[[3-[3-Fluoro-4-(4-acetyl- l- P-90 methylamine piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]- methyl]-N'-methylthiourea Isothiocyanate
Example Corresponding
No. Product to Amine No. Amine
402 (S)-N-[[3-[3-Fluoro-4-(4-acetyl- 1 - P-90 dimethvlamine piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]- methyl]-N',N'-dimethylthiourea
403 (S)-N-[[3-[3-Fluoro-4-(4-acetyl- 1 - P-90 azetidine piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]- methyl]- 1 -azetidinecarbothioamide
404 (S)-N-[[3-[3-Fluoro-4-(4-thiomorpholinyl)- P-90 anhydrous phenyl]-2-oxo-5-oxazolidinyl]methy!]- ammonia thiourea
405 (S)-N-[[3-[3-Fluoro-4-[4-(methoxyacetyl)- 1 - P-93 methylamine piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]- methyl]-N'-methylthiourea
406 (S)-N-[[3-[3-Fluoro-4-[4-(methoxyacetyl)J- P-93 dimethylamine piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]- methyl]-N',N'-dimethylthiourea
407 (S)-N-[[3-[3-Fluoro-4-[4-(methoxyacetyI)- 1 - P-93 azetidine piperazinyl]phenyl]-2-oxo-5- oxazolidinyl]methyl]- 1 - azetidinecarbothioamide
408 (S)-N-[[3-[3-Fluoro-4-[4-(acetoxyacetyl)-l- P-99 methylamine piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]- methyl]-N'-methylthiourea
409 (S)-N-[[3-[3-Fluoro-4-[4-(acetoxyacetyl)- 1 - P-99 dimethylamine piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]- methyl]-N',N'-dimethylthiourea
410 (S)-N-[[3-[3-Fluoro-4-[4-(acetoxyacetyI)-l- P-99 azetidine piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]- methyl]- 1 -azetidinecarbothioamide
41 1 (S)-N-[[3-[3-Fluoro-4-[4-(methoxycarbonyl)- P-105 methylamine l-piperazinyl]pheny!]-2-oxo-5-oxazolidinyl]- methyl]-N'-methylthiourea
412 (S)-N-[[3-[3-Fluoro-4-[4-(methoxycarbonyl)- P-105 dimethylamine l-piperazinyl]phenyl]-2-oxo-5-oxazolidiny!]- methyl]-N',N'-dimethylthiourea Isothiocyanate
Example Corresponding
No. Product to Amine No. Amine
413 (S)-N-[[3-[3-Fluoro-4-[4-(methoxycarbonyl)- P-105 azetidine l-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]- methyl]-l -azetidinecarbothioamide
414 (S)-N-[[3-[3-Fluoro-4-[4-(ethoxycarbonyl)-l- P-126 methylamine piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]- methyl]-N'-methylthiourea
415 (S)-N-[[3-[3-Fluoro-4-[4-(ethoxycarbonyl)-l- P-126 dimethylamine piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]- methyl]-N'.N'-dimethylthiourea
416 (S)-N-[[3-[3-Fluoro-4-[4-(ethoxycarbonyl)- 1 - P-126 azetidine piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]- methyl]- 1 -azetidinecarbothioamide
417 (S)-N-[[3-[3-Fluoro-4-(4-sulfamoyl- 1 - P-129 methylamine piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]- methyl]-N'-methylthiourea
418 (S)-N-[[3-[3-Fluoro-4-(4-sulfamoyl- 1 - P-129 dimethylamine piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]- methyl]-N',N'-dimethylthiourea
419 (S)-N-[[3-[3-Fluoro-4-(4-sulfamoyl-l- P-129 azetidine piperazinyl)phenyl]-2-oxo-5~oxazolidinyl]- methyl]- 1 -azetidinecarbothioamide
When in the general procedure of Example 100 an appropriate amount of the isothiocyanate and alcohol listed below are utilized in the same manner as Compound 82 and methanol are utilized, the respective products listed below are obtained.
TABLE J
Isothiocyanate
Example Corresponding No. Product to Amine No. Amine
420 (S)-N-[[3-[3-Fluoro-4-(4-acetyl- 1 - P-90 methanol piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]- methyl]-0-methylthiocarbamate Isothiocyanate
Example Corresponding No. Product to Amine No. Amine
421 (S)-N-[[3-[3-Fluoro-4-(4-acetyl- 1 - P-90 ethanol piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]- methyl]-O-ethylthiocarbamate
422 (S)-N-[[3-[3-Fluoro-4-(4-acetyl- 1 - P-90 isopropyl piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]- alcohol methyl]-O-«o-propylthiocarbamate
423 (S)-N-[[3-[3,5-Difluoro-4-(4-acetyl-l- P-91 methanol piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]- methyI]-O-methylthiocarbamate
424 (S)-N-[[3-[4-(4- Acetyl- 1- P-92 methanol piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]- methyl]-O-methylthiocarbamate
425 (S)-N-[[3-[3-Fluoro-4-[4-(methoxyacetyl)- 1 ■ P-93 methanol piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]- methyl]-O-methylthiocarbamate
426 (S)-N-[[3-[3-Fluoro-4-[4-(methoxyacetyl)-l- P-93 ethanol piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]- methyl]-O-ethylthiocarbamate
427 (S)-N-[[3-[3-Fluoro-4-[4-(methoxyacetyl)-l- P-93 isopropyl piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]- alcohol methyl]-O- Λ(7-propylthiocarbamate
428 (S)-N-[[3-[3J-Difluoro-[4-[4-(methoxy- P-94 methylaminel acetyl)- 1 -piperazinyl]phenyl]-2-oxo-5- oxazolidinyl]methyl]-O-methylthiocarbamate
429 (S)-N-[[3-[4-[4-(methoxyacetyl)- l- P-95 methylamine piperazinyl]phenyl]-2-oxo-5- oxazolidinyl]methyl]-O-methylthiocarbamate
430 (S)-N-[3-[3-Fluoro-4-[4-(cyanoacetyl)- l- P-96 methanol piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]- methyl]-O-methylthiocarbamate
431 (S)-N-[[3-[3,5-Difluoro-4-[4-(cyanoacetyl)- P-97 methanol l-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]- methyl]-O-methylthiocarbamate Isothiocyanate
Example Corresponding No. Product to Amine No. Amine
432 (S)-N-[[3-[4-[4-(Cyanoacetyl)-l- P-98 methanol piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]- methyl]-O-methylthiocarbamate
433 (S)-N-[[3-[3-Fluoro-4-[4-(acetoxyacetyl)-l- P-99 methanol piperazinyl]phenyl]-2-oxo-5-oxazo!idinyl]- methyl]-O-methylthiocarbamate
434 (S)-N-[[3-[3-Fluoro-4-[4-(acetoxyacetyl)- 1 - P-99 ethanol piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]- methyl]-O-ethylthiocarbamate
435 (S)-N-[[3-[3-Fluoro-4-[4J acetoxyacetyl)-! - P-99 isopropyl piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]- alcohol methyl]-0-/.rø-propylthiocarbamate
436 (S)-N-[[3-[3,5-Difluoro-4-[4-(acetoxyacetyl)- P-100 methanol l-piperazinyl]phenyI]-2-oxo-5-oxazolidinyl]- methyl]-O-methylthiocarbamate
437 (S)-N-[[3-[4-[4-(Acetoxyacetyl)- 1 - P-101 methanol piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]- methyl]-O-methylthiocarbamate
438 (S)-N-[[3-[3-Fluoro-4-[4-(benzyloxyacetyl)- P-102 methanol l-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]- methyl]-0-methylthiocarbamate
439 (S)-N-[[3-[3.5-Difluoro-4-[4-(benzyloxy- P-103 methanol acetyl)- 1 -piperazinyl]pheny l]-2-oxo-5- oxazolidinyl]methyl]-O-methylthiocarbamate
440 (S)-N-[[3-[3-Fluoro-4-[4-(methoxycarbonyl)- P-105 methanol l-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]- methyl]-O-methylthiocarbamate
441 (S)-N-[[3-[3-Fluoro-4-[4-(methoxycarbonyl)- P- 105 ethanol l-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]- methyl]-O-ethylthiocarbamate
442 (S)-N-[[3-[3-Fluoro-4-[4-(methoxycarbonyl)- P- 105 isopropyl l-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]- alcohol methyl]-O-/.rø-propylthiocarbamate Isothiocyanate
Example Corresponding No. Product to Amine No. Amine
443 (S)-N-[[3-[3,5-Difluoro-4-[4-(methoxy- P-106 methanol carbonyl)- 1 -piperazinyl]phenyl]-2-oxo-5- oxazolidinyl]methyl]-O-methylthiocarbamate
444 (S)-N-[[3-[4-[4-(methoxycarbonyl)-l- P-107 methanol piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]- methyl]-O-methylthiocarbamate
445 (S)-N-[[3-[3-Fluoro-4-[4-(methanesulfonyl)- P-108 methanol l-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]- methyl]-O-methylthiocarbamate
446 (S)-N-[[3-[3,5-Difluoro-4-[4-(methane- P-109 methanol sulfonyl)- l-piperazinyl]phenyl]-2-oxo-5- oxazolidinyl]methyl]-O-methylthiocarbamate
447 (S)-N-[[3-[4-[4-(methanesulfonyl)-l- P-1 10 methanol piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]- methyl]-O-methylthiocarbamate
448 (S)-N-[[3-[3-Fluoro-4-[4-(ethanesulfonyl)-l- P-1 1 1 methanol piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]- methyl]-O-methylthiocarbamate
449 (S)-N-[[3-[3,5-Difluoro-4-[4-(ethane- P-1 12 methanol sulfonyl)- 1 -piperazinyl]phenyl]-2-oxo-5- oxazolidinyl]methyl]cyclopropane- carbothioamide
450 (S)-N-[[3-[4-[4-(ethanesulfonyl)-l- P-113 methanol piperazinyl]phenyl]-2-oxo-5- oxazolidinyl]methyl]-O-methylthiocarbamate
451 (S)-N-[[3-[3-Fluoro-4-[4-(chloromethane- P-1 14 methanol sulfonyl)- 1 -piperazinyl]phenyl]-2-oxo-5- oxazolidinyl]methyl]-O-methylthiocarbamate
452 (S)-N-[[3-[3,5-Difluoro-4-[4Jchloro- P-1 15 methanol methanesulfonyl)- l-piperazinyl]phenyl]-2- oxo-5-oxazolidinyl]methyl]-O-methyl- thiocarbamate
453 (5)-N-[[3-[4-[4-(chloromethanesulfonyl)-l- P- 1 16 methanol piperazinyl]phenyl]-2-oxo-5- oxazolidinyl]methyl]-0-methylthiocarbamate Isothiocyanate
Example Corresponding No. Product to Amine No. Amine
454 (S)-N-[[3-[3-Fluoro-4-[4-(cyanomethane- P- 117 methanol sulfonyl)- l-piperazinyl]phenyl]-2-oxo-5- oxazolidinyl]methyl]-O-methylthiocarbamate
455 (S)-N-[[3-[3,5-Difluoro-4-[4-(cyanomethane- P-1 18 methanol sulfonyl)- 1 -piperazinyl]phenyl]-2-oxo-5- oxazolidinyl]methyl]-O-methylthiocarbamate
456 (S)-N-[[3-[4-[4-(Cyanomethanesulfonyl)-l- P-1 19 methanol piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]- methyl]-O-methylthiocarbamate
457 (S)-N-[[3-[3-Fluoro-4-[4-(N-methyl- P-120 methanol sulfamoyl)- l-piperazinyl]phenyl]-2-oxo-5- oxazolidinyl]methyl]-O-methylthiocarbamate
458 (S)-N-[[3-[3,5-Difluoro-4-[4-(N-methyl- P-121 methanol sulfamoyl)- 1 -piperazinyl]phenyl]-2-oxo-5- oxazolidinyl]methyl]-O-methylthiocarbamate
459 (S)-N-[[3-[4-[4-(N-methylsulfamoyl)-l- P-122 methanol piperazinyI]phenyl]-2-oxo-5-oxazolidinyl]- methyl]-O-methylthiocarbamate
460 (S)-N-[[3-[3-Fluoro-4-[4-(N,N-dimethyl- P-123 methanol sulfamoyl)- 1 -piperazinyl]phenyl]-2-oxo-5- oxazolidinyl]methyl]-O-methylthiocarbamate
461 (S)-N-[[3-[3,5-Difluoro-4-[4-(N,N-dimethyl- P-124 methanol sulfamoyl)- 1 -piperazinyl]phenyl]-2-oxo-5- oxazolidinyl]methyl]-O-methylthiocarbamate
462 (5)-N-[[3-[4-[4-(N,N-dimethylsulfamoyl)- l- P- 125 methanol piperazinyl]phenyl]-2-oxo-5- oxazolidinyl]methyl]-O-methylthiocarbamate
463 (5)-N-[[3-[3-Fluoro-4-[4-(ethoxycarbonyl)-l- P-126 methanol piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]- methyl]-O-methylthiocarbamate
464 (5')-N-[[3-[3-Fluoro-4-[4-(ethoxycarbonyl)- l- P-126 ethanol piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]- methyl]-O-ethylthiocarbamate Isothiocyanate
Example Corresponding No. Product to Amine No. Amine
465 (S)-N-[[3-[3-Fluoro-4-[4-(ethoxycarbonyl)- 1 - P-126 isopropyl piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]- alcohol methyl]-O-/so-propylthiocarbamate
466 (S)-N-[[3-[3.5-Difluoro-4-[4-(ethoxy- P-127 methanol carbonyl)-l-piperazinyl]phenyl]-2-oxo-5- oxazolidinyl]methyl]-O-methylthiocarbamate
467 (S)-N-[[3-[4-[4-(ethoxycarbonyl)-l- P-128 methanol piperazinyl]phenyl]-2-oxo-5- oxazolidinyl]methyl]-O-methylthiocarbamate
468 (S)-N-[[3-[3-Fluoro-4-(4-sulfamoyl-l- P-129 methanol piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]- methyl]-O-methylthiocarbamate,
469 (S)-N-[[3-[3-Fluoro-4-(4-sulfamoyl-l- P-129 ethanol piperazinyl)phenyl]-2-oxo-5- oxazolidinyl]methyl]-O-ethylthiocarbamate
470 (S)-N-[[3-[3-Fluoro-4-(4-sulfamoyl-l- P- 129 isopropyl piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]- alcohol methyl]-O-/sopropylthiocarbamate
471 (S)-N-[[3-[3,5-Difluoro-4-(4-sulfamoyl-l- P-130 methanol piperazinyl)phenyl]-2-oxo-5- oxazolidinyl]methyl]-O-methylthiocarbamate
472 (S)-N-[[3-[4-(4-sulfamoyl- 1 -piperazinyl)- P- 131 methanol phenyl]-2-oxo-5-oxazolidinyl]methyl]-O- methylthiocarbamate
473 (S)-N-[[3-[3-Fluoro-4-[4-(cyanomethyl)-l- P-132 methanol piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]- methyl]-O-methylthiocarbamate
474 (S)-N-[[3-[3,5-Difluoro-4-[4Jcyanomethyl)- P- 133 methanol l-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]- methyl]-O-methylthiocarbamate
475 (S)-N-[[3-[4-[4-( cyanomethyl)- 1 - P- 134 methanoll piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]- methyl]-O-methylthiocarbamate Isothiocyanate
Example Corresponding No. Product to Amine No. Amine
476 (S)-N-[[3-[3-Fluoro-4-[4-(2-fluoroethyl)-l- P-135 methanol piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]- methyl]-O-methylthiocarbamate
477 (S)-N-[[3-[3,5-Difluoro-4-[4-(2-fluoroethyl)- P-136 methanol l-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]- methyl]-O-methylthiocarbamate
478 (S)-N-[[3-[4-[4-(2-fluoroethyl)- 1 - P-137 methanol piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]- methyl]-O-methylthiocarbamate
479 (S)-N-[[3-[3-Fluoro-4-(4-formyl- 1 - P-138 methanol piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]- methyl]-O-methylthiocarbamate
480 (S)-N-[[3-[3,5-Difluro-4-(4-formyl- 1 - P-139 methanol piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]- methyl]-O-methylthiocarbamate
481 (S)-N-[[3-[4-(4-formyl-l-piperazinyl)- P-140 methanol phenyl]-2-oxo-5-oxazolidinyl]methyl]-O- methylthiocarbamate
EXAMPLE 482. (5S)-N-[[3-[3-FIuoro-4-(tetrahydro-l,4-thiazepιn-4(5H)- yl)phenyl]-2-oxo-5-o\azolidinyI]methyI]thioacetamide, thiazepine S-oxide
Step 1 Hexahydro-5-oxo- l,4-thιazepιne is prepared according to the procedure described by Gallego (J Org Chem 1993, 55, 3905-391 1 )
Step 2 Lithium aluminum hydride (5 5 mL of a I M solution in THF) is added dropwise to a stirred solution ot hexahydro-5-oxo- l 4-thιazepιne (721 5 mg) in dry THF (21 mL) cooled to 0 °C The reaction mixture is stirred at 0 °C for 10 min, then at room temperature for 4 h The reaction mixture is quenched by careful successive addition of water (0 2 mL), 5 N aqueous NaOH (0 2 mL) and water (0 74 mL) The reaction mixture becomes very thick and gel-like The reaction mixture is diluted with ether (50 mL) and filtered through a pad of cehte The filter cake is washed with ether ( 100 mL) The filtrate is concentrated to afford 616 6 mg of 1 ,4-hexahydrothιazepιne which is used immediately in the next step
Step 3 To a stirred solution of 1 4-hexahydrothιazepιne (596 0 mg) and 3,4- difluoronitrobenzene (0 51 mL) in acetonitrile ( 14 mL) is added diisopropylethylamine ( 1 0 mL) The yellow solution is heated at reflux for 18 h, then cooled and concentrated The residue is diluted with CH2C1, ( 100 mL) and washed with saturated aqueous NH4C1
(35 mL) The phases are separated and the orgamcs are dried (MgSO4), filtered and concentrated The residue is purified by flash chromatography using 20% EtOAc in hexane as the eluent to afford 830 2 mg of the nitrobenzene Mp 1 15- 1 16 °C, Anal Calcd tor CπHπFN,OJ5 C, 51 55, H, 5 1 1 , N, 10 93 S, 12 5 1 Found C, 51 47, H, 5 12, N, 10 79, S, 12 42
Step 4 To a stirred suspension of the nitrobenzene prepared in Step 3 (5 5 g) in EtOH (260 mL) is added a solution of 2 M aqueous CuSO4 ( 1 1 9 mL) The mixture is cooled to 0 °C and NaBH4 (4 1 g) is added in portions The reaction mixture turns very dark and is stirred at 0 °C for 10 min. at room temperature tor 30 min. and then heated at reflux for 3 h. The cooled reaction mixture is diluted with EtOAc (500 ml) and washed with water (200 mL). The aqueous mixture is extracted with EtOAc (3 x 200 mL). The combined organics are dried (MgS04). filtered and concentrated to atford the aniline intermediate
Step 5 The dark residue from Step 4 is dissolved in 2.1 acetone/water (255 mL) and cooled to 0 °C. To this stirred mixture is added solid NaHCO^ (5 4 g) followed by benzylchloro formate (1.1 mL) The reaction mixture is stirred at 0 °C for 10 min, then at room temperature for 24 h The reaction mixture is quenched with 10% aqueous NaHSO4 (200 mL) and then poured into EtOAc (300 mL). The phases are separated and the aqueous phase is extracted with EtOAc (2 x 250 mL). The combined organics are dried (MgSO ,), filtered and concentrated. The residue is purified by MPLC using 20%
EtOAc in hexane to afford 6.03 g of the benzylcarbamate as a yellow solid, mp 72-74 °C; Anal. Calcd for C,9H,,FN,O,S. C, 63.31 ; H, 5.87. N, 7.77, S, 8.89 Found: C, 63.31; H, 5.97; N, 7.69; S, 8.79.
Step 6. To a stirred solution of the carbamate from Step 5 (3.0 g) in dry THF (33 mL) under N, cooled to -78 °C, is added dropwise via syringe a 1.6 M solution of nBuLi in hexane (5 4 mL). The reaction mixture was stirred at -78 °C for 35 min, then R- glycidyl butyrate ( 1.2 mL) is added. The reaction mixture is stirred at -78 °C for 30 min, then at room temperature overnight during which time a precipitate forms. The reaction mixture is quenched with saturated aqueous NH4C1 (33 mL) and poured into EtOAc
(100 mL). The phases are separated. The organic phase is washed with saturated aqueous NaHCO^ (50 mL), brine ( 50 mL), dried (MgSO ), filtered and concentrated.
The residue is purified by flash chromatography using EtOAc as the eluent to afford 2.5 g of a hydroxymethyl oxazolidinone. Mp 100-102 °C. Anal. Calcd for C„H|9FN,O,S:
C, 55.20, H. 5.87, N, 8.58; S, 9.82. Found. C, 55 09, H, 5.91 ; N, 8 36, S, 9.57.
Step 7 To a stirred solution of the alcohol prepared in Step 6 ( 1 7 g) in CH,C1,
(35 mL) cooled to 0 °C, is added triethylamine ( 1 J mL) followed by methanesulfonyl chloride (0.5 mL) The reaction mixture is stirred at 0 °C for 10 mm. then at room temperature for 1 h. The reaction mixture is treated with water (35 mL) The phases are separated and the aqueous phase is extracted with CH,C1., (35 mL). The combined organic phases are dried (MgSO ), filtered and concentrated The residue is purified by flash chromatography using 80% EtOAc in hexane as the eluent to afford 2 1 g of the mesylate Mp 132- 142 °C Anal Calcd for C^FNJ^S, C, 47 51. H, 5 23, N, 6 93,
S, 15 85 Found C 47 18, H. 5 28, N. 6 84. S 15 60 Step 8 Ammonia gas is bubbled into a stirred suspension of the mesylate prepared in Step 7 (941 7 mg) in 1 1 THF/CH,OH (40 mL) until saturated (approx 5 min) The reaction mixture is heated in a sealed tube at 100 °C for 72 h The cooled reaction mixture is concentrated to give the crude amine, which is immediately suspended in CH2CI2 (35 mL) and cooled to 0 °C To this stirred suspension is added triethylamine (0 97 mL, 6 9 mmol) followed by di-tert-butyl dicarbonate (759 5 mg, 3 5 mmol) The reaction mixture becomes homogeneous and is stirred at RT for 18 h The reaction mixture is poured into CH2G2 (75 mL) and washed with H2O ( 1 x 50 mL) The organic phase is dried (MgSO4), filtered and concentrated The resulting residue is purified on a Biotage 40 S column using 30-35 % ethyl acetate in CH3OH as the eluent to afford 867 4 mg of the protected amine mp 74-75 °C Anal Cald C, 56 45, H, 6 63, N, 9 88 Found C, 56 95, H, 6 85, N, 9 55
Step 9 To a stirred suspension of the protected amine prepared in Step 8 (205 2 mg) in 1 1 CH}OH/H2θ (6 mL) cooled to 0°C is added sodium meta peπodate ( 1 13 5 mg) The resulting suspension is stirred at RT for 18 h The reaction mixture is filtered and the solid is washed with CH C12 (2 x 20 mL) The filtrate is extracted with H2O (1 x 10 mL) The phases are separated The aqueous phase is extracted with CH2CL ( 1 x 25 mL) The combined organic phases are dried (MgS0 ), filtered and concentrated The white solid residue is purified on a Biotage 12 M column using 5% CH^OH in CH2CI2 as the eluent to afford 187 3 mg of the sulfoxide mp 78-81 °C Step 10 Dry HCl gas is passed over the surface of a stirred solution of the sulfoxide prepared in Step 9 ( 179 3 mg) in CHiOH (2 mL) cooled to 0 °C for 1 minute The reaction mixture is stirred at 0 °C for 10 min, then at room temperature for 15 min, then concentrated The resulting yellow residue is suspended in THF (5 mL) and CH2CL (5 mL) and cooled to 0°C To this stirred suspension is added triethylamine (0 46 mL) followed by ethyldithioacetate (0 18 mL) The dark reaction mixture is stirred at RT overnight then concentrated The dark residue is diluted with CH CI2 (30 mL) and washed with LO (2 15 mL) The organic phases are dried (MgS0 ). filtered and concentrated. The dark residue is purified on a Biotage 12 M column using 5% CH3OH in CH2CI2 as the eluent to afford 71.5 mg of the title compound as a tan solid, mp 85-89 °C.
Following the general procedure outlined in Step 10 of Example 482, but substituting the dithioesters listed below, the compounds of Examples 483 to 495 of Table K can be obtained.
TABLE K
Example 496. (5S)-N-[[3-[3,5-Difluoro-4-(tetrahydro-l,4-thiazepin-4(5H yl)phenyI]-2-oxo-5-oxazolidinyl]methyl]thioacetamide, thiazepine S-oxide
NγCH3
The title compound can be prepared by the procedure of Example 482, by substituting an appropriate quantity of 2,6-difluoro-4-nitrobenzene (trifluoromethane) sulfonate for 3,4-difluoronitrobenzene in Step 1.
Utilizing the amine prepared in Example 496, but substituting the dithioester listed below for ethyl dithioacetate in the final step, the compounds of Examples 497 to 499 of Table L are obtained.
TABLE L
Example 500. (5S)-N-[[3-[4-(Tetrahydro-l,4-thiazepin-4(5H)-yI)phenyI]-2-oxo-5- oxazolidinyl]methyl]thioacetamide, thiazepine S-oxide.
The title compound can be prepared by the procedure of Example 482. by substituting an appropriate quantity of 4-fluoronιtrobenzene for 3,4-dιfluoronιtro- benzene in Step 1.
Utilizing the amine prepared in Example 500. but substituting the dithioester listed below for ethyl dithioacetate in the final step, the compounds of Examples 501 to 503 of Table M are obtained
TABLE M
Example 504. (5S)-N-[[3-[3-FIuoro-4-(tetrahydro-l,4-thiazepin-4(5H)-yl)phenyI]-2- oxo-5-oxazolidinyI]methyl]thioacetamide, thiazepine S,S-dioxide
S
Step 1 To a stirred solution of the thiazepine prepared in Step 8 of Example 482 (243.7 mg) in 25 % H2O/acetone (8 mL) is added 4-methylmorpholιne N-oxιde (201.5 mg) followed by a solution of osmium tetroxide in 2-methyl-2-propanol (2 5 wt %, 30 μL). The reaction mixture is stirred at room temperature for 18 h The reaction mixture is treated with saturated sodium bisulfate (8 mL), then poured into CH2CL (50 mL). The phases are separated The aqueous phase is extracted with CH2CI1 (2 x 25 mL) The combined organic phases are washed with brine ( 1 x 25 mL), dried (MgSO4), filtered and concentrated. The residue is purified on a Biotage 40 S column using 1 % CH3OH in CH2CL as the eluent to afford 216.1 mg (0.47 mmol, 83%) of the thiazepine S,S-dιoxιde as a white solid, mp 144-146 °C.
Step 2. Dry HCl gas is passed over the surface of a stirred solution of the thiazepine S,S-dιoxιde prepared in Step 1 ( 108.2 mg) in CH3OH(3 mL) at 0°C for 1 minute. The reaction mixture is stirred at 0 °C for 10 min and then at room temperature for 15 min The reaction is concentrated and the yellow residue is suspended in CH2CI2 (2 mL) and THF (2 mL). This stirred suspension is cooled to 0°C and triethylamine (0.27 mL) is added followed by a solution of ethyldithioacetate (0 1 1 mL) in THF (0.5 mL) with 0J5 mL rinse. The yellowish-green solution is stirred at 0°C for 10 min then at room temperature for 18 h. The reaction mixture is poured into CH2CL (20 mL) and washed with H2O (2 x 10 mL). The organic phase was dried (MgS0 ). filtered and concentrated The residue is purified on a Biotage 12 M column using 2 % CHtOH in CH2CL as the eluent to afford 77J mg of the title compound as a white solid, mp 88-90 °C
Following the general procedure outlined in Step 2 of Example 504, but substituting the dithioester listed below for ethyl dithioacetate. the compounds of Examples 505 to 507 of Table Ν are obtained TABLE N
Example 508. (5S)-N-[[3-[3,5-Difluoro-4-(tetrahydro-l,4-thiazepin-4(5H)- yl)phenyl]-2-oxo-5-oxazolidinyl]methyI]thioacetamide, thiazepine S,S-dioxide
The title compound can be prepared by the procedures of Examples 504 and 482. by substituting an appropriate quantity of 2.6-difluoro-4-nitrobenzene (trifluoromethane) sulfonate for 3,4-difluoronitrobenzene in Step 1 of Example 482.
Utilizing the amine prepared in Example 508, but substituting the dithioester listed below for ethyl dithioacetate in the final step, the compounds of Examples 509 to 51 1 of Table O are obtained.
TABLE O
Example 512. (5S)-N-[[3-[4-(Tetrahydro-l,4-thiazepin-4(5H)-yl)phenyI]-2-oxo-5- oxazolidinyl]methyl]thioacetamide, thiazepine S,S-dioxide
The title compound can be prepared by the procedure of Examples 504 and 482, by substituting an appropriate quantity of 4-fluoronιtrobenzene for 3,4-dιfluoronιtro- benzene in Step 1 of Example 482
Utilizing the amine prepared in Example 512, but substituting the dithioester listed below for ethyl dithioacetate in the final step, the compounds of Examples 513 to 515 of Table P are obtained
TABLE P
EXAMPLE 516. (5S)-N-[[3-[3-FIuoro-4-(tetrahydro-l,4-thiazepin-4(5H)- yl)phenyI]-2-oxo-5-oxazolidinyl]methyl]thioacetamide.
This compound is prepared according to the procedure of Step 8 in Example 482, but stubstituting an appropriate quantity of ethyl dithioacetate for di-tert-butyl dicarbonate; mp 129-131°C.
Utilizing the amine prepared in Step 8 of Example 482. but substituting an appropriate quantity of the dithioester listed below for di-tert-butyl dicarbonate, the compounds of Examples 517 to 529 of Table Q are obtained.
TABLE Q
EXAMPLE 530. (5S)-N-[[3-[3,5-Difluoro-4-(tetrahydro-l,4-thiazepin-4(5H)- yl)phenyi]-2-oxo-5-oxazoIidinyl]methyl]thioacetamide.
This compound can be prepared according to the procedures of Example 482 and Example 516, but substituting an appropriate quantity of 2,6-difluoro-4-nιtrophenyl trifluoromethane sulfonate for 3,4-difluoronitrobenzene in Step 1 of Example 482.
Utilizing the amine prepared in Example 530, but substituting an appropriate quantity of the dithioester listed below tor di-tert-butyl dicarbonate. the compounds of Examples 531 to 533 of Table R can be prepared.
TABLE R
EXAMPLE 534. (5S)-N-[[3-[4-(Tetrahydro-l,4-thiazepin-4(5H)-yl)phenyl]-2-oxo-5- oxazolidinyI]methyl]thioacetamide; mp 129-131°C
This compound can be prepared according to the procedures of Example 482 and Example 516, but substituting an appropriate quantity of 4-fluoronitrobenzene for 3,4- difluoronitrobenzene in Step 1 of Example 482.
Utilizing the amine prepared in Example 534, but substituting an appropriate quantity of the dithioester listed below for di-tert-butyl dicarbonate, the compounds of Examples 535 to 537 of Table S can be prepared. TABLE S
EXAMPLE 538. (5S)-N-[[3-[3-Fluoro-4-(tetrahydro-l,4-thiazepin-4(5H)- yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]thiourea, thiazepine S-oxide
This compound can be prepared by the procedure described in Example 33. but substituting the amine prepared in Example 482 for the amine 33.
By reaction of the isothiocyanate prepared in Example 538 with the amines and alcohols listed in Table T. the compounds of Examples 539 to 544 can be prepared. TABLE T
EXAMPLE 545. (5S)-N-[[3-[3,5-Difluoro-4-(tetrahydro-l,4-thiazepin-4(5H)- yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]thiourea, thiazepine S-oxide
This compound can be prepared by the procedure described in Example 33, but substituting the amine prepared in Example 496 for the amine 33.
By reaction of the isothiocyanate prepared in Example 545 with the amines and alcohols listed in Table U, the compounds of Examples 546 to 551 can be prepared.
TABLE U
EXAMPLE 552. (5S)-N-[[3-[4-(Tetrahydro-l,4-thiazepin-4(5j?/)-yl)phenyl]-2-oxo-5- oxazolidinyl]methyl]thiourea, thiazepine S-oxide
This compound can be prepared by the procedure described in Example 33, but substituting the amine prepared in Example 500 for the amine 33.
By reaction of the isothiocyanate prepared in Example 552 with the amines and alcohols listed in Table V, the compounds of Examples 553 to 558 can be prepared.
TABLE V
EXAMPLE 559. (5S)-N-[[3-[3-FIuoro-4-(tetrahydro-l,4-thiazepin-4(5H)- yl)phenyl]-2-oxo-5-oxazoIidinyI]methyl]thiourea, thiazepine S,S-dioxide
This compound can be prepared by the procedure described in Example 33, but substituting the amine prepared in Example 504 for the amine 33
By reaction of the isothiocyanate prepared in Example 559 with the amines and alcohols listed in Table W, the compounds of Examples 560 to 565 can be prepared TABLE W
EXAMPLE 566. (5S)-N-[[3-[3,5-Difluoro-4-(tetrahydro-l,4-thiazepin-4(5/7)- yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]thiourea, thiazepine S,S-dioxide
This compound can be prepared by the procedure described in Example 33, but substituting the amine prepared in Example 508 for the amine 33.
By reaction of the isothiocyanate prepared in Example 566 with the amines and alcohols listed in Table X, the compounds of Examples 561 to 572 can be prepared.
TABLE X
Example Compound Isothiocvanate Amine or No. Alcohol
568 (5S)-N-[[3-[3,5- Same as above (CΗ3)2NΗ
Difluoro-4-(tetrahydro- l,4-thiazepιn-4(5H)- yl)phenyl]-2-oxo-5- oxazolidinyljmethyl]-
Ν',Ν' -dimethylthiourea, thiazepine S.S-dioxide
569 (5S)-N-[[3-[3,5- Same as above Azetidine
Difluoro-4-(tetrahydro- l,4-thiazepin-4(5H)- yl)phenyl]-2-oxo-5- oxazolidinyl]methyl]- 1- azetidinecarbothioamide, thiazepine S.S-dioxide
570 (5S)-N-[[3-[3,5- Same as above CΗ3OΗ
Difluoro-4-(tetrahydro- l,4-thiazepin-4(5H)- yl)phenyl]-2-oxo-5- oxazolidinyl]methyl]-O- methylthiocarbamate, thiazepine S,S-dioxide
571 (5S)-N-[[3-[3,5- Same as above CΗ3CΗ.OΗ
Difluoro-4-(tetrahydro- l,4-thiazepin-4(5H)- yl)phenyl]-2-oxo-5- oxazolidinyl]methyl]-O- ethylthiocarbamate, thiazepine S.S-dioxide
572 (55)-N-[[3-[3,5- (CΗ 2CΗOΗ
Difluoro-4-(tetrahydro- Same as above l ,4-thiazepin-4(5H)- yl)phenyl]-2-oxo-5- oxazolidinyl]methyl]-O- j-opropylthiocarbamate, thiazepine S.S-dioxide
EXAMPLE 573. (5S)-N-[[3-[4-(Tetrahydro-l,4-thiazepin-4(5H)-yl)phenyl]-2-oxo-5- oxazolidinyl]methyI]thiourea, thiazepine S,S-dioxide
This compound can be prepared by the procedure described in Example 33, but substituting the amine prepared in Example 512 for the amine 33.
By reaction of the isothiocyanate prepared in Example 573 with the amines and alcohols listed in Table Y, the compounds of Examples 574 to 579 can be prepared.
TABLE Y
EXAMPLE 580. (5S)-N-[[3-[3-Fluoro-4-(tetrahydro-l,4-thiazepin-4(5/7)- yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]thiourea
This compound can be prepared by the procedure described in Example 33. but substituting the amine prepared in Step 8 of Example 482 for the amine 33.
By reaction of the isothiocyanate prepared in Example 580 with the amines and alcohols listed in Table Z, the compounds of Examples 581 to 586 can be prepared. TABLE Z
EXAMPLE 587. (5S)-N-[[3-[3,5-Difluoro-4-(tetrahydro-l,4-thiazepin-4(5H)- yI)phenyl]-2-oxo-5-oxazolidinyl]methyI]thiourea
This compound can be prepared by the procedure described in Example 33, but substituting the amine prepared in Example 530 for the amine 33.
By reaction of the isothiocyanate prepared in Example 587 with the amines and alcohols listed in Table AA, the compounds of Examples 588 to 593 can be prepared.
TABLE AA
EXAMPLE 594. (5S)-N-[[3-[4-(Tetrahydro-l,4-thiazepin-4(5H)-yl)pheπyl]-2-oxo-5- oxazolidinyl]methyI]thiourea
This compound can be prepared by the procedure described in Example 33, but substituting the amine prepared in Example 534 for the amine 33.
By reaction of the isothiocyanate prepared in Example 594 with the amines and alcohols listed in Table BB, the compounds of Examples 595 to 600 can be prepared. TABLE BB

Claims

WHAT IS CLAIMED:
1. A compound of the formula
wherein Z, is -O2S-, -0-, -N(R107)-, -OS-, or -S-; w is 0, 1, 2, or 3; R23 and R24 are the same or different and can be H or F; and
R1 is H, NH2, NHalkylCrC4; N(alkylCrC4)2; ^n
XJ ; alkylCrC4; OalkylC,-C4; SalkylC,-C4; alkylCrC4 substituted with 1-3F, 1-2C1, CN, or -COOalkylMQ,, or cycloalkylC -C6, wherein in each occurence of the alkyl group may be straight or branched; and R107 is a) R102O-C(R110)(Rm)-C(O)-, b) R103O-C(O)-, c) RI08-C(O)-, d) R109-SO2-, e) NC-CH2-, f) FCHCH,-, or g) R150R151NSO2.. wherein R102 is H, CH,-, phenyl-CH2-, or CH3C(O); each of Ruo and R111 is selected from H or CH3; R103 is alkylCrC, or phenyl; R108 is H, alkylCrC4, aryl(CH2)0.5, CNCH2-, C1CH2-, C12HC-, FH2C-, F2HC-, or cycloalkylC.,-C6; R150 and R151 are the same or different and are selected from H, alkylC C4, or R150 and R151 taken together with the nitrogen to which each is attached forms a monocyclic heterocyclic ring having from 3 to 6 carbon atoms.
2. A compound of claim 1 wherein Z2 is -O S-.
3. A compound of claim 2 which is (5S)-N-[[3-[3-Fluoro-4-(tetrahydro-l,4- thiazepin-4(5H)-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl] thioacetamide, thiazepine
S,S-dioxide.
4. A compound of claim 1 wherein Z2 is -OS-.
5. A compound of claim 4 which is (S)-N-[[3-[3-Fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- propanethioamide, thiomorpholine S-oxide;
(S)-N- [ [3- [3-Fluoro-4-(4-thiomorpholinyl)phenyl] -2-oxo-5-oxazolidinyl] methyl] - 2-methylpropanethioarnide, thiomorpholine S-oxide;
(S)-N-[[3-[3-Fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- cyclopropanecarbothio-amide, thiomorpholine S-oxide; (S)-N-[ [3- [3-Fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl] methyl] -
O-methylthiocarbamate, thiomorpholine S-oxide;
(S)-N- [ [3- [3-Fluoro-4-(4-thiomorpholinyl)phenyl] -2-oxo-5-oxazolidinyl] methyl] - O-ethylthiocarbamate, thiomorpholine S-oxide;
(S)-N- [ [3- [3-Fluoro-4-(4-thiomorpholinyl)phenyl] -2-oxo-5-oxazolidinyl] methyl] - O-isopropylthiocarbamate, thiomorpholine S-oxide;
(5S)-N- [ [3- [3-Fluoro-4-( tetrahydro- 1 ,4-thiazepin-4(5H)-yl )phenyl] -2-oxo-5- oxazolidinyl] methyl] thioacetamide, thiazepine S-oxide;
(S)-N-[[3-[3-Fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- N',N'-dimethylthiourea, thiomorpholine S-oxide; or (5)-N-[[3-[3-Fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-
1-azetidinecarbothioamide, thiomorpholine S-oxide.
6. A compound of claim 1 wherein Z2 is O.
7. A compound of claim 6 which is
(S)-N-[[3-[3-Fluoro-4-(4-morpholinyl)phenyl] -2-0X0-5- oxazolidinyl] methyl] -O- ethylthiocarbamate;
(S)-N-[[3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-2- methylpropanethioamide; (S)-N-[[3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- cyclopropane-carbothioamide
8. A compound of claim 1 wherein Z2 is -S-.
9. A compound of claim 8 which is (5S)-N-[[3-[4-(tetrahydro-l,4-thiazepine-
4(5Η)-yl)phenyl]-2-oxo-5-oxazolidinyl] methyl] -thioacetamide.
10. A compound of claim 1 wherein Z is -N(R' )-.
11. A compound of claim 10 which is (S)-N- [ [3- [3-Fluoro-4- [4-(hydroxyacetyD- 1-piperazinyl] phenyl-2-oxo-5- oxazolidinyl] methyl] propanethiomide;
(S)-N- [ [3- [3-Fluoro-4- [4-(hydroxyacetyD- 1-piperazinyl] phenyl] -2-oxo-5- oxazolidinyl] methyl] -2-methylpropanethioamide;
(S)-N- [ [3- [3-Fluoro-4- [4-(hydroxyacetyD- 1-piperazinyl] phenyl] -2-oxo-5- oxazolidinyl] methyl] cyclopropanecarbothioamide;
(S)-N- [ [3-Fluoro-4-(4-acetyl- l-piperazinyl)phenyl] -2-oxo-5- oxazolidinyl] methyl] thioacetamide;
(S)-N- [ [3- [3-Fluoro-4-(4-acetyl- l-piperazinyl)phenyl] -2-oxo-5- oxazolidinyl] methyl] propanethioamide; (S)-N- [ [3- [3-Fluoro-4-(4-acetyl- l-piperazinyl)phenyl] -2-oxo-5- oxazolidinyl] methyl] cyclopropanecarbothioamide;
(S)-N- [ [3- [3-Fluoro-4- [4-(methanesulfonyl )- 1-piperazinyl] phenyl] -2-oxo-5- oxazolidinyl] methyl] -2-methylpropanethioamide;
(iS)-N- [ [3- [3-Fluoro-4- [4-(methanesulfonyD- 1-piperazinyl] phenyl] -2-oxo-5- oxazolidinyl]methyl]cyclopropanecarbothioamide;
(5)-N-[[3-[3-Fluoro-4-(4-formyl-l-piperazinyl)phenyl]-2-oxo-5- oxazolidinyl] methyl] thioacetamide; iS)-N- 1 [3- [3-Fluoro-4-(4-formyl- l-piperazinyl)phenyl] -2-oxo-5- oxazolidinyl] methyl] propanethioamide; (S)-N- [ [3- [3-Fluoro-4-(4-formyl- l-piperazinyl)phenyl] -2-0X0-5- oxazolidinyl] methyl] -2-methylpropanethioamide;
(S)-N-[[3-[3-Fluoro-4-(4-formyl-l-piperazinyl)phenyl]-2-oxo-5- oxazolidinyl] methyl] cyclopropanecarbothioamide; or
(S)-N- [ [3-Fluoro-4-(4-acetyl- l-piperazinyl)phenyl] -2-0X0-5- oxazolidinyl] methyl] thioacetamide.
EP98961822A 1998-11-27 1998-11-27 Oxazolidinone antibacterial agents having a thiocarbonyl functionality Withdrawn EP1133493A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1998/025308 WO2000032599A1 (en) 1998-11-27 1998-11-27 Oxazolidinone antibacterial agents having a thiocarbonyl functionality

Publications (1)

Publication Number Publication Date
EP1133493A1 true EP1133493A1 (en) 2001-09-19

Family

ID=22268382

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98961822A Withdrawn EP1133493A1 (en) 1998-11-27 1998-11-27 Oxazolidinone antibacterial agents having a thiocarbonyl functionality

Country Status (8)

Country Link
EP (1) EP1133493A1 (en)
JP (1) JP2002531455A (en)
KR (1) KR20010107987A (en)
CN (1) CN1322204A (en)
AU (1) AU764980B2 (en)
CA (1) CA2351062A1 (en)
HK (1) HK1040707A1 (en)
WO (1) WO2000032599A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297242B1 (en) * 1999-08-12 2001-10-02 Ortho-Mcneil Pharmaceutical, Inc. N-substituted amidine and guanidine oxazolidinone antibacterials and methods of use thereof
WO2003008389A1 (en) * 2001-07-16 2003-01-30 Ranbaxy Laboratories Limited Oxazolidinone derivatives as potential antimicrobials
PL363960A1 (en) * 2000-07-17 2004-11-29 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
WO2002032857A1 (en) * 2000-10-17 2002-04-25 Pharmacia & Upjohn Company Methods of producing oxazolidinone compounds
GB0108793D0 (en) * 2001-04-07 2001-05-30 Astrazeneca Ab Chemical compounds
US6956040B2 (en) 2001-07-16 2005-10-18 Ranbaxy Laboratories Limited Oxazolidinone piperazinyl derivatives as potential antimicrobials
WO2004018439A1 (en) * 2002-08-22 2004-03-04 Orchid Chemicals & Pharmaceuticals Ltd Novel antibacterial agents
AU2003215861A1 (en) * 2003-04-07 2004-11-01 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
US7265140B2 (en) * 2003-09-23 2007-09-04 Pfizer Inc Acyloxymethylcarbamate prodrugs of oxazolidinones
US20090247545A1 (en) * 2004-10-11 2009-10-01 Mukund Keshao Gurjar Substituted oxazolidinone derivatives
WO2006043121A1 (en) * 2004-10-20 2006-04-27 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
CA2589171A1 (en) * 2004-11-29 2006-06-01 Pharmacia & Upjohn Company Llc Thiazepine oxazolidinones as antibacterial agents
AU2006231919A1 (en) 2005-04-06 2006-10-12 Pharmacia & Upjohn Company Llc 7-fluoro-1,3-dihydro-indol-2-one oxazolidinones as antibacterial agents
ATE449773T1 (en) 2005-06-29 2009-12-15 Pharmacia & Upjohn Co Llc HOMOMORPHOLINOXAZOLIDINONES AS ANTIBACTERIAL AGENTS
KR20070038236A (en) * 2005-10-05 2007-04-10 일동제약주식회사 A novel oxazolidinone formamide derivative and manufacturing process thereof
WO2007070506A2 (en) 2005-12-14 2007-06-21 Amgen Inc. Diaza heterocyclic sulfonamide derivatives and their uses
WO2007114326A1 (en) 2006-03-31 2007-10-11 Research Foundation Itsuu Laboratory Novel compound having heterocyclic ring
CA2692255A1 (en) * 2007-06-22 2008-12-31 Orchid Research Laboratories Limited Novel compounds and their use
EP2208729A4 (en) 2007-10-02 2011-04-27 Res Found Itsuu Lab Oxazolidinone derivative having 7-membered hetero ring
WO2012153155A1 (en) * 2011-05-06 2012-11-15 Egis Gyógyszergyár Nyilvãnosan Müködö Részvény-Társaság Process for the preparation of a rivaroxaban and intermediates formed in said process
US10550092B2 (en) * 2015-07-17 2020-02-04 The Global Alliance For Tb Drug Development, Inc. Substituted phenyloxazolidinones for antimicrobial therapy
WO2017066964A1 (en) * 2015-10-22 2017-04-27 Merck Sharp & Dohme Corp. Oxazolidinone compounds and methods of use thereof as antibacterial agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK283420B6 (en) * 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Oxazolidinones containing a substituted diazine moiety and their use as antimicrobials
MY115155A (en) * 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
JP2002501530A (en) * 1997-05-30 2002-01-15 ファルマシア・アンド・アップジョン・カンパニー Oxazolidinone antimicrobial agents with thiocarbonyl functionality
AU9001598A (en) * 1997-09-11 1999-03-29 Hokuriku Seiyaku Co. Ltd Thiourea derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0032599A1 *

Also Published As

Publication number Publication date
CN1322204A (en) 2001-11-14
AU764980B2 (en) 2003-09-04
HK1040707A1 (en) 2002-06-21
WO2000032599A1 (en) 2000-06-08
KR20010107987A (en) 2001-12-07
AU1705399A (en) 2000-06-19
JP2002531455A (en) 2002-09-24
CA2351062A1 (en) 2000-06-08

Similar Documents

Publication Publication Date Title
US6218413B1 (en) Oxazolidinone antibacterial agents having a thiocarbonyl functionality
US6255304B1 (en) Oxazolidinone antibacterial agents having a thiocarbonyl functionality
EP1133493A1 (en) Oxazolidinone antibacterial agents having a thiocarbonyl functionality
RU2175324C2 (en) Phenyloxazolidinones having c-c-bond with 4-8-membered heterocyclic rings
US5990136A (en) Isoxazoline derivatives useful as antimicrobials
WO2003006440A2 (en) Amide-containing compound having improved solubility and method of improving the solubility of an amide-containing compound
EP1599470A1 (en) Antibacterial indolone oxazolidinones, intermediates for their preparation and pharmaceutical compositions containing them
US20040127530A1 (en) Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives
US6972286B2 (en) Oxazolidinones having a benzannulated 6- or 7-membered heterocycle
NZ511963A (en) Oxazolidinone antibacterial agents having a thiocarbonyl functionality
MXPA01005287A (en) Oxazolidinone antibacterial agents having a thiocarbonyl functionality
MXPA99011069A (en) Oxazolidinone antibacterial agents having a thiocarbonyl functionality
CZ418799A3 (en) Oxazolidine antibacterial substances containing thiocarbonyl functional group
AU2002248133A1 (en) Oxazolidinones having a benzannulated 6-or 7-membered heterocycle as antibacterial agents

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010615

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20010615;LT PAYMENT 20010615;LV PAYMENT 20010615;MK PAYMENT 20010615;RO PAYMENT 20010615;SI PAYMENT 20010615

17Q First examination report despatched

Effective date: 20020912

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PHARMACIA & UPJOHN COMPANY LLC

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PHARMACIA & UPJOHN COMPANY LLC

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070601